Methods and compositions for modulating myeloperoxidase (MPO) expression

By modulating MPO expression and activity in bone marrow cells using gene editing, the method addresses the limitations of existing inhibitors, reducing neuroinflammation and improving cognitive function in Alzheimer's and multiple sclerosis models.

JP7594752B2Active Publication Date: 2024-12-05LEMPO THERAPEUTICS LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021523134
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-05
Filing Date
2019-07-04
Publication Date
2024-12-05
Estimated Expiration
2039-07-04

AI Technical Summary

Technical Problem

Existing methods to inhibit myeloperoxidase (MPO) activity are limited in addressing undesirable effects mediated by other domains of MPO and do not prevent the formation of anti-MPO antibodies, which can lead to vasculitis in conditions like Alzheimer's disease, and fail to effectively modulate NET formation and related inflammatory responses.

Method used

The method involves modulating MPO expression and activity in undifferentiated bone marrow cells using gene editing compounds and undifferentiated bone marrow cell populations to regulate MPO levels systemically, thereby influencing immune cell function and reducing NET formation and inflammation.

Benefits of technology

This approach effectively reduces neuroinflammation and improves cognitive function in models of Alzheimer's disease and multiple sclerosis by suppressing MPO activity, while avoiding the formation of anti-MPO antibodies and targeting multiple MPO activities beyond the active site.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594752000005
    Figure 0007594752000005
  • Figure 0007594752000006
    Figure 0007594752000006
  • Figure 0007594752000007
    Figure 0007594752000007
Patent Text Reader

Abstract

The present invention relates to methods for modulating myeloperoxidase (MPO) expression and / or activity in a mammalian subject by modulating MPO levels and / or activity in undifferentiated bone marrow (BM) cells of the subject ex vivo and / or in vivo. The present invention further provides therapeutic methods and compositions for treating MPO-associated disorders. [Selected Figure] Figure 4A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to methods and compositions for modulating myeloperoxidase (MPO) expression and their use in the treatment of MPO-associated conditions. [Background technology]

[0002] Related technical documents The following documents are considered to be relevant to the subject matter disclosed herein as background art: [1]Nauseef WM,Borregaard N.Neutrophils at work.Nat Immunol.2014;15:602-611. [2]Delgado-Rizo V, Martinez-Guzman MA, Iniguez-Gutierrez L, Garcia-Orozco A, Alvarado-Navarro A, Fafutis-Morris M.Neutrophil extracellular traps and its implications in inflammation:An overview.Front Immunol.2017;8. [3]Winterbourn CC, Kettle AJ, Hampton MB.Reactive Oxygen Species and Neutrophil Function.Annu Rev Biochem.2016;85:765-792. [4] Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. Myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis.Cell Rep.2014;8:883-896. [5]Strzepaa A,Pritchardc KA,Dittel BM.Myeloperoxidase:A new player in autoimmunity.Cell Immunol.2017;317:1-8. [6]Khan AA,Alsahli MA,Rahmani AH.Myeloperoxidase as an Active Disease Biomarker:Recent Biochemical and Pathological Perspectives.Med.Sci.2018 633. [7]Zenaro E,Pietronigro E,Bianca V Della,et al.Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin.Nat Med.2015;21(8):880-886. [8]Azevedo EPC,Guimaraes-Costa AB,Torezani GS,et al.Amyloid fibrils trigger the release of neutrophil extracellular traps(NETs),causing fibril fragmentation by NET-associated elastase.J Biol Chem.2012;287(44):37206-37218. [9]Gellhaar S,Sunnemark D,Eriksson H,Olson L,Galter D.Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease.Cell Tissue Res.2017;369(3):445-454.

[10] Naegele M,Tillack K,Reinhardt S,Schippling S,Martin R,Sospedra M.Neutrophils in multiple sclerosis are characterized by a primed phenotype.J Neuroimmunol.2012;242(1-2):60-71.

[11] Rivers TM.Observations on attempts to produce acute disseminated encephalomyelitis in monkeys.J Exp Med.1933;58(1):39-53.

[12] Richard JF,Roy M,Audoy-Remus J,Tremblay P,Vallieres L.Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6,ICAM1 and ITGαM.Brain Pathol.2011;21(6):661-671.

[13] Carlson T,Kroenke M,Rao P,Lane TE,Segal B.The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.J Exp Med.2008;205(4):811-823.

[14] Wu F,Cao W,Yang Y,Liu A.Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL / 6 mice.Histochem Cell Biol.2010;133(3):313-322.

[15] Aube B, Levesque SA, Pare A, et al. Neutrophils Mediate Blood-Spinal Cord Barrier Disruption in Demyelinating Neuroinflammatory Diseases. J Immunol. 2014;193(5):2438-2454.

[16] Pun PBL, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43(4):348-364.

[17] Zhang H, Ray A, Miller NM, Hartwig D, Pritchard KA, Dittel BN. Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity. J Neurochem. 2016;136(4):826-836.

[18] Karin Steinbach, Melanie Piedavent, Simone Bauer, Johannes T. Neumann, and Manuel A. Friese. Neutrophils Amplify Autoimmune Central Nervous System Infiltrates by Maturing Local APCs. J Immunol 2013;191:4531-4539.

[19] Malle1 E, Furtmuller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development. British Journal of Pharmacology 2007;152, 838-854.

[20] International Publication No. WO 2015 / 148716.

[21] Van Der Veen BS, Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease.Antioxidants & redox signaling,2009,11.11:2899-2937.

[22] YU, Guoliang;SHIKAN ZHENG,Hao Zhang.Inhibition of myeloperoxidase by N-acetyl lysyltyrosylcysteine ​​amide reduces experimental autoimmune encephalomyelitis-induced injury and promotes oligodendrocyte regeneration and neurogenesis in a murine model of progressive multiple sclerosis.Neuroreport,2018,29.3:208. The acknowledgment of the above documents in this specification should not be inferred to mean that they are in any way relevant to the patentability of the subject matter disclosed herein.

[0003] 2. Background of the Invention Neutrophils are phagocytic granule-containing cells that are distributed throughout the bloodstream and are known as central mediators of the innate immune response. Early inflammatory initiating signals resulting from bacterial infection or tissue injury induce neutrophils to migrate from the bloodstream, through the endothelial cell barrier, towards the site of injury to mediate the early inflammatory response. This response is primarily due to the phagocytosis of bacterial cells or foreign material, and the release of cytokines and granules that contain proteolytic enzymes and reactive oxygen species (ROS) [1]. A recently established characteristic of neutrophils is their ability to form neutrophil extracellular traps (NETs). The production of NETs (known as NETosis) is a tightly regulated mechanism whereby DNA is released from the cell together with multiple bactericidal proteins to form reticular traps after chromatin decondensation [2].

[0004] Myeloperoxidase (MPO) is a heme-containing peroxidase expressed by several myeloid cells and is the most common protein expressed by neutrophils (constituting 5% of the net mass of neutrophils). MPO catalyzes the formation of the toxic substance hypochlorous acid (HClO) as well as other oxidants [3]. Recently, MPO titration of mouse neutrophils was shown to promote chromatin decondensation and NET formation. Furthermore, neutrophils from MPO-deficient human donors were found to be unable to produce NETs, ​​indicating that MPO is essential for NET formation.

[0005] MPO has been shown to be a key factor in many conditions, including cardiovascular, inflammatory, neurodegenerative, renal and immune-mediated diseases [5-6]. Van Der Been et al. reported the intimate involvement of MPO in several diseases, especially those characterized by acute or chronic inflammation

[21] .

[0006] More specifically, Alzheimer's disease (AD) and dementia are progressive neurodegenerative disorders characterized by the decline of global cognitive functions, including memory, orientation, judgment, and reasoning, and are the most common form of dementia in the elderly. Immune cells have long been known to be involved in AD pathogenesis, and reactive glial cells were previously described by Alois Alzheimer. Astrocytes and microglial cells have been extensively studied in the context of AD and are known to cluster around amyloid-β plaques. When these cells are activated, they secrete various inflammatory mediators that may result in oxidative damage to neural and surrounding vascular tissues, promoting chronic inflammation. Although previously considered less relevant to brain physiology and pathology, the role of peripheral immune cells in AD has been increasingly studied in recent years. This role was strongly supported by a genome-wide association study performed last year that identified multiple loci within immune-related genes expressed by myeloid cells as AD susceptibility loci. Recently, Zenaro and coworkers reported that brain-infiltrating neutrophils promote AD-like pathology in two mouse models by releasing the proinflammatory cytokine IL-17 and by producing NETs. Neutrophil depletion or inhibition of neutrophil migration into the CNS resulted in improved cognition and memory as well as reduced neuroinflammation and Aβ burden. Finally, they also reported that NET-forming neutrophils are elevated in the brains of AD patients in contrast to healthy controls [7]. Furthermore, NET release from neutrophils was also shown to be triggered by amyloid fibrils, supporting the formation of NETs in neurodegenerative brains [8], and furthermore, MPO-immunoreactive cells were reported in specific neurodegenerative regions in the brains of AD and PD patients [9]. Furthermore, brain-infiltrating neutrophils were shown to promote AD-like pathology in two AD mouse models by releasing the proinflammatory cytokine IL-17 and by producing NETs. On the other hand, neutrophil depletion or inhibition of neutrophil migration into the CNS with anti-LY6G resulted in improved cognition and memory and reduced neuroinflammation and amyloid-β levels.More recently, increased neutrophil adhesion in cortical capillaries, which reduced cerebral blood flow, was reported in the brains of AD model mice.

[0007] Furthermore, multiple sclerosis (MS), the most common neurodegenerative disease in young adults, is a chronic autoimmune disease characterized by immune attack of myelin sheaths in the brain and spinal cord, primarily mediated by T cell infiltration through the blood-brain barrier (BBB). The pathogenesis of MS, unlike non-autoimmune neurodegenerative diseases, involves innate and acquired immune cells, but several lines of evidence indicate the involvement of neutrophil-mediated tissue damage. MS-derived neutrophils exhibit a primed phenotype, in addition to increased degranulation and NET formation and enhanced oxidative burst

[10] . Multiple lines of evidence also indicate the involvement of neutrophils in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS

[11] . During EAE, neutrophils are recruited to the cerebral vasculature

[12] , infiltrate the CNS

[13] , and accumulate within areas of demyelination and axonal damage

[14] . Furthermore, neutrophils have been linked to the disruption of the BBB and the brain-spinal barrier (BSCB), and administration of anti-neutrophil antibodies has been shown to interfere with EAE development

[15] .

[0008] Endothelial barrier disruption by neutrophils may allow leukocytes to enter the CNS and promote EAE / MS pathology. Neutrophils were shown to accumulate in the CNS shortly before the onset of clinical symptoms and correlate with lesion localization

[13] . Endothelial barrier disruption by neutrophils was suggested to occur through the release of reactive oxygen species (ROS)

[16] . Accordingly, inhibition of MPO during EAE was shown to restore BBB integrity and ameliorate disease severity

[17] . However, although preclinical single-dose antibody-mediated neutrophil depletion delayed the onset of experimental autoimmune encephalomyelitis and serial depletion attenuated its development, the generation of myelin-specific T cell responses remained unaffected. This study further revealed that neutrophil-associated enzymes such as myeloperoxidase and neutrophil elastase did not contribute to the development of CNS inflammation according to analyses using knockout mice and inhibitors, respectively [18–19].

[0009] Several strategies have been used previously to inhibit active MPO. For example, azides, hydrazides, and hydroxamic acids were used to inhibit MPO by modifying the heme moiety [7]. Furthermore, Yu et al. described a specific inhibitor of MPO, N-acetyl lysyl tyrosyl cysteine ​​amide (KYC), for the treatment of multiple sclerosis using the EAE mouse model

[22] . WO2015148716 discloses methods and compositions for ex vivo expansion of hematopoietic cells using a combination of small molecule drugs and cytokines / growth factors. Multiple genes were affected, especially MPO

[20] .

[0010] When targeting the modification of the heme active site of MPO, prior art inhibitors fail to address the undesirable effects mediated by other domains of MPO. Furthermore, the use of such inhibitors fails to prevent the formation of anti-MPO antibodies that can lead to vasculitis in pathologies such as AD. Thus, there is a need to provide safe, efficient and specific methods and compositions for specifically and efficiently targeting MPO and its various activities in subjects suffering from MPO-associated conditions. Summary of the Invention

[0011] In a first aspect, the present disclosure provides a method for regulating the expression and / or activity of myeloperoxidase (MPO) in a mammalian subject. More specifically, the method of the present invention may include administering to the subject an effective amount of at least one of (a) at least one gene editing compound capable of or adapted to regulate the expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject. Alternatively or additionally, the method may administer to the subject (b) an undifferentiated BM cell population exhibiting regulated expression and / or activity of MPO. It should be noted that the administration of any composition or kit comprising at least one of (a) and (b) or (a) and (b) is also encompassed in the method of the present invention.

[0012] In a further aspect, the present disclosure provides a method for treating, preventing, ameliorating, suppressing or delaying the onset of an MPO-related condition in a mammalian subject. The method of the present invention may include administering to the subject a therapeutically effective amount of at least one of (a) at least one gene editing compound capable of modulating the expression and / or activity of MPO in at least one undifferentiated BM cell of the subject, and (b) an undifferentiated BM cell population exhibiting modulated expression and / or activity of MPO. The administration of any composition or kit comprising at least one of (a) and (b) or (a) and (b) is also encompassed by the method of the present invention.

[0013] In some further aspects thereof, the invention provides kits comprising at least one of: (a) at least one gene editing compound capable of or adapted to modulate expression and / or activity of MPO in at least one undifferentiated BM cell of a subject; and (b) a population of undifferentiated BM cells exhibiting modulated expression and / or activity of MPO.

[0014] In some further aspects thereof, the disclosure provides pharmaceutical compositions comprising at least one therapeutically effective amount of (a) at least one gene editing compound capable of or adapted to modulate expression and / or activity of MPO in at least one undifferentiated BM cell of a subject, and (b) an undifferentiated BM cell population exhibiting modulated expression and / or activity of MPO. The composition may optionally further comprise at least one of a pharma- ceutically acceptable carrier, diluent, and / or excipient.

[0015] A still further aspect of the present invention relates to at least one of the above-mentioned cells transduced or transfected with at least one gene editing compound capable of modulating the expression and / or activity of MPO in undifferentiated BM cells.

[0016] Other aspects of the invention relate to at least one of the compositions, kits and cells of the invention for use in a method for modulating MPO expression and / or activity. Yet further aspects of the invention provide at least one of the compositions, kits and cells of the invention for use in a therapeutic method for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-associated condition in a mammalian subject.

[0017] In yet some further aspects, the invention provides a therapeutically effective amount of at least one of (a) at least one gene editing compound adapted to modulate expression and / or activity of MPO in at least one undifferentiated BM cell of a mammalian subject, and (b) a population of undifferentiated BM cells exhibiting modulated expression and / or activity of MPO, for use in a method for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-associated condition in said subject. The invention further provides methods for inhibiting nephrosis and associated conditions. These and other aspects of the invention will become apparent from the description below. For a better understanding of the subject matter disclosed herein and to illustrate how the invention may be put into practice, embodiments will now be described, by way of non-limiting examples only, with reference to the accompanying drawings, in which: [Brief description of the drawings]

[0018] [Figure 1] Establishment of an experimental autoimmune encephalomyelitis (EAE) model in C57BL / 6 mice. Clinical scores in C57BL / 6 female mice induced with EAE disease with the indicated concentrations of myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) and pertussis toxin (PT). ≥4 mice per group. [Diagram 2] Bone marrow (BM) transplantation rescues lethality in irradiated C57BL / 6 mice. Body weight follow-up of 2-month-old male C57 / BL6 mice transplanted with BM cells from WT mice, Lin-enriched BM cells, or saline after exposure to a lethal radiation dose (9 Gy). [Figure 3A-3F]Transplantation of BM from MPOTm1 / Lus into 5xFAD mice. FIG. 3A is a graph showing the weight follow-up of 2-month-old non-transgenic littermates that were irradiated and transplanted with BM from WT mice. FIG. 3B is a graph showing the weight follow-up of 2-month-old non-transgenic littermates that were irradiated and transplanted with BM from MpoTm1 / Lus mice. FIG. 3C is a graph showing the weight follow-up of 2-month-old 5xFAD transgenic mice that were irradiated and transplanted with BM from WT mice. FIG. 3D is a graph showing the weight follow-up of 2-month-old 5xFAD transgenic mice that were irradiated and transplanted with BM from MpoTm1 / Lus mice. FIG. 3E is a peroxidase activity assay of blood from WT-BM transplanted mice. FIG. 3F is a peroxidase activity assay of blood from MpoTm1 / Lus-BM transplanted mice. [Figure 4A-4C] Generation of 5XFAD mice with MPO-deficient bone marrow. FIG. 4A is a schematic of the treatment of the following mouse groups. Eight-week-old 5XFAD mice and their non-transgenic littermates were lethally irradiated and transplanted with bone marrow from WT C57BL / 6 or MPOTm1 / Lus mice. The number of mice in each group is indicated in brackets. FIG. 4B is an analysis of MPO mRNA expression in bone marrow cells from 10-month-old mice. Data are means ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed t-test. FIG. 4C is a schematic of the timeline of the experimental design. [Figure 5A-5E] MPO deletion suppresses the increase in anxiety-related behavior in 5XFAD mice. FIG. 5A is a graph showing the time spent in the corners of 7-month-old mice subjected to the open field maze test. FIG. 5B is a graph showing the time spent in the center of 7-month-old mice subjected to the open field maze test. FIG. 5C is a graph showing the total distance traveled by the mice. FIG. 5D is a graph showing the time spent in the open arms of mice subjected to the elevated plus maze test. FIG. 5E is a graph showing the time spent in the closed arms of mice subjected to the elevated plus maze test. Data are mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed t-test. [Figures 6A-6E] MPO deficiency protects against learning and memory decline in 5XFAD mice. Figure 6A is a graph showing the relative number of novel arm explorations in 7-month-old mice using two Y-maze trials (indicating short-term spatial memory). Figure 6B is a graph showing novel arm exploration time in 7-month-old mice using two Y-maze trials (indicating short-term spatial memory). Figure 6C is a graph showing escape latency in 8-month-old mice in the Morris water maze test (indicating spatial learning). Figure 6D is a graph showing total distance traveled in the Morris water maze test (indicating spatial learning). Figure 6E is a graph showing freezing behavior in the fear conditioning test in 9-month-old mice. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed t-test. [Figure 7A-7E] MPO deficiency does not affect amyloid-β plaque burden in 5XFAD mice. Figure 7A is a representative image of hippocampal sections stained with DAPI / ThioS from WT mice transplanted with WT bone marrow cells. Scale bar = 200 μm. Figure 7B is a representative image of hippocampal sections stained with DAPI / ThioS from 5XFAD mice transplanted with WT bone marrow cells. Scale bar = 200 μm. Figure 7C is a representative image of hippocampal sections stained with DAPI / ThioS from WT mice transplanted with MPO-KO bone marrow cells. Scale bar = 200 μm. Figure 7D is a representative image of hippocampal sections stained with DAPI / ThioS from 5XFAD mice transplanted with MPO-KO bone marrow cells. Scale bar = 200 μm. Figure 7E is a graph showing quantification of ThioS plaque density. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed Mann-Whitney test. [Figure 8A-8N]Low S100β expression in 5XFAD MPO KO mice. FIG. 8A is a representative image of hippocampal sections stained with DAPI from WT mice transplanted with WT bone marrow cells. FIG. 8B is a representative image of hippocampal sections stained with DAPI from 5XFAD mice transplanted with WT bone marrow cells. FIG. 8C is a representative image of hippocampal sections stained with DAPI from WT mice transplanted with MPO-KO bone marrow cells. FIG. 8D is a representative image of hippocampal sections stained with DAPI from 5XFAD mice transplanted with MPO-KO bone marrow cells. FIG. 8E is a representative image of hippocampal sections stained with S100β from WT mice transplanted with WT bone marrow cells. FIG. 8F is a representative image of hippocampal sections stained with S100β from 5XFAD mice transplanted with WT bone marrow cells. FIG. 8G is a representative image of hippocampal sections stained with S100β from WT mice transplanted with MPO-KO bone marrow cells. FIG. 8H is a representative image of hippocampal sections stained with S100β from 5XFAD mice transplanted with MPO-KO bone marrow cells. FIG. 8I is a representative image of hippocampal sections stained with DAPI / S100β from WT mice transplanted with WT bone marrow cells. FIG. 8J is a representative image of hippocampal sections stained with DAPI / S100β from 5XFAD mice transplanted with WT bone marrow cells. FIG. 8K is a representative image of hippocampal sections stained with DAPI / S100β from WT mice transplanted with MPO-KO bone marrow cells. FIG. 8L is a representative image of hippocampal sections stained with DAPI / S100β from 5XFAD mice transplanted with MPO-KO bone marrow cells. FIG. 8M is a graph showing quantification of S100β mean intensity. FIG. 8N is a graph showing S100β mRNA expression analysis of hippocampal samples. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed Mann-Whitney test. [Figure 9A-9E]Low levels of inflammatory markers in 5XFAD MPO KO mice. Figure 9A is a graph showing mRNA expression analysis of IL-1β in hippocampal samples. Figure 9B is a graph showing mRNA expression analysis of CXCL10 in hippocampal samples. Figure 9C is a graph showing mRNA expression analysis of CCL2 in hippocampal samples. Figure 9D is a graph showing mRNA expression analysis of TNFα in hippocampal samples. Figure 9E is a graph showing mRNA expression analysis of VCAM1 in hippocampal samples. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed Mann-Whitney test. [Figure 10A-10C] Low APOE levels in 5XFAD MPO KO mice. Figure 10A is a photograph of a Western blot analysis of hippocampal cell lysates detected with an anti-APOE antibody. Figure 10B is a graph showing the Western blot analysis data expressed as % of each sample relative to the WT-WT group mean. Figure 10C is a graph showing the mRNA expression analysis of APOE in hippocampal samples. Data are means ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed Mann-Whitney test. [Figures 11A-11N]Plasmid cloning and lentivirus production. Figure 11A is a FACS analysis of isolated non-transduced Lin- cells after 24 hours. Figure 11B is a FACS analysis of 10 μL of isolated Lin- cells transduced with GFP-encoded particles after 24 hours. Figure 11C is a FACS analysis of isolated Lin- cells transduced with 10 μL of CRISPR / Ca9-encoded lentiviral particles targeting gRNA2 (SEQ ID NO: 5) in the MPO gene after 24 hours. Figure 11D is a FACS analysis of isolated Lin- cells transduced with 10 μL of CRISPR / Ca9-encoded lentiviral particles targeting gRNA6 (SEQ ID NO: 6) in the MPO gene after 24 hours. Figure 11E is a FACS analysis of isolated non-transduced Lin- cells after 48 hours. Figure 11F is a FACS analysis of 2 μL of isolated Lin- cells transduced with GFP-encoded particles after 48 hours. FIG. 11G is a FACS analysis of isolated Lin-cells transduced with 2 μl of CRISPR / Ca9-encoded lentiviral particles targeting gRNA2 (SEQ ID NO: 5) in the MPO gene after 48 hours. FIG. 11H is a FACS analysis of isolated Lin-cells transduced with 2 μl of CRISPR / Ca9-encoded lentiviral particles targeting gRNA6 (SEQ ID NO: 6) in the MPO gene after 48 hours. FIG. 11I is a FACS analysis of 5 μl of isolated Lin-cells transduced with GFP-encoded particles after 48 hours. FIG. 11J is a FACS analysis of isolated Lin-cells transduced with 5 μl of CRISPR / Ca9-encoded lentiviral particles targeting gRNA2 (SEQ ID NO: 5) in the MPO gene after 48 hours. FIG. 11K is a FACS analysis of isolated Lin-cells transduced with 5 μl of CRISPR / Ca9-encoded lentiviral particles targeting gRNA6 (SEQ ID NO: 6) in the MPO gene after 48 hours. Figure 11L is a FACS analysis of 10 μl of isolated Lin− cells transduced with GFP-encoding particles after 48 hours. Figure 11M is a FACS analysis of isolated Lin− cells transduced with 10 μl of CRISPR / Ca9-encoding lentiviral particles targeting gRNA2 (SEQ ID NO:5) in the MPO gene after 48 hours.FIG. 11N is a FACS analysis of isolated Lin − cells transduced with 10 μl of CRISPR / Ca9-encoding lentiviral particles targeting gRNA6 (SEQ ID NO: 6) in the MPO gene after 48 hours. [Figure 12] T7 analysis of MPO cleavage. Photograph of an agarose gel showing the products of T7 analysis of full-length DNA and cleavage products. The gel shows untreated and sorted or unsorted cells edited with Cas9 and crRNA:tracrRNA for each crRNA used. Lane A: untreated 293 cells, amplified with primers around the H502 locus. Lane B: 293 cells treated with RNP anti-T173. Lane C: 293 cells treated with RNP anti-D260. Lane D: 293 cells treated with RNP anti-H502. Lane E: 293 cells treated with RNP anti-T173, enriched for fluorescently labeled tracrRNA. Lane F: 293 cells treated with RNP anti-D260, enriched for fluorescently labeled tracrRNA. Lane G: 293 cells treated with RNP anti-H502, enriched for fluorescently labeled tracrRNA. Lane H: T7 negative control. Lane I: T7 positive control. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Myeloperoxidase (MPO) is a heme-containing protein that is involved in the host defense mechanism against infection and is mainly located in granules of neutrophils. MPO is involved in various immune-mediated, neurodegenerative and inflammatory diseases.

[0020] MPO RNA is detected only in bone marrow and is the only MPO protein that reaches various target tissues throughout the body. This transcription of the MPO gene in bone marrow is initiated early during the myoblast stage of myeloid cell differentiation and is terminated when myeloid precursors are induced to differentiate.

[0021] The inventors suggest that by specifically affecting the gene expression of MPO in the primitive immature cells of bone marrow, it is possible to modulate MPO expression and subsequent MPO activity, ultimately resulting in neutrophils with regulated MPO (removing / suppressing or establishing / increasing MPO expression and / or activity). The in situ modulation of specific myeloid genes of MPO in immature cells is therefore proposed by the inventors as an effective, selective and precise way to affect MPO expression and subsequent activity in neutrophils and / or macrophages or any other immune system or component-related cells. Interestingly, although several pathologies are associated with the accumulation of MPO in various organs throughout the body, such as the brain, the modulation of MPO described herein is performed by gene editing of the MPO-encoding gene or transcript in undifferentiated BM, cells, and not in the target organ (e.g., the brain or any component thereof). Thus, the methods described herein of MPO protein modulation in neutrophils and / or macrophages of BM cells via in vivo or ex vivo gene editing provide a broad method of modulation that is not limited to a particular target tissue. In other words, by specifically modulating (e.g., depleting) MPO in BM cells, and thus modulating the immune system of a subject, the present invention provides a powerful method of treating disorders that affect other organs or tissues that are not necessarily directly related to the immune system.

[0022] It is further suggested that such methods described herein are advantageous over other methods using MPO protein inhibitors, such as azides, hydrazides and hydroxamic acids, for various reasons. First, substantial regulation of MPO activity using known MPO protein inhibitors requires sustained administration to address the sustained formation of neutrophils and / or macrophages expressing MPO. Second, known MPO protein inhibitors are usually designed to bind to MPO active sites (e.g., hemoglobin binding sites) and thereby affect protein activity, particularly peroxidase activity. Thus, this approach is limited to MPO functions mediated by its active site. This method does not address the regulation of other MPO activities, such as the inhibition of nephosis, which is described in more detail below, or other activities of MPO disclosed in the present invention, particularly activities that are not mediated by the MPO active site. In other words, MPO activities mediated by other MPO sites, other than the binding site, cannot be regulated using known MPO inhibitors. Furthermore, the use of such inhibitors does not prevent the formation of anti-MPO antibodies that can lead to vasculitis in pathologies such as AD.

[0023] Thus, the present disclosure is based on the novel concept of modulating the expression and / or activity of MPO in undifferentiated BM cells, for modulating MPO in a subject in need thereof, and further for the development of compounds that modulate MPO gene expression at the transcriptional site, i.e., in bone marrow and particularly in primitive, immature, undifferentiated bone marrow cells. Thus, by targeted modulation of a subject's immune system by specifically modulating (e.g., ablation) MPO levels, activity or expression, the present invention provides a method of affecting MPO levels and / or activity in other organs or tissues (e.g., the brain) and uses thereof for the effective treatment of disorders directly or indirectly related to MPO expression and / or activity (enhanced, reduced or normal levels). More specifically, by manipulating the immune system of a treated subject in vivo or by replacing said immune system with cells that exhibit regulated MPO expression (e.g., BM cells that differentiate to form neutrophils and / or macrophages), the present invention provides a tool to affect MPO expression and / or activity in other organs and tissues of the treated subject, thereby treating disorders or conditions that may be associated with or affected by MPO expression and / or activity in a different organ or tissue.

[0024] As demonstrated by the present invention, bone marrow cells with regulated MPO expression can serve as an efficient platform for allogeneic or autologous bone marrow transplantation.

[0025] In addition, the compounds and regulated bone marrow cell populations developed herein can be used to treat a variety of conditions directly or indirectly associated with MPO expression and / or activity, such as disorders or conditions associated with low MPO expression and / or activity, conditions associated with high MPO expression and / or activity, or conditions that exhibit normal levels of MPO expression and / or activity but can be affected by increasing or decreasing MPO levels, expression or activity.

[0026] Thus, in a first aspect, the present disclosure provides a method for regulating the expression and / or activity of myeloperoxidase (MPO) in a mammalian subject. More specifically, the method of the present invention may include administering to the subject an effective amount of at least one of (a) at least one gene editing compound capable of and / or adapted to regulate the expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, and (b) an undifferentiated BM cell population exhibiting regulated expression and / or activity of MPO. It is further understood that the method of the present invention further provides an effective amount of at least one of (a) at least one gene editing compound capable of and / or adapted to regulate the expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, and (b) an undifferentiated BM cell population exhibiting regulated expression and / or activity of MPO for use in the method for regulating the expression and / or activity of myeloperoxidase (MPO) in a mammalian subject.

[0027] The present invention provides methods, compositions, cells, kits and systems for regulating the expression and / or activity of MP1.As used herein, myeloperoxidase (MPO) is the most toxic enzyme found in the azurophil granules of neutrophils.MPO utilizes H2O2 to generate hypochlorous acid (HClO) and other reactive moieties, which kill pathogens during infection.

[0028] The MPO gene is located on the long arm of chromosome 17, q12-24, and the primary transcript of this gene consists of 11 introns and 12 exons. Alternative splicing of MPO mRNA gives rise to two transcripts of 3.6 and 2.9 kB. The primary transcript is an 80 kDa precursor protein that undergoes a series of modifications, including signal peptide cleavage, N-linked glycosylation, and limited deglycosylation, to form a catalytically inactive MPO precursor (apoproMPO). In the next step, MPO acquires catalytic activity by incorporation of an iron-heme molecule into the catalytic center. Heme is covalently bound by two ester bonds and a third sulfonium bond that specifically orients one heme molecule into the enzyme pocket, unique for heme-containing enzymes. The unique arrangement of the heme moiety endows MPO with an extremely high oxidative potential, allowing chlorination at physiological pH. Cleavage of proMPO produces a 59 kDa α-subunit and a 13.5 kDa β-subunit, which are covalently linked via a heme moiety. A disulfide bridge links the two heavy-light protomers in the mature 150 kD MPO. MPO expression levels depend on allelic polymorphisms in the promoter region. A G to A substitution at position -463 (G-463A) results in a 25-fold reduction in MPO transcription. This substitution occurs within the Alu receptor response element (AluRRE), a cluster of nuclear receptor binding sites. This substitution alters the consensus sequence for the Sp1 transcription factor, which is essential for enhanced MPO transcription. A G to A substitution that results in reduced MPO transcription is also found at position -129 (G-129A). Neutrophils are the main source of MPO, and MPO accounts for 5% of the dry weight of these cells, making MPO the most abundant protein in neutrophils. MPO is transcribed only in promyelocytes during neutrophil differentiation in bone marrow. MPO expression is induced by G-CSF, which promotes the differentiation of multipotent progenitor cells into granulocytes by regulating the transcription factors C-EBP and PU.1. C-EBP and PU.1 enhance the commitment of granulocyte-macrophage progenitors to neutrophils and macrophages. Neutrophil differentiation results in reduced MPO transcription, which is undetectable in mature cells.

[0029] In promyelocytes, MPO is packaged into azurophil granules together with several other antimicrobial proteins, serine proteases and lysosomal hydrolases. The packaging of proteins in azurophil granules results in the asynchronous formation of a heterogeneous population of azurophil granules. In promyelocytes, at least three classifications of azurophil granules exist. Low electron density nucleated azurophil granules have a uniform MPO distribution, whereas MPO in large spherical granules is detected at the granule periphery.

[0030] In addition, MPO is synthesized by promyelomonocytic cells, where it accounts for 1% of total cellular protein. Monocytes released into the circulation stop synthesizing MPO, which is further downregulated during their differentiation into macrophages.

[0031] In the context of this disclosure, unless otherwise indicated, it is further to be understood that "MPO" encompasses both the MPO gene and the MPO protein. The human MPO gene has a sequence as provided by Accession Number: NC_000017.11. In some further specific embodiments, such a sequence may comprise the nucleic acid sequence represented by SEQ ID NO: 1. In some further specific embodiments, the human MPO protein is represented by Accession Number: NP_000241. In some further specific embodiments, the MPO protein may comprise the amino acid sequence represented by SEQ ID NO: 2. In some further specific embodiments, the invention further provides a mouse MPO coding sequence as provided by Accession Number: NC_000077, which may comprise the nucleic acid sequence represented by SEQ ID NO: 15. In some further embodiments, the mouse MPO protein is represented by Accession Number: NP_034954. In some further embodiments, the mouse MPO protein may comprise the amino acid sequence represented by SEQ ID NO: 16.

[0032] The methods of the present invention are based on modulating MPO levels and / or activity in a subject in need thereof by providing a gene editing system (in vivo or ex vivo) that modulates the expression and / or activity of MPO in the subject's undifferentiated BM cells. Alternatively, such modulation may be performed by providing BM cells (particularly obtained from an allogeneic subject) with modulated MPO expression and / or activity.

[0033] As used herein, the term "undifferentiated or immature bone marrow cells" refers to cells in bone marrow that have the capacity to turn into differentiated cell types with specific properties. Bone marrow (BM) is a soft, spongy, gelatinous tissue found in the internal cavities of bones, and plays an important role in the development of cells of the lymphatic and especially blood systems.

[0034] In some embodiments, the undifferentiated BM cells can be hematopoietic stem cells (HSCs). HSCs are primitive immature undifferentiated cells in the BM, capable of self-renewal and differentiation. HSCs divide through myeloid progenitors and lymphoid progenitors into the myeloid and lymphoid lineages of blood cells, respectively, and produce all mature blood cells, including the three types of blood cells found in the circulation: white blood cells (leukocytes), red blood cells (erythrocytes), and platelets (thrombocytes). In some embodiments, the undifferentiated BM cells are progenitor cells. Progenitor cells are the main functional components of bone marrow and include progenitor cells and lymphoid cells that are destined to mature into blood. In some embodiments, the undifferentiated BM cells are common myeloid progenitors (CMPs). CMPs are also designated as myeloid stem cells, and are the first branch of cell differentiation after HSCs. Both myeloid and lymphoid lineages are involved in dendritic cell formation. Myeloid cells include monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, and megakaryocytes to platelets. Lymphoid cells include T cells, B cells, and (natural killer cells).

[0035] HSCs and progenitor cells can be identified or isolated, for example, by using a combination of several different cell surface markers, for example, by the use of flow cytometry. For example, HSCs lack expression of mature blood cell markers. Furthermore, both HSCs and progenitor cells can be identified or isolated, for example, by specific molecules represented as cluster of differentiation (CD).

[0036] More specifically, as used herein, surface clustering refers to a nomenclature protocol used to identify and examine surface molecules that provide targets for immunophenotyping of cells. CD molecules function as important cellular receptors or ligands for cells.

[0037] In some embodiments, the undifferentiated BM cells are CD34 positive cells (CD34 + Cluster of differentiation 34 (CD34) is a transmembrane phosphoglycoprotein present on hematopoietic stem cells as a cell surface glycoprotein and is associated with the selection and enrichment of hematopoietic stem cells for bone marrow transplantation. In addition, CD34 may function as a cell-cell adhesion molecule and mediate the binding of hematopoietic stem cells to bone marrow extracellular matrix or direct binding to stromal cells. In some embodiments, undifferentiated BM cells may also be characterized as CD38 positive cells (CD38 + Cluster of differentiation 38 (CD38), also known as cyclic ADP-ribose hydrolase, is a glycoprotein found on the surface of many immune cells and has been used as a prognostic marker for leukemia.

[0038] In some embodiments, the undifferentiated BM cells may be HSCs or progenitor cells. In some embodiments, the undifferentiated BM cells may include any combination of HSCs and progenitor cells. In some embodiments, the undifferentiated BM cells may include any combination of HSCs and CMPs. Furthermore, in some embodiments, the methods and compositions of the present invention include CD34 BM cells that can mature into neutrophils. +In some embodiments, the methods and compositions of the present invention may regulate MPO expression, levels and / or activity in CD34 cells that can mature into macrophages. + It should be appreciated that in some embodiments, the methods and compositions of the present invention provide for modulation of macrophage and / or neutrophil activity and function.

[0039] In the present disclosure, a mammalian subject may be administered a gene editing system that can modulate MPO expression and / or activity in BM cells, thereby providing in vivo modulation of MPO, or alternatively or additionally, cells that exhibit altered MPO expression or activity, thereby providing ex vivo modulation. It should be noted that the present invention further encompasses MPO modulation in a subject, including in vivo and ex vivo approaches and any combination thereof. Such administration results in modulation of MPO expression and / or activity in the subject. As used herein, a gene editing compound refers to a compound that can modulate at least a single gene in the body. The term "modulation" encompasses any change or modification in at least one gene in the body, such as an increase or decrease in expression and / or activity, compared to a control or normal or baseline level of expression / activity determined under a particular condition. In some embodiments, the gene editing compound or system administered to the subject, or the undifferentiated BM cell population, may result in suppression or elimination of MPO expression and / or activity in the subject.

[0040] It should be noted that in some alternative embodiments, the gene editing compound / system or undifferentiated BM cell population administered to the subject can establish, strengthen or increase the expression and / or activity of MPO in the subject.Therefore, the targeted manipulation of the subject's immune system achieves the general manipulation of the activity and / or level and expression of MPO in various organs and tissues of the subject.Furthermore, the specific and targeted manipulation of the subject's immune system treats disorders related to MPO.

[0041] In further particular embodiments, at least one gene editing compound or system can be administered to regulate the activity and / or expression of MPO in a subject. Gene editing compounds can regulate the expression and / or activity of MPO by various mechanisms. For example, gene editing compounds regulate MPO expression and / or activity by genetic modification of chromosomal DNA to produce knockdown cells, organisms, etc. In addition, gene editing compounds / systems regulate MPO expression and / or activity by transient / temporary modification (transient knockdown).

[0042] The gene editing compounds or systems used by the methods of the invention (as well as the compositions, cells, kits and uses described below) may in some embodiments be natural compounds (such as enzymes, short DNA or RNA oligonucleotides), synthetic compounds or compounds. In some embodiments, at least one gene editing compound may be an oligonucleotide. Such oligonucleotides may bind to active genes or any transcripts thereof, resulting in reduced expression, for example, by blocking transcription (in the case of gene binding by antisense oligonucleotides), by degradation of mRNA transcripts (e.g., by small interfering RNA (siRNA) or RNase-H dependent antisense), or by blocking nuclease cleavage sites used for mRNA translation, including miRNAs, pre-mRNA splicing sites, or maturation of other functional RNAs (e.g., by morpholino oligos or other RNase-H independent antisense).

[0043] In some further embodiments, the gene editing compound of the present invention may comprise any nucleic acid modifier protein and at least one target recognition sequence. More specifically, and in some further embodiments, the gene editing system applicable in the present invention may comprise at least one nucleic acid modifier protein and at least one target recognition sequence. Such recognition sequence may, in some embodiments, comprise a nucleic acid sequence that specifically directs the modifier protein to a target gene, in particular, the MPO-encoding gene. In some embodiments, the nucleic acid modifier protein may comprise any protein or protein complex that modifies a coding or non-coding nucleic acid sequence. In some still further embodiments, the modification caused by the modifier protein may modulate the expression of an MPO protein product that is encoded or controlled by the target nucleic acid sequence of such modifier. Alternatively, the modifier applicable in the present invention may modulate the stability or activity of such MPO. Such modifications include nucleolytic cleavage (e.g., by nucleases), methylation, demethylation, activation or repression of protein expression (of coding or non-coding sequences, such as regulatory sequences), and the like. Thus, in some embodiments, the nucleic acid modifier can be at least one of a nuclease, a methyltransferase, a demethylase, a transcription factor, a transcriptional repressor, any fusion protein thereof, and any complex comprising at least one of the aforementioned modifiers, and any combination thereof.

[0044] In some embodiments, the modifier protein of the present invention may comprise at least one nuclease. It should be understood that the term "nuclease" as used herein, in some embodiments, refers to an active nuclease with nucleolytic activity. However, in some embodiments, it should be understood that the term "nuclease" as used herein further encompasses molecules (referred to herein as inactive nucleases) that have the structural characteristics of a nuclease but exhibit reduced, incomplete or no nucleolytic activity on any nucleic acid molecule, particularly DNA or RNA. As used herein, an inactive nuclease further encompasses any fragment, mutant or fusion protein of an inactive nuclease. More specifically, it is a fusion protein of an inactive nuclease with any other protein, for example, a transcription factor or repressor, a methyltransferase, a demethylase, as detailed hereafter.

[0045] More specifically, as used herein, the term "nuclease" refers in some embodiments to an enzyme that exhibits nucleolytic activity, in particular capable of cleaving phosphodiester bonds between nucleic acid (e.g., DNA and / or RNA) monomers. Nucleases variously cause single-stranded and double-stranded breaks in their target molecules. There are two primary classifications based on the locus of activity: exonucleases digest nucleic acids from both ends; endonucleases act on regions in the middle of the target molecule. They are further subclassified as deoxyribonucleases and ribonucleases. The former act on DNA and the latter on RNA. Nucleases must bind to nucleic acids before cleaving the molecule, providing some degree of recognition. Nucleases belong to the esterase subgroup of hydrolases, along with phosphodiesterases, lipases and phosphatases. This group includes exonucleases, which are enzymes that function by cleaving nucleotides one at a time from the end (exo) of a polynucleotide chain. The hydrolysis reaction that cleaves the phosphodiester bond occurs at the 3' or 5' end. Eukaryotes and prokaryotes have three exonucleases involved in the normal turnover of mRNA: 5'→3' exonuclease (Xrn1), which is a dependent decapping protein; 3'→5' exonuclease, an independent protein; and poly(A)-specific 3'→5' exonuclease. Members of this family include exodeoxyribonucleases that produce 5'-phosphomonoesters, exoribonucleases that produce 5'-phosphomonoesters, exoribonucleases that produce 3'-phosphomonoesters, and exonucleases that are active on both ribo- or deoxy-. Members of this family include exonucleases II, III, IV, V, VI, VII, and VIII. As mentioned above, endonucleases are enzymes that cleave phosphodiester bonds within a polynucleotide chain. Some endonucleases, such as deoxyribonuclease I, cleave DNA relatively nonspecifically (regardless of sequence), while many of the so-called restriction endonucleases or restriction enzymes cleave only at very specific nucleotide sequences.

[0046] In some embodiments, the nuclease may be an active enzyme having nucleolytic activity, as specified above, hi some alternative embodiments, the nuclease may be a defective enzyme.

[0047] A defective enzyme (e.g., defective mutant, variant or fragment) can refer to an enzyme that exhibits reduced activity by about 1%, 2%, 3%, 4%, 5% to about 100%, specifically, about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 65% to about 70%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 95% to about 99.9%, and more specifically, about 98% to about 100% reduced activity, as compared to an active nuclease.

[0048] As indicated above, the gene editing system of the present invention further comprises at least one target recognition sequence. As used herein, a "target recognition sequence" is a nucleic acid sequence (RNA or DNA) that directs a nucleic acid modifier protein, e.g., a nuclease, to a specific target location within a nucleic acid sequence. Recognition of a target by a target recognition sequence is, in some embodiments, facilitated by base pairing interactions. These target recognition sequences are particularly important in the case of inducible nucleases. In some embodiments, in the case of a nuclease that exhibits nucleolytic activity, directing the nuclease to a specific site may result in cleavage of a phosphodiester bond between nucleic acid (e.g., DNA and / or RNA) monomers, which in some embodiments results in its specific destruction. Also, in some alternative embodiments, when a non-active nuclease, particularly a fusion protein thereof, is used, the direction of such defective nuclease by the recognition sequence may result in targeted modulation (e.g., activation or repression, methylation or demethylation) of the target nucleic acid sequence targeted by the target. It is noted that the target recognition sequence may comprise from about 10 nucleotides to 70 nucleotides or more. In some further embodiments, the target recognition sequence may include multiple nucleotides, as specified below as spacers. In certain embodiments, the nuclease used by the method of the present invention may be an inducible nuclease. In some other embodiments, the gene editing compound may include a polypeptide, particularly an enzyme. In some embodiments, the gene editing compound may include at least one programmable genetically modified nuclease (PEN) or any variant or protein thereof. As used herein, the term "programmable genetically modified nuclease (PEN)" refers to a synthetic or natural enzyme, also known as "molecular DNA scissors", that is used to replace, remove or modify sequences in a highly targeted manner. PENs target and cleave specific genomic sequences (recognition sequences), such as DNA sequences. At least one PEN may be derived from a natural nuclease or an artificial enzyme, all of which are involved in DNA repair of double-stranded DNA damage and may enable direct genome editing.In some alternative or additional embodiments, the gene editing compound according to the present disclosure also encompasses any nucleic acid molecule comprising a nucleic acid sequence encoding at least one PEN, or any kit, composition or vehicle comprising at least one PEN or any nucleic acid sequence encoding a PEN. In some embodiments, the at least one PEN can be at least one of a meganuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector-based nuclease (TALEN), a Fok1 nuclease, or a clustered regularly interspaced short palindromic repeats (CRISPR / Cas) system, or any fusion protein or chimera thereof.

[0049] In some embodiments, at least one PEN can be a meganuclease. Meganucleases are endodeoxyribonucleases characterized by a large recognition site (a double-stranded DNA sequence of 12-40 base pairs), such that this site usually occurs only once in any given genome. Meganucleases are specific natural restriction enzymes, in particular including the LAGLIDADG family of homing endonucleases, found primarily in the mitochondria and chloroplasts of eukaryotic unicellular organisms. In some embodiments, at least one PEN can be a megaTAL. MegaTALs are fusion proteins that combine a homing endonuclease, such as the LAGLIDADG family, with the modular DNA-binding domain of a TALEN.

[0050] In certain embodiments, the nuclease used by the methods and compositions of the present invention can be an inducible nuclease. Also, in some specific embodiments, the nuclease is at least one transcription activator-like effector nuclease (TALEN). TALENs are restriction enzymes that can be genetically modified to cleave specific sequences of DNA. They are created by fusing a TAL effector DNA binding domain to the DNA cleavage domain of a nuclease. More specifically, TALENs are artificial endonucleases designed by fusing the DNA binding domain (multiple nearly identical repeats of about 34 amino acids each) obtained from TAL (transcription activator-like) effector (TALE) proteins to the cleavage domain of FokI endonuclease. Each TALE repeat independently recognizes its corresponding nucleotide (nt) base with two variable residues [called repeat variable diresidues (RVD)] so that the repeat linearly represents the nucleotide sequence of the binding site.

[0051] In some further alternative embodiments, the inducible nuclease used by the methods and compositions of the present invention can be at least one zinc finger nuclease (ZFN). ZFN is an artificial restriction enzyme generated by fusing a zinc finger DNA binding domain to a DNA cleavage domain. The zinc finger domain can be genetically engineered to target a specific desired DNA sequence, which allows the zinc finger nuclease to target a unique sequence within a complex genome. More specifically, ZFN is an artificial endonuclease generated by combining a small zinc finger (ZF; about 30 amino acids) DNA binding / recognition domain (Cys2His2) with a type IIS non-specific DNA cleavage domain from FokI restriction enzyme. However, the cleavage activity of FokI endonuclease requires dimerization. Since the ZF module recognizes a 3bp sequence, a prerequisite exists for multiple fingers in each ZFN monomer to recognize and bind to a longer DNA target sequence.

[0052] In some other embodiments, the inducible nuclease used by the methods and compositions of the present invention may be Fok1 nuclease or any fusion protein thereof, as discussed below. The enzyme Fok1 (Fok-1) is naturally found in Flavobacterium oceanocoites and is a bacterial type IIS restriction endonuclease consisting of an N-terminal DNA binding domain and a C-terminal non-specific DNA cleavage domain. In some embodiments of the present invention, Fok1 may be directed to its target (e.g., at the MPO gene) by a target recognition sequence. Such target recognition sequences, as discussed above, may in some embodiments be nucleic acid sequences that specifically direct Fok1 to the target site. The recognition sequence may be directly or indirectly (i.e., via a linker) attached to Fok1. Thus, when the protein is bound to double-stranded DNA via the target recognition sequence, the DNA cleavage domain is activated and cleaves 9 nucleotides downstream of the first strand and 13 nucleotides upstream of the second strand of the nearest nucleotide of the target site. More specifically, when Fok1 is used as the nucleic acid modifier protein of the present invention, specific targeting to the MPO coding sequence can be achieved by directly or indirectly (e.g., via a linker) linking at least one target recognition sequence to Fok1, which can be at least one nucleic acid sequence (e.g., RNA or DNA) that specifically hybridizes to the target site. Furthermore, in some embodiments, at least one PEN can be a clustered regularly interspaced short palindromic repeats (CRISPR / Cas) system. In some embodiments, the methods described herein use a CRISPR system as a PEN for regulating MPO expression and / or activity. The clustered regularly interspaced short palindromic repeats (CRISPR) system is a bacterial immune system modified for genome engineering.

[0053] In some specific embodiments, the methods described herein may use a PEN that may include at least one clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR binding (cas) protein system. Thus, in more specific embodiments, the methods of the present invention may include administering to the subject an effective amount of at least one of (a) at least one CRISPR / cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one guide RNA (gRNA) targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA. The methods of the present invention may optionally include the use of any kit, composition, or vehicle that includes at least one of (a) and (b).

[0054] It should be noted that when both sequences of the CRISPR / Cas system of the present invention are provided as nucleic acid sequences, they may be provided separately as two or more nucleic acid molecules, or together as a single nucleic acid molecule comprising both sequences, in particular a construct, vector or any vehicle comprising both (a) and (b).

[0055] As indicated above, the present invention may, in some embodiments thereof, provide sequences of gene editing systems (e.g., gRNA and / or Cas proteins), or at least parts thereof, as nucleic acid sequences or molecules. The terms "nucleic acid", "nucleic acid sequence", or "polynucleotide" and "nucleic acid molecule" refer to polymers of nucleotides, including, but not limited to, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), DNA / RNA hybrids containing regularly and / or irregularly alternating deoxyribosyl and ribosyl moieties (i.e., alternating nucleotide units have -OH, then -H, then -OH, then -H, etc., at the 2' position of the sugar moiety), and modifications of these polynucleotides, including attachment of various substances or moieties to the nucleotide units at any position. The term should also be understood to include single-stranded (such as sense or antisense) and double-stranded polynucleotides, as equivalents, analogs of RNA or DNA made from nucleotide analogs and applicable to the described embodiments. The preparation of nucleic acids is well known in the art. It should be noted that the nucleic acid molecules (or polynucleotides) according to the present invention can be produced by chemical synthesis or by recombinant DNA technology. Methods for producing nucleic acid molecules are well known in the art. The nucleic acids according to the present invention can be of variable nucleotide length. For example, in some embodiments, the nucleic acid molecules according to the present invention comprise 1-100 nucleotides, such as about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides. In other embodiments, the nucleic acid molecules according to the present invention comprise 100-1,000 nucleotides, such as about 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides. In further embodiments, the nucleic acid molecules according to the present invention comprise about 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000 or 10,000 nucleotides. In still further embodiments, a nucleic acid molecule according to the invention comprises more than 10,000 nucleotides, such as 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000 or 100,000 nucleotides.

[0056] As mentioned above, the present invention may provide a nucleic acid molecule contained in a construct, vector or any other vehicle. As used herein, a vector is a nucleic acid molecule of a specific sequence that is introduced into a host cell, thereby producing a transformed host cell. A vector may contain a nucleic acid sequence, such as an origin of replication, that allows it to replicate in a host cell. A vector may also contain other gene sequences known in the art, including one or more selectable marker genes and a promoter sequence that induces nucleic acid expression. Many vectors useful for transferring nucleic acids into target cells, particularly BM cells, such as plasmids, cosmids, minicircles, phages, viruses (discussed in detail below), may be applicable in the present invention. The vectors containing the nucleic acid may be maintained episomally, for example, as plasmids, minicircle DNA, transposons, viruses such as cytomegalovirus, adenovirus, or they may be integrated into the target cell genome by homologous recombination or random integration (e.g., retrovirus-derived vectors such as lentivirus, AAV, MMLV, HIV-1, ALV, etc.). More specifically, in some embodiments, the vector may be a viral vector. In certain embodiments, such a viral vector can be any one of a recombinant adeno-associated vector (rAAV), a single-stranded AAV (ssAAV), a self-complementary fAAV (scAAV), a simian vacuolar virus 40 (SV40) vector, an adenovirus vector, a helper-dependent adenovirus, a retrovirus vector, and a lentivirus vector.

[0057] More specifically, as indicated above, in some embodiments, viral vectors are applicable in the present invention. The term "viral vector" refers to a replication-competent or replication-deficient viral particle capable of transferring a nucleic acid molecule into a host.

[0058] The term "virus" refers to any intracellular obligate parasite with no machinery for protein synthesis or energy generation. Viral genomes can be RNA or DNA enveloped in a lipid membrane protein coat structure. Examples of viruses useful in the practice of the present invention include Baculoviridae, Parvoviridae, Picornoviridae, Herpesviridae, Poxviridae, Adenoviridae, and Picotomaviridae. The term recombinant virus includes chimeric (or multimeric) viruses, i.e., vectors constructed with complementary coding sequences from two or more viral subtypes.

[0059] Also, in some specific embodiments, lentiviral vectors may be used in the present invention. Lentiviral vectors are derived from lentiviruses, a subclass of retroviruses. Commonly used retroviral vectors are "defective", i.e., unable to produce viral proteins necessary for productive infection. Rather, vector replication requires propagation in a packaging cell line. To generate viral particles containing the nucleic acid sequence of the present invention, the retroviral nucleic acid containing the nucleic acid is packaged into a viral capsid by the packaging cell line. Different packaging cell lines provide envelope proteins (homotropic, amphotropic or xenotropic) that are incorporated into different capsids, which determine the specificity for the cells (homotropic for mouse and rat; amphotropic for most mammalian cell types, including human, dog and mouse; and xenotropic for most mammalian cell types, except mouse cells, except mouse cells). Appropriate packaging cell lines may be used to ensure that the packaged viral particles target the cells. Methods for introducing retroviral vectors containing a nucleic acid sequence of the present invention into packaging cell lines, and for harvesting viral particles produced by the packaging lines, are well known in the art.

[0060] In still further embodiments, the viral vector applicable in the present invention may be an adeno-associated virus (AAV). The term "adenovirus" is synonymous with the term "adenovirus vector". AAV is a small (about 20 nm) single-stranded DNA virus with a protein capsule belonging to the Parvoviridae family, and in particular refers to viruses of the Adenovirus genus. The term Adenoviridae collectively refers to animal adenoviruses of the Mastadenovirus genus, including but not limited to human, bovine, equine, canine, porcine, murine and simian Adenovirus subgenera. In particular, human adenoviruses include subgenera A through F as well as the individual serotypes thereof, and the individual serotypes and subgenera A through F include, but are not limited to, human adenovirus types 1, 2, 3, 4, 4a, 5, 6, 7, 8, 9, 10, 11 (Ad IIA and Ad IIP), 12, 13, 14, 15, 16, 17, 18, 19, 19a, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34a, 35, 35p, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 91.

[0061] AAV is often referred to as a dependovirus because it cannot replicate in the absence of helper virus co-infection (usually adenovirus or herpesvirus infection). AAV infection generates only a mild immune response and is considered non-pathogenic, a fact that is also reflected in a lower biosafety level requirement when working with recombinant AAV (rAAV) compared to other commonly used vector systems. Due to its low immunogenicity and absence of cytotoxic response, AAV-based expression systems offer the possibility to express genes of interest for months in quiescent cells.

[0062] The rAAV vector production system usually consists of a DNA-based vector containing the DNA of interest, which is flanked by inverted terminal repeats. Construct size is limited to approximately 4.7-5.0 kb, which corresponds to the length of the wild-type AAV genome. rAAV is produced in cell lines. The expression vector is co-transfected with a helper plasmid that mediates expression of the AAV rep gene, which is important for viral replication, and the cap gene, which encodes the encapsidation protein. Recombinant adeno-associated viral vectors can transduce dividing and non-dividing cells, and different rAAV serotypes can transduce a variety of cell types. These single-stranded DNA viral vectors have high transduction rates and the unique property of stimulating endogenous homologous recombination without disrupting double-stranded DNA in the host genome.

[0063] In some embodiments, the present invention utilizes CRISPR system for specific regulation of MPO gene.As indicated above, the gene editing system of the present invention can be provided as a nucleic acid molecule in a delivery vector or vehicle.However, it should be understood that any gene editing system used can also be administered as a protein or as a ribonucleoprotein complex, as will be discussed below in relation to the specific gene editing system applicable to the present invention.

[0064] As shown above, in some embodiments, the gene editing system applicable to the present invention is a CRISPR-Cas system. CRISPR-Cas systems are classified into two classes. Class 1 system uses a complex of multiple Cas proteins to degrade exogenous nucleic acid. Class 2 system uses a single large Cas protein for the same purpose. More specifically, class 1 can be classified into types I, III, and IV, and class 2 can be classified into types II, V, and VI.

[0065] Thus, in some embodiments, the Cas protein may be at least one member of class 1 and class 2 CRISPR binding systems. In some embodiments, the cas protein may be at least one member of any one of type II, type I, type III, type IV, type V, and type VI CRISPR binding systems. As used herein, CRISPR arrays, also known as SPIDRs (Spacer Interspersed Direct Repeats), constitute a family of DNA loci that are usually specific to a particular bacterial species. CRISPR arrays are a distinct class of interspersed short sequence repeats (SSRs) that were first recognized in Escherichia coli. In the following years, similar CRISPR arrays were found in Mycobacterium tuberculosis, Haloferax mediterranei, Tanocaldococcus yannaschii, Thermotoga maritima, and other bacteria and archaea. It is to be understood that the present invention contemplates the use of any known CRISPR system, in particular any of the CRISPR systems disclosed herein. The CRISPR-Cas system was developed in prokaryotes to protect against phage attack and unwanted plasmid replication by foreign DNA or RNA targeting. The CRISPR-Cas system targets DNA molecules based on short homologous DNA sequences, called spacers, that exist between the repeats. These spacers guide the CRISPR binding (Cas) protein to matching (and / or complementary) sequences, called protospacers, in the foreign DNA, which are then cleaved. Spacers can be rationally designed to target any DNA sequence, for example, the MPO gene sequence. Furthermore, the recognition sequences can be designed to separately recognize and target any desired target.

[0066] In some particular embodiments, the RNA-guided DNA-binding protein nuclease of the system of the present invention can be a CRISPR class 2 system, and in some further particular embodiments, such a class 2 system can be a CRISPR type II system.

[0067] Type II CRISPR-Cas systems include the HNH-type system (Streptococcus-like; also called Nmeni subtype in the case of Neisseria meningitidis serogroup A strain Z2491, or CASS4), in which, in addition to the widely distributed Cas1 and Cas2, a single, very large protein, Cas9, appears to be sufficient for crRNA generation and target DNA cleavage. Cas9 contains at least two nuclease domains, a RuvC-like nuclease domain near the amino terminus and an HNH (or McrA-like) nuclease domain in the middle of the protein, although the function of these domains remains to be determined. However, the HNH nuclease domain is restriction enzyme-rich and has endonuclease activity responsible for target cleavage.

[0068] It is further noted that the type II system comprises at least one of Cas9, Cas1, Cas2, csn2, and Cas4 genes. It is understood that any type II CRISPR-Cas system, particularly any one of type II-A or B, is applicable to the present invention. Thus, in some further and alternative embodiments, the at least one cas gene used in the methods, compositions, cells, kits, uses and systems of the present invention can be at least one cas gene of a type II CRISPR system (type II-A or type II-B). In further specific embodiments, the at least one cas gene of a type II CRISPR system used in the methods and systems of the present invention can be a cas9 gene. It is understood that such systems can further comprise at least one of Cas1, Cas2, csn2, and Cas4 genes. Thus, in some specific embodiments, the Cas protein used by the methods of the present invention can be Cas9 or any fragment, mutant, variant, or derivative thereof.

[0069] Double-stranded DNA (dsDNA) cleavage by Cas9 is a hallmark of the "type II CRISPR-Cas" immune system. The CRISPR-binding protein Cas9 is an RNA-guided DNA endonuclease that uses RNA:DNA complementary to the target site (protospacer). After recognition between Cas9 and the target sequence, cleavage of double-stranded DNA (dsDNA) occurs, generating a double-strand break (DSB).

[0070] The CRISPR type II system used herein requires the inclusion of two essential elements: a "guide" RNA (gRNA) and a non-specific CRISPR binding endonuclease (Cas9). The gRNA is a short synthetic RNA composed of a "scaffold" sequence (also called tracrRNA) required for Cas9 binding and a "spacer" or "targeting" sequence of about 20 nucleotides in length that determines the genomic target to be modified. Guide RNA (gRNA) as used herein refers to a synthetic fusion of the endogenous tracrRNA and a targeting sequence (also called crRNA), providing both the scaffold / binding capacity for the Cas9 nuclease and targeting specificity. It is also referred to as "single guide RNA" or "sgRNA".

[0071] CRISPR was originally employed to "knock out" target genes in various cell types and organisms, but modifications to the Cas9 enzyme have expanded the applications of CRISPR to "knock in" target genes, selectively activating or suppressing target genes, purifying specific regions of DNA, and even imaging DNA in live cells using fluorescence microscopy. Furthermore, the ease of gRNA generation makes CRISPR one of the most scalable genome editing techniques and has recently been utilized for genome-wide screening. In most CRISPR systems, the target sequence in the genome to be edited must be present immediately upstream of a protospacer adjacent motif (PAM). In other systems, such as type III, the PAM is not present.

[0072] In CRISPR systems based on PAM sequence recognition, such as CRISPR type II, the PAM is absolutely necessary for target binding, and its exact sequence depends on the species of Cas9 (5'NGG3' in the case of Streptococcus pyogenes Cas9). In some embodiments, the nucleic acid modifier protein used in the methods of the present invention is Cas9. In certain embodiments, Cas9 from Streptococcus pyogenes may be used in the methods and systems of the present invention. However, it should be understood that any known Cas9 may be applicable. Non-limiting examples of Cas9 useful in the present disclosure include, but are not limited to, Streptococcus pyogenes (SP) (also referred to herein as SpCas9), Staphylococcus aureus (SA) (also referred to herein as SaCas9), Neisseria meningitidis (NM) (also referred to herein as NmCas9), Streptococcus thermophilus (ST) (also referred to herein as StCas9), and Treponema denticola (TD) (also referred to as TdCas9). Furthermore, in some embodiments of the present disclosure, the endonuclease is selected from methanogenic Archaea C7, Corynebacterium diphtheriae, Corynebacterium YS-314, Glutamate-producing Bacillus subtilis (ATCC13032), Glutamate-producing Bacillus subtilis R, Corynebacterium kloppenstettii (DSM44385), Mycobacterium abscessus (ATCC19977), Nocardia farcinica IFM10152, Rhodococcus erythropolis PR4, Rhodococcus josti, RFIA1, Rhodococcus opacus B4 (uid36573), Acidothermus cellulolyticus 11B, Arthrobacter chlorophenolicus A6, Cluyvera flavida (DSM17836), Thermomonospora curverta (DSM43183), Bifidobacterium dentium Bd1, Bifidobacterium longum DJO10A, Slacchia heliotrinireducens (DSM20476), Persephonera marina EX H1, Bacteroides fragilis NCTC9434, Capnocytophaga okratiae (DSM7271), Flavobacterium psychrophilum JIP02 86, Akkermansia muciniphila (ATCCBAA835), Roseiflexus castenholzii (DSM13941), Roseiflexus RS1, Synechocystis PCC6803, Yersinia minutum Pei191, Uncultured Termite Group 1 Bacterial Phylotype Rs D17, Fibrobacter succinogenes S85, Bacillus cereus (ATCC10987), Listeria innocua, Lactobacillus casei, Lactobacillus rhamnosus rhamnosus GG, Lactobacillus salivarius UCC118, Streptococcus agalactiae-5-A909, Streptococcus agalactiae NEM316, Streptococcus agalactiae 2603, Streptococcus dysgatetiae subsp. equisimilis GGS124, Streptococcus equi subsp. zooepidemicus MGCS10565, Streptococcus gallolyticus UCN34 (uid46061), Streptococcus gordonii Challis subst CH1, Streptococcus mutans NN2025 (uid46353), Streptococcus mutans, Streptococcus pyogenes M1 GAS, Streptococcus pyogenes MGAS5005, Streptococcus pyogenes MGAS2096, Streptococcus pyogenes MGAS9429, Streptococcus pyogenes MGAS10270, Streptococcus pyogenes MGAS6180, Streptococcus pyogenes MGAS315, Streptococcus pyogenes SSI-1, Streptococcus pyogenes MGAS10750, Streptococcus pyogenes NZ131, Streptococcus thermophilus CNRZ1066, Streptococcus thermophilus LMD-9, Streptococcus thermophilus LMG18311, Clostridium botulinum A3 Loch Maree, Clostridium botulinum B Eklund 17B, Clostridium botulinum Ba4 657, Clostridium botulinum FLangeland, Clostridium cellulolyticum H10, Finegordia magna (ATCC29328), Eubacterium rectale (ATCC33656), Mycoplasma gallisepticum, Mycoplasma mobile 163K, Mycoplasma penetrans, Mycoplasma synoviae 53, Streptobacillus moniliformis (DSM12112), Bradyrhizobium BTAil, Nitrobacter hamburgensis X14, Rhodopseudomonas palustris BisB18, Rhodopseudomonas palustris BisB5, Parvibacrum labmentivorans DS-1, Dinostheobacter shibae DFL12, Gluconacetobacter diazotrophicus Pal 5 FAPERJ, Gluconacetobacter diazotrophicus Pal 5 JGI, Azospirillum B510 (uid46085), Rhodospirillum rubrum (ATCC11170), Diaphorobacter TPSY (uid29975), Ferminaephorobacter eiseniae EF01-2, Neisseria meningitidis 053442, Neisseria meningitidis alpha 14, Neisseria meningitidis Z2491, Desulfovibrio surexigens DSM 2638, Campylobacter jejuni doylei 26997, Campylobacter jejuni 81116, Campylobacter jejuni, Campylobacter lari RM2100, Helicobacter hepaticus, Vorrinella succinogenes, Tormonas auensis DSM 9187, Pseudoalteromonas atlantica T6c, Schwanella pareana (ATCC 700345), Legionella pneumophila Paris, A. The protein may be a Cas9, Cas13, Cas6, Cpf1, CMS1 protein derived from or expressed by Cutinobacillus succinogenes 130Z, Schwanella pareana, Francisella tularensis subsp. novicida U112, Francisella tularensis subsp. halactica, Francisella tularensis FSC198, Francisella tularensis subsp. tularensis, Francisella tularensis WY963418, or Treponema denticola (ATCC35405), or any variant thereof.

[0073] In some specific, non-limiting embodiments, the Cas9 of S. pyogenes M1 GAS, in particular the protein id: AAK339636.1, may be applicable in the methods, compositions, cells, kits, uses and systems of the present invention. In some embodiments, the Cas9 protein may be encoded by the nucleic acid sequence represented by SEQ ID NO:3. In further specific embodiments, the Cas9 protein may comprise the amino acid sequence represented by SEQ ID NO:4, or a derivative, mutant, variant or any fusion protein thereof. Once expressed, the Cas9 protein and gRNA provided by the methods and compositions of the present invention form a riboprotein complex through the interaction between the gRNA "scaffold" domain and a surface-exposed positively charged groove on Cas9. Upon gRNA binding, Cas9 undergoes a conformational change that changes it from an inactive non-DNA binding structure to an active DNA binding structure. Importantly, the "spacer" sequence of the gRNA is left free to interact with the target DNA. The Cas9-gRNA complex binds any target genomic sequence with a PAM, but the degree to which the gRNA spacer matches the target DNA determines whether Cas9 will cleave or, in the case of a fusion protein containing a catalytically inactive Cas9, perform some other operation. Also, in some specific embodiments, base editor enzymes may be used with the compositions and methods of the present invention. More specifically, Cas9-based base editors utilize catalytically inactive Cas9 fused to enzymes, particularly synthetic and non-natural enzymes, that catalyze specific nucleotide substitutions. Known base editors can substitute C to T, A to G, T to C, and G to A. "Base editing" enzymes allow the direct irreversible conversion of one target DNA base to another in a programmable manner, without the need for cleavage of the dsDNA backbone or a donor template. More specifically, these chimeric enzymes (also referred to herein as fusion proteins) are based on the fusion of CRISPR / Cas9 with a cytidine deaminase enzyme that retains the ability to be targeted by guide RNA but cannot induce dsDNA breaks. Thus, these enzymes mediate the direct conversion of cytidine to uridine, thereby performing a C→T (or G→A) substitution.Furthermore, once the Cas9-gRNA complex binds the putative DNA target, a "seed" sequence at the 3' end of the gRNA targeting sequence begins annealing to the target DNA, and if the seed and target DNA sequences match, the gRNA continues annealing to the target DNA in the 3' to 5' direction.

[0074] Cas9 will only cleave the target if there is sufficient homology between the gRNA spacer and the target sequence. Furthermore, the Cas9 nuclease has two functional endonuclease domains: RuvC and HNH. Upon target binding, Cas9 undergoes a second conformational change that positions the nuclease domains to cleave the opposite strand of the target DNA. The end result of Cas9-mediated DNA cleavage is a double-strand break (DSB) in the target DNA that occurs approximately 3-4 nucleotides upstream of the PAM sequence.

[0075] The resulting DSBs can then be repaired by one of two common repair pathways, the efficient but error-prone non-homologous end joining (NHEJ) pathway and the less efficient but high-fidelity homology-directed repair (HDR) pathway. Programmable gene-modified nuclease (PEN) strategies for genome editing can be based on cellular activation of the HDR mechanism (knock-in systems) or the NHEJ mechanism (knock-out systems) following specific double-stranded DNA breaks.

[0076] In some specific embodiments, the targeted gene that is knocked out, particularly the MPO gene, is repaired by the NHEJ pathway, which in most cases results in the dysfunction of the targeted gene (deletion / insertion / nonsense mutation, etc.). As discussed above, Cas9 creates double-strand breaks (DSBs) through the combined activity of two nuclease domains, RuvC and HNH. The exact amino acid residues in each nuclease domain that are important for endonuclease activity are known (D10A in HNH and H840A in RuvC for S. pyogenes Cas9), and modified versions of the Cas9 enzyme (called "Cas9 nickase") that contain only one active catalytic domain have been generated. Although Cas9 nickase still specifically binds DNA based on gRNA, the nickase can only cut one of the DNA strands, resulting in a "nick", or single-strand break, rather than a DSB. DNA nicks are rapidly repaired by HDR (homologous recombination repair) using the intact complementary DNA strand as a template. Thus, two nickases targeting opposite strands are required to generate DSBs in the target DNA (often referred to as "double nick" or "dual nickase" CRISPR system). This requirement dramatically increases target specificity. The reason is that it is unlikely that two off-target nicks will be generated within close enough range to cause a DSB. Thus, it should be understood that the present invention further encompasses the use of any mutant, variant or derivative of Cas9, including the double nickase approach to generate double nick-induced DSBs, to increase specificity and reduce off-target effects. Thus, it should be understood that the present invention further encompasses the use of the double nickase approach to generate double nick-induced DSBs in the methods, cells and compositions of the present invention to increase specificity and reduce off-target effects. A specific example of increasing specificity is the use of a nuclease such as Fok1 fused to dCas9, which acts as a linker to the targeting gRNA.More specifically, a well-characterized dimerization-dependent FokI nuclease domain is fused to an RNA-guided catalytically inactive Cas9 (dCas9) protein, thereby providing enhanced specificity due to the dimerization required for Fok1 nuclease activity. In yet another embodiment, the invention further encompasses the option of providing a pre-crRNA that can be processed into several final gRNA products that can target the same or different targets, particularly the MPO gene. Also, in some more specific embodiments, the crRNA contained within the gRNA of the invention can be a single-stranded ribonucleic acid (ssRNA) sequence complementary to the target genomic DNA sequence. In some specific embodiments, the target genomic DNA sequence within the MPO gene can be located immediately and further upstream of the protospacer adjacent motif (PAM).

[0077] In some embodiments, the gRNA or crRNA used by the methods, compositions, cells, kits, uses and systems of the present invention may target a protospacer comprising a nucleic acid sequence represented by any one of SEQ ID NOs: 43, 44, 45, 46, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 and 106 of the human MPO gene, or a fragment of any of them. In some further embodiments, the gRNA used by the methods, compositions, cells, kits, uses and systems of the present invention may target a protospacer comprising a nucleic acid sequence represented by any one of SEQ ID NOs: 5, 6, 8, 9, 10, 11, 12, 13, 14 of the human MPO gene, or a fragment of any of them. Still further, in some embodiments, the gRNA used in the methods of the present invention may target a protospacer comprising a nucleic acid sequence corresponding to the MPO protein, in particular the human MPO gene and various sites in the MPO gene that encode various domains in the protein.

[0078] In some specific embodiments, targeting specific sites in the MPO gene may result in knockout of the entire MPO molecule or modulate its function and activity, particularly when HDR is used to replace specific residues or sequences in the MPO gene. In some embodiments, the gRNA used in the methods of the invention may target a protospacer that includes a nucleic acid sequence that corresponds to the active site of MPO. In more specific embodiments, the gRNA of the invention may target a protospacer located in a different domain of MPO, particularly when induced to modulate human MPO protein, levels, expression and / or activity. In some specific embodiments, the human MPO includes an amino acid sequence represented by SEQ ID NO:2. Such domains or sequences may include domains or sequences required for protomer biosynthesis and processing, domains or specific residues that mimic human MPO defects, domains or sequences required for protomer heme binding, and domains or sequences required for proper protein glycosylation. In more specific embodiments, the gRNA used in the methods of the invention may target a protospacer that includes a nucleic acid sequence that encodes a protospacer encompassed by a domain or residues required for protomer biosynthesis and processing. Such sequences may encode domains that include residues or sequences present between residues 120-190 or / and residues 320-380 of MPO, particularly the human MPO amino acid sequence depicted in SEQ ID NO:2. gRNAs targeting any protospacer contained within such domains or sequences that encode such residues will thus result in a conformational change in the protein or an alteration in protomer biosynthesis and processing. Additionally, in some embodiments, gRNAs used in the methods of the invention may target protospacers encompassed by the domain or protospacers that include nucleic acid sequences that encode residues that mimic the human MPO deletion substitution. Such protospacers may be located within the nucleic acid sequence encoding residues 150-260 of human MPO depicted in SEQ ID NO:2 and / or residues 480-580 of human MPO depicted in SEQ ID NO:2.In some further embodiments, the gRNA used in the methods of the invention may target a protospacer encompassed by a domain or a protospacer that includes a nucleic acid sequence that encodes residues required for protomer heme binding. In some specific embodiments, such a protospacer may be located within a nucleic acid sequence encoding residues 250-270 and / or residues 390-510 of human MPO as depicted in SEQ ID NO:2. In some further embodiments, the gRNA used in the methods of the invention may target a protospacer encompassed by a domain or a protospacer that includes a nucleic acid sequence that encodes residues required for proper protein glycosylation. Such a protospacer may be located within a nucleic acid sequence encoding residues 300-360 of human MPO as depicted in SEQ ID NO:2. In some specific embodiments, the gRNA or crRNA used in the methods of the invention targets a specific protospacer in the human MPO gene. Additional target sites within the human MPO gene that may be targeted with the methods, compositions, and kits of the invention may include residues C167, C180, C319, C158, R128, N355, T173, M251, R569, R499, G501, Q257, D260, M409, E408, H261, H502, and N355 of human MPO, as represented by SEQ ID NO: 2. It is noted that the invention encompasses the use of any one of these residues as a target as discussed herein. In some further specific embodiments, the crRNA (gRNA) used as a target recognition sequence in the present invention may comprise a nucleic acid sequence represented by any one of SEQ ID NO: 33 (herein referred to as T173), SEQ ID NO: 34 (herein referred to as D260), SEQ ID NO: 35 (herein referred to as H502), and SEQ ID NO: 42 (herein referred to as C319) that targets the corresponding target protospacer in human MPO. In some embodiments, the crRNA sequence of SEQ ID NO: 33 of the present invention may target a sequence comprising the sequence TGCACATCCCGGTGATGGTG (also represented as SEQ ID NO: 43).In some further embodiments, the crRNA sequence of SEQ ID NO: 34 of the present invention may target a sequence comprising the sequence CAGGGGTGAAGTCGAGGTCG (also represented as SEQ ID NO: 44). In some further embodiments, the crRNA sequence of SEQ ID NO: 35 of the present invention may target a sequence comprising the sequence GGATGAGGGTGTGGCCGTAG (also represented as SEQ ID NO: 45). In some further embodiments, the crRNA sequence of SEQ ID NO: 42 of the present invention may target a sequence comprising the sequence GGATGGTGATGTTGCTCCCGGGG (also represented as SEQ ID NO: 46). In some further embodiments, the crRNA (gRNA) used as a target recognition sequence according to the present invention may comprise a nucleic acid sequence represented by any one of 47, 50, 55, 60, 63, 66, 71, 74, 77, 80, 85, 88 and 91. In some further embodiments, these gRNAs target a protospacer within the human MPO nucleic acid sequence. In more specific embodiments, these protospacers comprise the nucleic acid sequences represented by SEQ ID NOs: 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, and 106, respectively.

[0079] In some other specific embodiments, the gRNA or crRNA used in the present invention targets a specific protospacer in the mouse MPO gene. In some embodiments, the gRNA sequence of the present invention may target a protospacer sequence comprising the sequence CCCCCAACGATCAGCTGACA (also represented as SEQ ID NO: 5). In some embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence CAGCGGGGTGTACGGCAGCG (also represented as SEQ ID NO: 6). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence GCACTCATGTTCATGCAGTG (also represented as SEQ ID NO: 8). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence TGCGATACTTGTCATTCGGT (also represented as SEQ ID NO: 9). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence AGTAAAACAGGAGCTCCGTG (also represented as SEQ ID NO: 10). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence ACGCTTCCAAGACAATGGCA (also represented as SEQ ID NO: 11). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence ACGCCATCTTCATACTCTGC (also represented as SEQ ID NO: 12). In some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence ATCAAGCGGAGCCTCCAAAG (also represented as SEQ ID NO: 13). And in some further embodiments, the gRNA sequence of the present invention may target a sequence comprising the sequence AGAGTACCTGTAACATTGAA (also represented as SEQ ID NO: 14). In some embodiments, the gRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 that targets the above-defined protospacer sequence of mouse MPO.In some further embodiments, the crRNA used as a target recognition sequence according to the present invention may comprise a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, and SEQ ID NO:47, 50, 55, 60, 63, 66, 71, 74, 77, 80, 85, 88 and 91.

[0080] As shown herein, the gRNA transcribed by the transgene of the present invention may be at least partially complementary to any protospacer in the target genomic DNA, particularly the MPO gene. In certain embodiments, "complementarity" refers to the association between two structures, each in a lock-and-key fashion. In nature, complementarity is a fundamental principle of DNA replication and transcription, as it is a property shared between two DNA or RNA sequences, such that when they are aligned antiparallel to each other, the nucleotide bases at each position in those sequences are complementary (e.g., A and T or U, C and G). Also, in some further embodiments, the gRNA or crRNA used in the methods of the present invention may comprise at least a portion of the nucleic acid sequence of the target protospacer.

[0081] As noted above, in some specific embodiments, the genomic DNA sequence targeted by the gRNA of the present system may be located immediately upstream of the PAM sequence.

[0082] In some embodiments, the methods, compositions, cells, kits, uses and systems of the invention may comprise several gRNAs, in particular two or more gRNAs. Thus, in some embodiments, the polynucleotide encoding the gRNA of the invention comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 , 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more, in particular, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 or more spacers. That is, in some embodiments, the gRNA or crRNA coding sequence may encode 1 to 200 or more of the same or different gRNAs that target at least two or more different positions on the MPO coding sequence. It should be further understood that the spacers of the nucleic acid sequence encoding the gRNA of the present invention can be the same or different spacers. In further embodiments, these spacers can target the same or different target protospacers within the MPO gene.In some other embodiments, such a spacer is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 120, 121, 122, 1 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more target protospacers may be targeted. These target sequences may be derived from a single region or portion of the MPO gene or may be derived from several target regions or portions of the MPO gene or coding sequence.

[0083] As used herein, the term "spacer" refers to a non-repetitive or repetitive spacer sequence designed to target a specific sequence. In some specific embodiments, the spacer may comprise about 15 to about 50 nucleotides, particularly about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more nucleotides. More specifically, the spacer may comprise 20 to 35 nucleotides.

[0084] In general, the guide or targeting RNA encoded by the CRISPR system of the present invention may include CRISPR RNA (crRNA) and transactivating RNA (tracrRNA). However, it should be noted that in some specific CRISPR systems, such as Cpf1-based CRISPR-Cas system and CRISPR types I-E, the guide RNA does not include tracrRNA. The sequence of the targeting RNA encoded by the CRISPR spacer is not particularly limited, other than the requirement that it be directed (i.e., have a segment that is identical or complementary to) a target sequence (also referred to herein as a "protospacer") in the MPO gene. Such a protospacer comprises a nucleic acid sequence that has sufficient complementarity to the targeting RNA encoded by the CRISPR spacer contained within the nucleic acid sequence encoding the gRNA of the methods, compositions, cells, kits, uses, and systems provided by the present invention. Thus, in some embodiments, the encoded gRNA or crRNA comprises a sequence that is at least partially identical to the nucleic acid sequence of the targeting protospacer. In some other embodiments, the RNA-guided DNA-binding protein nuclease of the system of the invention may be any one of the newly identified clustered regularly interspaced short palindromic repeats (CRISPR) systems. It is understood that the present invention provides Cas9, particularly any fragment, derivative, or variant of Cas9, including the amino acid sequence depicted in SEQ ID NO: 4, or any fragment, variant, derivative, and mutant thereof, or any chimeric or fusion protein thereof. It is understood that the methods, compositions, cells, kits, and systems of the present invention, in some embodiments thereof, provide Cas proteins, particularly Cas9 proteins, as gene editing systems. It is noted that an "amino acid sequence" or "peptide sequence" refers to the order in which amino acid residues linked by peptide bonds are located in the chain of peptides and proteins. The sequence is usually reported from the free amino group-containing N-terminus to the amide-containing C-terminus.When an amino acid sequence represents the primary structure of a protein, it is often called a peptide, a protein sequence, but a distinction must be made between the terms "amino acid sequence" or "peptide sequence" and "protein", since a protein is defined as an amino acid sequence folded into a specific three-dimensional arrangement and is usually subject to post-translational modifications such as phosphorylation, acetylation, glycosylation, manosylation, amidation, carboxylation, sulfhydryl bond formation, cleavage, etc. "Fragment or peptide" refers to a portion of the Cas9 protein described above. A "fragment" of a molecule, such as any of the amino acid sequences of the present invention, refers to any amino acid subset of the Cas9 protein. It may also include its "variants" or "derivatives". "Peptide" is intended to refer to a particular amino acid subset that has a functional activity. "Functional" means having the same biological function, for example, the ability to perform a specific RNA-guided nuclease reaction.

[0085] It should be understood that the present invention encompasses any variant or derivative of the Cas9 protein of the present invention and any polypeptide that is substantially identical or homologous. The term "derivative" is used to define an amino acid sequence (polypeptide) having any of insertions, deletions, substitutions and modifications to the amino acid sequence (polypeptide) that do not change the activity of the original polypeptide. In this context, the derivative or fragment of the Cas9 protein used according to the present invention may be any derivative or fragment of the Cas9 protein, in particular that represented by SEQ ID NO: 4, that does not reduce or change the activity of the Cas9 protein. The term "derivative" also refers to its homologs, variants and analogs. A protein ortholog or homolog has sequence homology or identity to a protein of interest according to the invention, and may share at least 50%, at least 60%, and in particular 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or more, in particular with respect to the entire sequence of a protein of interest according to the invention, for example a Cas9 protein, comprising the amino acid sequence represented by SEQ ID NO: 4. In particular, a homolog comprises or consists of an amino acid sequence that is at least 50%, at least 60%, and in particular 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 4, in particular to the entire sequence represented by SEQ ID NO: 4.

[0086] In some embodiments, a derivative refers to a polypeptide that differs from a polypeptide specifically defined in the present invention by an insertion, deletion or substitution of an amino acid residue. As used herein, the terms "insertion", "deletion" or "substitution" are understood to mean any addition, deletion or substitution to a polypeptide of 1 to 50 amino acid residues, 20 to 1 amino acid residues, and particularly 1 to 10 amino acid residues, respectively, as disclosed in the present invention. More specifically, the insertion, deletion or substitution can be any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. It is noted that the insertion, deletion or substitution encompassed by the present invention can occur at any position of the modified peptide, as well as at either its N' or C' terminus.

[0087] With respect to amino acid sequences, those skilled in the art will understand that individual substitutions, deletions or additions to nucleic acid, peptide, polypeptide or protein sequences that result in the change, addition or deletion of a single amino acid or a small percentage of amino acids in the coding sequence are "conservatively modified variants", and that the change results in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables that result in functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, and do not exclude, the polymorphic variants, interspecies homologs, interspecies homologs and alleles of the invention. For example, substitutions can be made when an aliphatic amino acid (G, A, I, L or V) is replaced by another member of the group, or when a polar residue is replaced by another residue, such as the replacement of lysine with arginine, the replacement of aspartic acid with glutamic acid, or the replacement of asparagine with glutamine. Each of the following eight groups includes other representative amino acids that are conservative substitutions for one another: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine ​​(C), methionine (M). Thus, in some embodiments, the invention encompasses a Cas9 protein or any derivative thereof, particularly a derivative that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more conservative substitutions relative to the amino acid sequence represented by SEQ ID NO:4. More specifically, an amino acid "substitution" is the result of replacing one amino acid with another amino acid having similar structural and / or chemical properties, i.e., a conservative amino acid replacement. Amino acid substitutions may be made on the basis of polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of the residues involved.For example, non-polar, "hydrophobic" amino acids are selected from the group consisting of valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tryptophan (W), cysteine ​​(C), alanine (A), tyrosine (Y), histidine (H), threonine (T), serine (S), proline (P), glycine (G), arginine (R) and lysine (K); The "positively charged" amino acids are selected from the group consisting of arginine (R), lysine (K), aspartic acid (D), glutamic acid (E), asparagine (N), and glutamine (Q), and the "positively charged" amino acids are selected from the group consisting of arginine (R), lysine (K), and histidine (H), and the "acidic" amino acids are selected from the group consisting of aspartic acid (D), asparagine (N), glutamic acid (E), and glutamine (Q).

[0088] Variants of the polypeptides of the present invention, particularly Cas9 used according to the present invention, may have at least 80% sequence similarity or identity, often at least 85% sequence similarity or identity, 90% sequence similarity or identity, or at least 95%, 96%, 97%, 98%, or 99% sequence similarity or identity at the amino acid level to the protein of interest, such as the various polypeptides of the present invention. As indicated above, nucleases and in particular inducible nucleases such as Cas9 used in the methods, compositions, cells, kits, uses and systems of the present invention may in some embodiments be catalytically inactive nucleases or any fusion proteins disclosed in the present invention, which may allow further manipulation of the level, expression and / or activity of MPO. In such cases, only the targeting properties of these inducible nucleases are used for targeted manipulation of the target sequence (e.g., targeting of the target nucleic acid sequence using gRNA). In such cases, nucleolytic activity is not desirable. In some embodiments, inducible nucleases without nucleolytic activity may be used. Thus, in some particular embodiments, the Cas9 enzyme used for the system of the present invention can be a defective enzyme, such as Cas9 lacking all nucleolytic activity, e.g., dCas9. dCas9 is a mutant Cas9 lacking nucleolytic activity. A non-limiting example of such a mutant can be a mutant with at least one point mutation at D10A (aspartic acid to alanine at position 10) and H840A (histidine to alanine at position 840). Such mutants can be used as a modular RNA-guided platform to recruit different protein effectors to DNA in a highly specific manner in cells (Qi et al., Cell 152:1173-1183 (2013)). Both inhibitory and activating effectors can be fused to dCas9 to repress or activate gene expression, respectively. Thus, in some embodiments, fusion proteins of dCas9 and an activating effector (e.g., a transcription factor or demethylase) or a fusion of dCas9 and a repressor may be used in the methods, compositions, cells, kits, uses, and systems of the invention.More specifically, activation or inhibition can be determined by sgRNA that recognizes the target DNA sequence based on homologous base pairs only. Inhibition by dCas9 is achieved when naked mutagenesis protein is guided to the target. This inhibition is more effective when the guide directs dCas9 to the promoter region of the desired gene, particularly the MPO gene, and when the guide sequence is complementary to the non-template strand of the gene. However, this is not essential, and in some cases, induction to a different region in the gene, or reverse template, can be suppressed as efficiently as well.

[0089] Repression by dCas9 can be enhanced by fusing dCas9 to known repressors. A non-limiting example of such a repressor can be a Kruppel-associated box (KRAB) domain, which enhances repression of the target (Gilbert et al., Cell 154:442-451 (2013)). In some alternative embodiments, where enhanced expression and / or activity of MPO is desired, activation by dCas9 can be achieved when a transcriptional activator is fused thereto. A non-limiting example of such an activator can be the herpes simplex virus protein vmw65, also known as VP16 (Gilbert et al., Cell 154:442-451 (2013)). Alternatively, the guide RNA itself can be modified (instead of or in addition to dCas9) to recruit an activator or repressor and thus recruit naked dCas9 and direct the outcome (Zalatan et al., Cell 160:339-350 (2015)). For example, the guide can encode an RNA domain that recruits a specific binding protein. This RNA binding protein can be fused to an activator (e.g., VP16) or repressor (e.g., Krab), such that recruitment of the repressor or activator and dCas9 together results in the desired outcome, specifically repression or activation of the MPO gene.

[0090] When a gene editing system is used to manipulate the level, expression and / or activity of MPO according to the present invention, it is understood that such a system can be delivered as a nucleic acid sequence encoding a construct comprising components of the system, for example, nucleic acid sequences encoding Cas9 and a specific gRNA. However, it is understood that the present invention, in some embodiments thereof, further embraces the option of using a Cas9 / gRNA ribonucleoprotein complex (Cas9 RNP) comprising purified Cas9 and purified gRNA delivered as a functional complex. In some specific embodiments, purified gRNA can be generated by PCR amplification of annealed gRNA oligos or in vitro transcription of linearized gRNA containing plasmids (such as Addgene plasmid 42250). Cas9 (or any variant of Cas9 discussed herein) can be purified from bacteria by the use of a bacterial Cas9 expression plasmid. In some further embodiments, Cas9 RNP delivery to target cells can be performed via lipid-mediated gene transfer or electroporation in some specific non-limiting embodiments.

[0091] As indicated above, the methods, compositions, cells, kits, uses and systems of the present invention may further include the use of nucleases that cleave RNA. Thus, in some embodiments, the inducible RNA nucleases that may be used according to the present invention may be advantageously CRISPR-Cas systems that target RNA (e.g., CRISPR-Cas type II-A and novel specific CRISPR-Cas C2c2). As indicated above, the methods of the present invention may involve the use of gene editing systems as described herein, or the use of undifferentiated BM cells that exhibit regulated MPO expression and / or activity. Thus, in some embodiments, when cells are used according to the methods of the present invention, the undifferentiated BM cell populations applicable herein may be BM cell populations that have been transduced or transfected with at least one gene editing compound that can regulate the expression and / or activity of MPO in these cells. It should be noted that in some embodiments, such undifferentiated BM cell populations may be derived from autologous or allogeneic or syngeneic sources. In yet further alternative embodiments, the methods of the invention may use allogeneic subject undifferentiated BM cell populations that exhibit reduced or ablated MPO expression and / or activity, hi some embodiments, the methods of the invention may use undifferentiated BM cell populations that have been genetically engineered to ablate MPO expression and / or activity.

[0092] Thus, in some embodiments, cells suitable for the methods of the present invention may be derived from an autologous source. When referring to the origin of the cells, the term "autologous" refers to cells derived or introduced from the same subject treated by the methods of the present invention. In some further embodiments, cells suitable for the methods of the present invention may be cells derived from an autologous source. When referring to the origin of the cells, the term "allogeneic" refers to cells derived or introduced from a different subject of the same species, referred to herein as a donor.

[0093] More specifically, as indicated above, it is to be understood that the method of the present invention also encompasses the option that the modification of the MPO gene may be performed ex vivo on the subject's cells (cells of autologous origin) or on cells of allogeneic origin. In some other alternative embodiments, allogeneic undifferentiated BM cells that exhibit regulated MPO expression and / or activity may be used. Thus, cells from autologous or allogeneic (or syngeneic) origin may be administered to the subject by adoptive transfer. The term "adoptive transfer" as defined herein applies to all therapeutic procedures that consist of the introduction of components of the immune system, in particular cells that are already capable of mounting a specific immune response. Still further, in some embodiments, the cells suitable for the present application may be immobilized HSP. Hematopoietic stem cells (HSCs) are normally found in the bone marrow, but can be forced into the blood by a process called bone marrow mobilization, which is used to harvest a large number of HSCs in peripheral blood. One of the mobilizing agents of choice for the present invention may be granulocyte colony stimulating factor (G-CSF). The resulting HSCs are further referred to as mobilized HSCs.

[0094] In the case of bone marrow injection, the target cells may be HSPCs, and in the case of systemic injection, the target cells may be mobilized HSPCs (if the patient is subjected to a pretreatment of fixation). It is noted that bone marrow injection, and in some embodiments, systemic injection, of gene editing compounds may be particularly suitable for in vivo manipulation of MPO in a subject.

[0095] The present invention provides methods and compositions for regulating, in particular reducing, the level, expression and activity of MPO in a subject, in particular in any tissue or organ of said subject, by simply regulating the expression and / or activity of MPO in undifferentiated BM cells by transplanting (e.g. adoptive transfer) BM cells that show in vivo, in particular reduced expression, level and / or activity modified by the gene editing system of the present invention or ex vivo.Thus, as surprisingly shown by the present invention, effective regulation of MPO level and / or activity of certain tissues, for example brain tissues, which may show a significant increase in MPO immunoreactive cells in brain regions affected by neurodegeneration in PD and AD, can be achieved by regulating MPO level and / or activity in BM cells.More specifically, in some embodiments, the regulation of MPO was carried out in BM cells, when said regulation was not carried out in the target brain tissue or any of its components, for example astrocytes, microglia and / or nerves. As described herein, the methods of the invention include modulating MPO expression and / or activity by administering at least one gene editing / system capable of in vivo modulation of MPO expression and / or activity in the BM cells of the subject being treated, such as CRISPR / Cas9, PEN, as described above, or by administering undifferentiated BM cells (manipulated ex vivo or obtained from an MPO-deficient allogeneic subject) that exhibit modulated MPO expression and / or activity. As also described herein, the term modulation refers to any change or improvement, such as an increase or decrease in MPO expression and / or activity, compared to the original unmodulated expression and / or activity of MPO or the normal or baseline level of MPO expression / activity measured under a control or specified condition.

[0096] Thus, in some embodiments, modulating MPO expression and / or activity can include suppressing or eliminating the level, expression and / or activity of MPO in the subject. In some embodiments, when "reducing" or "suppressing" MPO expression or level or activity is referred to, it is intended that such reduction or suppression can be about a 10% to 100% decrease or decrease in MPO expression, level, stability and / or activity. As used herein, the term "reducing" or "suppressing" refers to an effect that is successively smaller in size, amount, number, or intensity. 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, or more of MPO expression, level, stability and / or activity, compared to a suitable control, e.g., in the cells of a healthy subject, particularly a suitable control in the cells of a healthy subject exhibiting a normal level and / or activity of MPO. 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, For a reduction, decrease, elimination, attenuation or inhibition of MPO expression, level, stability and / or activity by 1%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or about 100% or more.

[0097] However, by providing methods, compositions, cells, kits and systems for modulating MPO expression and activity, it should be understood that the present invention, in some alternative embodiments thereof, further encompasses modulation of MPO expression and / or activity, which may include enhancing, establishing or increasing MPO expression and / or activity in a subject in need thereof.

[0098] In some embodiments, when referring to "increasing" or "enhancing" MPO expression or level or activity, it is intended that such increase or enhancement may be about a 10% to 100% increase or enhancement of MPO expression and / or stability. As used herein, the terms "increasing," "enhancing" or "enhancing" refer to an effect of successively greater size, amount, number, or intensity. In particular, it refers to a 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 70%, 800%, 900%, 1000% or greater increase in MPO expression, level, stability and / or activity compared to a suitable control. Increase or elevation also refers to an increase or elevation of about 2 to 10%. 6 It is further noted that the increase in expression, level, stability and / or activity of MPO may be a fold or greater increase. It is further understood that the increase in expression, level, stability and / or activity of MPO may be in the translation or stability of said MPO and / or in the activity of said MPO. In the above cases, where percentage values ​​are provided, e.g., 10%, 50%, 120%, 500%, etc., it is understood that this is interchangeable with "fold change" values, i.e., 0.1, 0.5, 1.2, 5, etc., respectively. Thus, the term increase refers to an increase of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more fold.

[0099] As indicated above, the present invention provides methods, compositions, cells, kits and systems for regulating (e.g., reducing or enhancing) the expression and / or activity of MPO. As used herein, MPO expression may also reflect protein stability. More specifically, as used herein, "expression" generally refers to the process by which genes, particularly MPO gene coding information, are converted into structures present and functional in cells. Thus, in the present invention, "expression" of a gene may refer, in particular, to transcription into a polynucleotide, translation into a protein, or post-translational modification of a protein. As used herein, protein stability refers to the physical (thermodynamic) and chemical stability of a protein, and relates to the net balance that determines whether the protein is in its native folded structure or in a denatured state. More specifically, the level of a protein such as MPO in a cell is determined not only by the synthesis rate discussed above, but also by the degradation rate of the protein in the cell and its half-life, which varies widely from minutes to days. In eukaryotic cells, two major pathways mediate protein degradation: the ubiquitin-proteasome pathway previously mentioned herein, and lysosomal proteolysis.

[0100] In some further embodiments, the methods of the invention may modulate (reduce or enhance) the activity of MPO. More specifically, as used herein, MPO activity refers to any activity carried out by MPO, including, for example, the production of reactive intermediates such as hypochlorous acid (HOCl), hypobromous acid (HOBr), and hypothiocyanous acid (HOSCN), tyrosyl radicals, and hydrogen peroxide (HO) and chloride anion (Cl). - ), bromide (Br - ), thiocyanate (SCN - ), peroxidase activity that catalyzes the production of reactive nitrogen intermediates from tyrosine and nitrite. In some further embodiments, MPO activity may be associated with intracellular killing of bacteria (e.g., Pseudomonas aeruginosa) and fungi (e.g., Candida albicans) by neutrophils via the MPO / HOCl system.

[0101] In some further embodiments, MPO activity also refers to any process that is at least partially caused or directly or indirectly mediated by MPO. As previously indicated herein, it should be understood that such activity can be mediated by the heme domain of MPO or by any other MPO domain. A non-limiting embodiment of such activity relates to NETosis mediated by MPO. More specifically, neutrophil extracellular traps (NETs) are networks of extracellular fibers that are mainly composed of DNA from neutrophils that bind pathogens. NETs allow neutrophils to kill extracellular pathogens while minimizing damage to host cells.

[0102] NET activation and release, or NETosis, is a dynamic process that has two forms, suicidal NETosis and vital NETosis. Overall, many of the key components of the process are similar for both NETosis types, however, important differences exist in the activation pathways of the stimulus, timing, and final outcome - the process begins with NADPH oxidase activation of the protein-arginine deiminase 4 (PAD4) via reactive oxygen species (ROS) intermediates. PAD4 is involved in the citrullination of histones in neutrophils, resulting in chromatin decondensation. Next, azurophil granule proteins such as myeloperoxidase (MPO) and neutrophil elastase (NE) enter the nucleus and subsequently the decondensation process, resulting in the breakdown of the nuclear membrane. The uncondensed chromatin enters the cytoplasm where additional granule and cytoplasmic proteins are added to the early stage NETs. The end result of the process depends on which NETosis pathway is activated. Suicide-type NET release was first described in a study that pointed out that the release of NETs by a pathway distinct from apoptosis or necrosis results in neutrophil death. In suicide-type NET release, intracellular NET formation is followed by the disruption of the cell membrane, releasing it into the extracellular space. This NETosis pathway can be initiated by activation of Toll-like receptors (TLRs), Fc receptors, and complement receptors by various ligands, such as antibodies and PMA. Upon activation of these receptors, downstream signaling results in the release of calcium from the endoplasmic reticulum. This intracellular influx of calcium then activates NADPH oxidase, activating the NETosis pathways described above. Survival-type NET release can be stimulated by bacterial lipopolysaccharide (LPS), other bacterial products, TLR4-activated platelets, or complement proteins in parallel with TLR2 ligands. Survivable NET release is made possible by nuclear blebbing, resulting in DNA-loaded vesicles that are released by excytosis, leaving the cell membrane intact. Their rapid formation and release does not result in neutrophil death, but the cells are devoid of DNA, raising the question of whether cells without DNA can be considered alive.It is noted that neutrophils can continue to phagocytose and kill pathogens after release of survival NETs, ​​clearly demonstrating the antibacterial versatility of neutrophils. As detailed above, MPO activity can be mediated by mechanisms that are separate from MPO catalytic activity ("non-enzymatic action"). In some other embodiments, the term MPO activity refers to at least one of MAPK and NFkB activity, ROS production, surface integrin upregulation, and degranulation, as well as reduced apoptosis leading to increased inflammation in the lung. In some specific embodiments, the term MPO activity refers to the inhibition of apoptosis of human neutrophils. In some embodiments, the term MPO activity encompasses / is related to the process resulting from binding of MPO to CD11b / CD18 integrin. In some embodiments, MPO activity refers to the simulation of the polymorphonuclear neutrophil (PMN) signaling pathway to induce PMN activity. In some other embodiments, MPO activity refers to the ability of MPO to act as a survival signal for neutrophils, thereby contributing to the prolongation of inflammation. In some other embodiments, the term MPO activity refers to endothelial cell activation. In some other embodiments, the term MPO activity refers to dendritic cell (DC) function and suppression of adaptive immunity. DCs are antigen-presenting cells (also known as accessory cells) of the mammalian immune system, and their function is to process antigenic material and present it on the cell surface to T cells of the immune system. DCs act as messengers between the innate and adaptive immune systems.

[0103] In some embodiments, MPO activity refers to the effect of the complement regulatory activity of factor H (FH) through the binding of MPO to FH. It has been suggested that MPO-FH interaction may be involved in the pathogenesis of (ANCA)-associated vasculitis (AAV) by contributing to the activation of the alternative complement pathway. In some embodiments, MPO activity refers to the amplification of high glucose-induced endothelial dysfunction in the vasculature. In some embodiments, MPO activity refers to binding to human platelets, inducing actin cytoskeleton rearrangements, and affecting the mechanical stiffness of human platelets. This, in turn, promotes the upregulation of store-operated Ca 2+This results in enhanced influx (SOCE) and agonist-induced human platelet aggregation. In some embodiments, MPO activity refers to reduced phosphorylation of endothelial NO synthase (eNOS). This can further lead to reduced NO production, which in turn increases calpain activity by reducing its nitrosylation. In some embodiments, MPO activity refers to the binding of MPO to red blood cell (RBC) membranes.

[0104] In yet some further embodiments, MPO activity refers to lipid peroxidation as previously described herein, and in some embodiments, in particular to LDL peroxidation. In some embodiments, MPO activity may refer to lipid carbamylation. In yet some further embodiments, MPO activity may refer to glycocalyx binding.

[0105] Thus, in some embodiments, the methods, cells, compositions and kits of the present invention can regulate, in particular inhibit, decrease or reduce, at least one of the MPO activities identified above, or any combination thereof. The methods of the present invention allow for the regulation, in particular reduction or increase, of MPO expression, level and / or activity in a subject, in particular by applying to the subject a gene editing tool that results in the manipulation of in vivo MPO expression and / or activity in the undifferentiated BM cells of the subject. Alternatively or additionally, the subject can be administered an undifferentiated BM cell population that exhibits the required regulated expression and / or activity of MPO. It should be noted that the manipulation can occur ex vivo, and in the case where BM cells of allogeneic or autologous origin are contacted with the editing tool provided by the present invention, and immediately after the manipulation of MPO expression and / or activity, the cells are introduced into the subject (in the case of autologous cells, reintroduced). The introduction of such BM cells into the subject to be treated results in the manipulation of MPO expression and / or activity in the subject. Alternatively, as also shown by the Examples, BM cells of an allogeneic subject exhibiting modulated (increased or decreased) MPO expression and / or activity may be introduced into a subject, resulting in manipulation of MPO in the subject. Thus, in some embodiments, such manipulation encompasses in vivo (i.e., in the mammalian body) or ex vivo (i.e., in cells removed from the body) manipulation of MPO expression and / or activity, as described herein below.

[0106] In some embodiments, the method may include administering at least one gene editing compound to a subject in need thereof, thereby allowing in vivo manipulation of MPO in undifferentiated BM cells of the subject. Note that such administration methods are known in the art and are further detailed below.

[0107] In some embodiments, the method includes ex vivo application. In the context of the present disclosure, ex vivo refers to contacting at least one gene editing compound or system provided in the present invention with BM cells removed, collected or obtained from a subject. These cells can be contacted with the gene editing system under conditions suitable for regulating the expression and / or activity of MPO in the cells. As used herein, the term "contact" means to bring together, bring together, incubate together or mix. Thus, a first item is contacted with a second item when a first item and a second item are brought together or brought together, for example, by contacting or mixing them with each other. In the context of the present invention, the term "contact" includes all means or steps that allow interaction between the gene editing compound of the present invention and the cells or the subject to be regulated if performed in vivo. In some embodiments, before or after the contacting step, the BM cells can be subjected to sorting to isolate undifferentiated cells. It should be noted that isolating undifferentiated BM cells from the BM removed, collected or obtained from a subject is an optional step. In some embodiments, BM cells can be contacted with at least one gene editing compound, particularly any gene editing compound or system disclosed by the present invention. In some embodiments, isolated undifferentiated BM cell populations comprising HSC and / or progenitor cells can be contacted with at least one gene editing compound. In some alternative embodiments, BM cells are contacted with at least one gene editing compound, and undifferentiated BM cell populations comprising HSC and / or progenitor cells are isolated.

[0108] In some embodiments, at least one gene editing compound can be contacted with a BM cell population, particularly an undifferentiated BM cell population, for a period of time sufficient to allow modulation of MPO and to generate an altered BM cell population.

[0109] Thus, in some of its aspects, the disclosure provides modified BM cell populations, in some embodiments, in such BM cell populations, at least some of the cells (e.g., 20% or more, 30% or more, 40% or more, 50%, 60%, 70%, 80%, 90% or more, or 100%), and preferably most of the cells, exhibit modulated MPO expression and / or activity. In some embodiments, the modified BM cell population may include undifferentiated BM cells, in particular HSCs and / or progenitor cells that exhibit modulated MPO expression and / or activity. In some embodiments, the modified BM cell population may include HSCs with modulated MPO expression and / or activity. In the present invention, the term "modified BM cells" or "modified BM cell population" is used to refer to BM cells that have been modified ex vivo by modulating MPO expression and / or activity.

[0110] As indicated above, the present invention provides a method for manipulating a subject's immune system, in particular by targeting MPO in undifferentiated BM cells of a subject, thereby resulting in the manipulation of MPO levels in any tissue and organ of said subject. As indicated in the following aspects, the present invention further uses such modulation for therapeutic applications, in particular for the treatment of MPO-related conditions. It should therefore be appreciated that in some specific non-limiting embodiments, the present invention provides methods, compositions and kits for modulating the level, expression and / or activity of MPO in a subject by manipulating the immune system of a subject, in particular the subject's BM cells, to exhibit modulated MPO levels, expression and / or activity. In other words, by providing an engineered immune system (of autologous or allogeneic or syngeneic origin) or by in vivo manipulating the immune system of a subject using the gene editing system provided herein (e.g., administering the compounds of the gene editing system to the subject), said subject's BM cell population exhibits modulated MPO levels, expression and / or activity. Thus, the kits and compositions of the present invention provide a pioneering strategy for modulating the expression and / or activity of MPO in any tissue and organ of said subject. This strategy exhibits clear effective therapeutic applications. In some further specific embodiments, such manipulation of the subject's immune system can be achieved by transplanting BM cells that exhibit regulated levels, expression, and / or activity of MPO into a subject in need thereof, which in some embodiments undergoes immune ablation prior to transplantation. By transplanting BM cells that exhibit regulated (e.g., reduced or eliminated) levels, expression, or activity of MPO, the transplanted subject exhibits regulated expression of MPO in any tissue and organ. It should be understood that the transplanted BM cells can be autologous BM cells obtained from the same subject and ex vivo manipulated with the gene editing system of the present invention to regulate the level, expression, or activity of MPO, as described in more detail by the present invention. For example, in some specific embodiments, BM cells obtained from a subject can be subjected ex vivo to the gene editing system of the present invention, which can result in the elimination and reduction of MPO levels, expression, and / or activity.Alternatively, undifferentiated BM cells of allogeneic or syngeneic origin that exhibit (naturally or by applying the gene editing system of the present invention) regulated MPO levels, expression and / or activity can be used. Such autologous or allogeneic BM cells that are MPO deficient can be reintroduced into a subject that can be treated with an immune ablative compound, whereby these engineered and transplanted BM cells replace the immune system of the subject. This procedure results in the depletion of MPO in any organ or tissue of the subject. It should be understood that the MPO-depleted BM cells can be obtained from the subject or from an allogeneic subject. More specifically, transplantation of these autologous or allogeneic BM cells into a subject, or in other words, replacement of the immune system cells of the subject with BM cells that exhibit regulated MPO levels, expression and / or activity (e.g., removed or reduced MPO levels, expression and / or activity), results in the regulation of MPO levels, expression and / or activity in all tissues and organs of said subject. MPO is involved in the suppression of adaptive immune responses as shown by enhanced T cell-mediated cutaneous delayed-type hypersensitivity and two models of antigen-induced arthritis in Mpo- / - mice. Mechanistically, MPO released from neutrophils suppresses LPS-induced DC activation, as measured by reduced IL-12 production and resulting CD86 expression, limiting T cell proliferation and proinflammatory cytokine production. In contrast, the pathogenic role of MPO in promoting autoimmune inflammation was demonstrated in K / BxN arthritis and collagen-induced arthritis (CIA) models using MPO-deficient mice, which show reduced disease severity. Also, elevated MPO levels and activity have been observed in many inflammatory conditions and autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis (RA). MPO is involved in regulating vasculature function associated with chronic vascular diseases such as atherosclerosis. In the extracellular matrix (ECM), MPO functions as a nitric oxide (NO) scavenger that consumes NO resulting in endothelial relaxation. MPO and its oxidative species present in atherothrombotic tissue selectively regulate apolipoprotein AI (apo-I) promoting lipid peroxidation, conversion of LDL to highly uptake atherogenic forms, generating dysfunctional HDL particles that are more susceptible to degradation, and reducing the ability of apoA-I to promote cholesterol efflux.Furthermore, high systemic levels of MPO and its oxidation products are associated with increased cardiovascular risk. As indicated above, MPO has been implicated in a variety of pathologies, and modulation of MPO expression provides a specific therapeutic avenue for treating disorders or conditions caused thereby.

[0111] The present invention, in some embodiments thereof, further includes a method of regulating MPO expression and / or activity in a subject suffering from at least one MPO-associated condition. The method is as described herein above. In some further embodiments, the present invention also includes the use of the method of regulating MPO level and / or activity as disclosed herein, particularly for treating and suppressing at least one MPO-associated disorder in a subject in need thereof.

[0112] Thus, in a further aspect, the present disclosure provides a method for treating, preventing, ameliorating, suppressing or delaying the onset of an MPO-associated condition in a mammalian subject. More specifically, in some embodiments, the method of the present invention may comprise administering to said subject at least one therapeutically effective amount of (a) at least one gene editing compound capable of or adapted to modulate the expression and / or activity of MPO in at least one undifferentiated BM cell of the subject, and (b) an undifferentiated BM cell population exhibiting modulated expression and / or activity of MPO. It should be understood that the methods described herein encompass treating a subject suffering from an MPO-associated condition with (a), (b), or any combination thereof. It should still be understood that in some of its aspects, the present invention provides a therapeutically effective amount of at least one of: (a) at least one gene editing compound capable of, or adapted to, modulate expression and / or activity of MPO in at least one undifferentiated BM cell of a mammalian subject, for use in a method of treating, preventing, ameliorating, suppressing or delaying the onset of an MPO-associated condition; and (b) a population of undifferentiated BM cells exhibiting modulated expression and / or activity of MPO.

[0113] As described herein, BM cell populations, and in particular, undifferentiated BM cell populations, in some embodiments may refer to undifferentiated immature BM cells, in particular HSCs, in which expression and / or activity of MPO is modulated. In some embodiments, when cells are used according to the methods of the invention, the undifferentiated BM cell population is transduced or transduced with at least one gene editing compound capable of modulating expression and / or activity of MPO in the cells, such that the MPO gene is modulated.

[0114] The undifferentiated BM cell population is administered to a subject in need thereof to replace BM cells in the subject having abnormal MPO expression and / or activity, particularly in a subject exhibiting an MPO-associated condition. It is understood that in some embodiments, replacement of the BM cell population of the subject being treated may include replacement of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or 100% of the subject's cell population with BM cells exhibiting modulated MPO expression, level, and / or activity. As will be understood, administration of the undifferentiated BM cell population is referred to as a bone marrow transplant in some embodiments herein.

[0115] In some embodiments, the BM cell population and particularly the undifferentiated BM cell population may be obtained from an autologous source or from an allogeneic source. In some embodiments, the bone marrow transplant may be an autologous bone marrow transplant. The term autologous bone marrow transplant refers to a transplant in which BM cells are removed, collected or obtained from a subject and then transplanted into the same subject. In the context of the present disclosure, an autologous bone marrow transplant may, in some embodiments, include the following steps: (a) collecting or obtaining BM cells from a subject; (b) contacting the BM cells with at least one gene editing compound, particularly under conditions suitable for manipulating MPO expression and / or activity; and (c) transplanting (or reintroducing) the BM cells into the same subject. In some embodiments, the above step (a) may be followed by isolation of HSC and / or progenitor cells. In some alternative embodiments, the above step (b) may be followed by isolation of HSC and / or progenitor cells. In some specific embodiments, autologous bone marrow transplantation may include the following steps: (a) removing, collecting or obtaining BM cells from a subject; (b) isolating undifferentiated cells, such as HSCs and / or progenitor cells, from the BM cells; (c) contacting the undifferentiated cells with at least one gene editing compound; and (d) transplanting the undifferentiated cells into the same subject. In some embodiments, bone marrow transplantation may be allogeneic bone marrow transplantation. The term allogeneic bone marrow transplantation refers to transplantation in which BM cells are removed from a subject (herein referred to as a donor) and then transplanted into a different subject (herein referred to as a recipient).

[0116] In the context of the present disclosure, allogeneic bone marrow transplantation may include the following steps: (a) removing, collecting, or obtaining BM cells from a donor; (b) optionally contacting the BM cells with at least one gene editing compound of the present invention; and (c) transplanting the BM cells into a recipient. In some embodiments, the above step (a) may be followed by isolation of HSCs and / or progenitor cells. In some alternative embodiments, the above step (b) may be followed by isolation of HSCs and / or progenitor cells. In some specific embodiments, allogeneic bone marrow transplantation may include the following steps: (a) removing, collecting, or obtaining BM cells from a donor subject; (b) isolating undifferentiated cells, such as HSCs and / or progenitor cells, from the BM cells; (c) contacting the undifferentiated cells with at least one gene editing compound under suitable conditions that allow MPO manipulation; and (d) transplanting the undifferentiated cells into a recipient.

[0117] It should be noted that autologous and allogeneic bone marrow transplants may include a step of storing BM cells or undifferentiated BM cells prior to transplantation into the same or a different subject. In yet another alternative step, the BM cells may be further consumed prior to transplantation.

[0118] It should be noted that in some embodiments, autologous as well as allogeneic bone marrow transplants are characterized by modulated MPO expression and / or activity compared to the transplanted subject's original (unmodulated) MPO expression and / or activity. In other words, the transplanted BM cells or transplanted undifferentiated BM cells are characterized as having a different, modulated MPO expression and / or activity compared to the BM cells or undifferentiated BM that are to be replaced by the transplantation process.

[0119] Allogeneic bone marrow transplantation according to the present disclosure encompasses transplantation of BM cells obtained from a donor exhibiting regulated MPO expression and / or activity. In some embodiments, the BM cells used for allogeneic bone marrow transplantation by the methods, compositions, kits and systems of the present invention may be undifferentiated BM cells having regulated MPO expression and / or activity obtained by contacting the BM cells with at least one gene editing agent adapted to regulate the expression and / or activity of MPO in the cells. Thus, in some specific embodiments, the method of allogeneic bone marrow transplantation may include the steps of removing, recovering or obtaining BM cells from a donor, contacting the cells (optionally undifferentiated cells, in particular HSCs and / or progenitor cells) with at least one gene editing compound to produce regulated BM cells. In some embodiments, the MPO-regulated BM cells may be transplanted into a recipient subject. Also, in some alternative embodiments, the BM cells or allograft for allogeneic bone marrow transplantation may be a BM cell population obtained from a subject exhibiting aberrant MPO expression and / or activity (regulated expression and / or activity). These BM cells can be further selected prior to transplantation to isolate undifferentiated BM cells. In some specific embodiments, the bone marrow cells used by the methods of the present invention for allogeneic bone marrow transplantation can be a BM cell population obtained from a subject exhibiting suppressed or ablated MPO expression and / or activity. This results in reduced or suppressed MPO expression and / or activity in the transplanted subject. In some alternative embodiments, the bone marrow cells for allogeneic bone marrow transplantation can be a BM cell population obtained from a subject exhibiting detectable or elevated MPO expression and / or activity. This results in increased or elevated MPO expression and / or activity in the transplanted subject.

[0120] It should be understood that the present invention further encompasses the use of syngeneic undifferentiated BM cells of a genetically identical subject of the same species, optionally engineered to allow for regulated MPO expression and / or activity.

[0121] In some embodiments, BM cells for allogeneic bone marrow transplant may be a BM cell population (optionally undifferentiated BM cells) obtained from a subject exhibiting aberrant MPO expression and / or activity (modulated expression and / or activity) and may be further modulated by contacting the cells (optionally undifferentiated cells: HSCs and / or progenitor cells) with at least one gene editing compound to produce modulated BM cells.

[0122] In this regard, it should be noted that the BM cells must be histotype compatible with the recipient. In some embodiments, the methods described herein may further comprise the application of chemotherapeutic agents and / or irradiation, and / or the use of antibodies and / or chimeric antigen receptor (CAR) binding ablation, or the like, or any combination thereof, to the recipient subject prior to administration, in particular prior to transplantation of the BM cells. In some further embodiments, in order to obtain the BM cells from the donor, the methods may further comprise a fixation step of the cells, as discussed later herein.

[0123] In the context of the present disclosure, obtaining or transplanting can be performed by any method known in the art, such as bone marrow biopsy and / or bone marrow aspiration. Bone marrow aspiration can be performed under local or general anesthesia. In addition, BM transplantation can be performed by any method known in the art, such as injection.

[0124] Furthermore, in the case of bone marrow injection, the target cells may be HSPCs, and in the case of systemic injection, the target cells may be mobilized HSPCs (if the patient is subjected to fixation pretreatment). It is noted that both bone marrow injection as well as systemic injection (e.g., intravenous IV) may be particularly suitable for in vivo manipulation and targeting of BM cells with the gene editing compounds of the present invention that manipulate MPO expression and / or activity.

[0125] In some further embodiments, the patient treated by the method of the present invention may be subjected to a pretreatment, which may include immune ablation. Treatment of some types of conditions, such as cancer, autoimmune diseases, often involves immune ablation, for example, before transplantation of bone marrow cell grafts, to eliminate the patient's own immune system. Immune ablation can be achieved by total body irradiation or high-dose chemotherapy, the use of antibodies, chimeric antigen receptor (CAR) binding ablation, etc., or any combination thereof. Thus, the term "immune ablation" or "immunoablation" refers to the destruction of a patient's immune tolerance for medical purposes. Still further, in some embodiments, the patient treated by the method of the present invention may be subjected to a pretreatment with steroids. In some embodiments, such treatment may be steroid administration, which is also used to suppress immune responses. In pharmacological (supraphysiological) administration, steroids, such as glucocorticoids, are used to suppress various allergic diseases, inflammatory diseases, and autoimmune diseases.

[0126] As described herein above, the gene editing compounds used in the methods, compositions and kits of the present invention may modulate the expression and / or expression of MPO in undifferentiated BM cells of the treated subject in vivo, or the expression and / or expression of MPO in autologous or allogeneic BM cells ex vivo. In the methods of the present invention, the at least one gene editing compound may comprise at least one PEN, any nucleic acid molecule comprising a sequence encoding said PEN, or any kit, composition or vehicle comprising at least one PEN or a nucleic acid sequence encoding such a PEN.

[0127] In some embodiments, at least one PEN may comprise at least one CRISPR / Cas system. In such embodiments, the method of the present invention may comprise administering to the subject an effective amount of (a) at least one polypeptide comprising at least one Cas protein, or any nucleic acid sequence encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA. The method of the present invention may use a kit, composition or vehicle comprising at least one of (a) and (b).

[0128] As described herein, in some embodiments, the Cas protein applicable to the methods of the invention may be at least one member of class 1 and class 2 CRISPR binding systems. In some particular embodiments, the Cas protein that may be used in the methods of the invention may be a member of class 2 CRISPR binding system type II. And in some further particular embodiments, the Cas protein may be Cas9 or any fragment, mutant, variant or derivative thereof. It is understood that all gene editing systems described herein in relation to other aspects of the invention are also applicable to this aspect.

[0129] In some embodiments, the method of the present invention provides at least one gRNA or crRNA as an element of the CRISPR / Cas system. In some embodiments, the crRNA may target at least one protospacer comprising a nucleic acid sequence represented by any one of SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, and SEQ ID NO:94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, and 106 of the human MPO gene, or any fragment thereof. Such a crRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:88, and SEQ ID NO:91. Also in some further specific embodiments, the gRNA used in the method of the present invention may target the mouse MPO gene. In some specific embodiments, such gRNA targets a protospacer in mouse MPO that comprises a nucleic acid sequence represented by SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, or any fragment thereof. In some further specific embodiments, the gRNA provided by the methods of the invention may comprise a nucleic acid sequence represented by SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

[0130] The therapeutic methods provided by the present invention may be particularly applicable to the treatment of subjects suffering from MPO-associated conditions. As used herein, the term MPO-associated conditions or diseases includes conditions associated with increased, absent or reduced abnormal expression and / or activity of MPO. In other words, the methods described herein are effective in treating conditions associated with absent or reduced MPO expression and / or activity or conditions associated with elevated MPO expression and / or activity. As will be understood, the relative terms "increased", "absent", "reduced" or "reduced" describing MPO expression and / or activity are relative to a control or normal or baseline level of expression / activity determined under a particular condition.

[0131] The terms "associated," "linked," and "related," used interchangeably herein, when referring to conditions, should be understood to mean a disease, condition, or any condition where at least one shared causal relationship exists simultaneously more than coincidentally, or where at least one disease, disorder, condition, or condition is the cause of a second disease, disorder, condition, or condition. In some specific embodiments, the methods of the invention may be applicable to MPO-associated conditions associated with increased (elevated) MPO expression and / or activity. In some embodiments, the methods of the invention may be applicable to subjects that may exhibit normal (non-elevated and non-reduced) levels of MPO, however, it should be understood that reducing the amount of MPO may exhibit beneficial effects in any of the conditions or disorders of the above subjects, not necessarily related to MPO levels. Thus, in some embodiments, modulation of MPO by the methods of the invention may result in suppression or reduction of MPO expression and / or activity, thereby reversing conditions associated with increased or elevated MPO expression. In some embodiments, the MPO-associated condition treatable by the methods of the invention can be at least one of an immune-related disorder, a neurodegenerative disease, a respiratory disorder, a proliferative disorder, a vascular disorder, or any combination thereof.

[0132] In some embodiments, the MPO-associated condition may be an immune-related disorder. As used herein, "immune-related disorder" or "immune-mediated disorder" more specifically encompasses any condition associated with a subject's immune system, through suppression or activation of the immune system, or any condition that can be treated, prevented, or ameliorated by reducing the degradation of a particular component of a subject's immune response, such as an adaptive or innate immune response. Immune-related disorders may include infectious conditions (e.g., viral infections), metabolic disorders, autoimmune diseases, vasculitis, inflammation, and proliferative disorders, particularly cancer. In some embodiments, the immune-related condition may be an autoimmune disease. In some embodiments, the methods of the present invention are applicable in the treatment of autoimmune diseases. Autoimmune diseases are conditions that result from an abnormal immune response against normal body sites. Examples of autoimmune diseases include rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (lupus), type 1 diabetes, psoriasis / psoriatic arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, and vasculitis.

[0133] In some particular embodiments, the methods of the present invention are particularly applicable to autoimmune diseases such as multiple sclerosis (MS), antineutrophil cytoplasmic antibody (ANCA) associated disorders, and systemic lupus erythematosus (SLE).

[0134] In some embodiments, the methods of the present invention are applicable to MS and any related condition or symptoms associated therewith. The term "multiple sclerosis" (MS), as defined herein, is a chronic inflammatory neurodegenerative disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. MS is the most common neurological disease among young adults, usually appearing between the ages of 20 and 40. Symptoms of MS vary from the appearance of vision problems such as blindness in one eye, double vision, to other symptoms such as muscle weakness fatigue, pain, numbness, stiffness and shaking, loss of coordination and tremors, dizziness, slurred speech, difficulty swallowing, and emotional disturbances. As the disease progresses, patients lose the ability to walk, experience cognitive decline, loss of self-control in daily activities, and can become severely disabled and dependent.

[0135] MS symptoms progress as immune system elements attack brain cells, especially glia and / or neurons, damaging the protective myelin sheath of axons. The areas where these attacks occur are called lesions, disrupting the transmission of messages through the brain. Multiple sclerosis is classified into four types characterized by disease progression: (1) Relapsing-Remitting MS (RRMS), which is characterized by relapses (attacks of worsening symptoms) followed by remissions (periods of stabilization and possible recovery; in some remissions there is complete recovery, in others there is partial or no recovery). Symptoms of RRMS can vary from mild to severe, and relapses can last for days or months. Over 80% of people with MS begin with relapsing-remitting cycles; (2) Secondary Progressive MS (SPMS) develops in people with relapsing-remitting MS. In SPMS, relapses occur but without significant periods of remission (stabilization), and disability continues to worsen; (3) Primary Progressive MS (PPMS), which progresses slowly and steadily from its onset and accounts for less than 20% of MS cases. There are no periods of remission, and symptoms do not usually decrease in intensity; and (4) Progressive Relapsing MS (PRMS). In this type of MS, humans experience a steady worsening of symptoms and attacks during periods of remission. It should be understood that the methods of the present invention are applicable to any type, stage, or condition of MS patients. Treatment with the methods of the present invention may, in some embodiments, result in amelioration of any symptoms and / or an extension of the period of remission between attacks.

[0136] In some further embodiments, the method of the present invention is applicable to SLE and any related condition or symptoms associated therewith. More specifically, systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease. Symptoms vary from person to person and can range from mild to severe. Common symptoms include painful and fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, fatigue, and most commonly a red rash on the face. The disease is characterized by periods of illness called erythema, during which there are periods of remission when there are few symptoms.

[0137] The cause of SLE is unclear, but is thought to be related to genetics as well as environmental factors. There are numerous other types of lupus erythematosus, including discoid lupus erythematosus, neonatal lupus, and subacute cutaneous lupus erythematosus. It is understood that the present invention encompasses each of these types.

[0138] Furthermore, in some embodiments, the method of the present invention may be related to other autoimmune diseases. For example, it may be related to the treatment of ANCA-associated disorders. As used herein, antineutrophil cytoplasmic antibodies (ANCA) include perinuclear antineutrophil cytoplasmic antibodies (P-ANCA), which mainly target MPO or EGPA, and therefore also known as MPO-ANCA; cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), which mainly target proteinase 3 (PR3) protein, and therefore also known as PR3-ANCA, and mainly associated with GPA; and atypical ANCA (a-ANCA), also known as x-ANCA, which is a group of autoantibodies against antigens in the cytoplasm of neutrophil granulocytes (the most common type of white blood cell) and monocytes, mainly of IgG type. p-ANCA is also associated with several pathologies, which are quite specific but insensitive to ulcerative colitis; most cases of primary sclerosing cholangitis; focal necrotizing and crescentic glomerulonephritis; and rheumatoid arthritis.

[0139] Furthermore, these ANCA not only activate neutrophils and monocytes by membrane-bound PR3 / MPO binding, but also interact with the endothelium and increase the expression of adhesion factors. Several studies have investigated the ANCA titer in predicting disease relapse during vasculitis remission, but the association between ANCA titer and the requirement for permanent dialysis during the active phase of AAV has not been well documented. In Asian countries, MPO-ANCA-associated vasculitis is more common than PR3-ANCA-associated vasculitis. They are detected as blood tests for a number of autoimmune diseases, but are particularly associated with systemic vasculitis, the so-called ANCA-associated vasculitis (AAV), which includes granulomatosis with polyangiitis, microscopic polyangiitis, primary microimmune necrotizing crescentic glomerulonephritis (a type of renal-confined microscopic polyangiitis), eosinophilic granulomatosis with polyangiitis (previously known as Churg-Strauss syndrome) and drug-induced vasculitis. PR3-induced c-ANCA is present in 80-90% of granulomatosis with polyangiitis, 20-40% of microscopic polyangiitis, 20-40% of microimmune crescentic glomerulonephritis, and 35% of eosinophilic granulomatosis with polyangiitis. c-ANCA (atypical) is also present in 80% of cystic fibrosis (with BPI as target antigen), as well as inflammatory bowel disease, primary sclerosing cholangitis, and rheumatoid arthritis (with antibodies against multiple antigenic targets). p-ANCA with MPO specificity is found in 50% of microscopic polyangiitis, 50% of primary microimmune necrotizing crescentic glomerulonephritis, and 35% of eosinophilic granulomatosis with polyangiitis. p-ANCA, which have specificity for other antigens, are associated with inflammatory bowel disease, rheumatoid arthritis, drug-induced vasculitis, autoimmune liver disease, drug-induced syndromes, and parasitic infections. Atypical ANCA are associated with drug-induced systemic vasculitis, inflammatory bowel disease, and rheumatoid arthritis.

[0140] More specifically, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AVV) is a systemic disease characterized by inflammation and necrosis of small blood vessels, resulting in multiple organ damage and dysfunction. The kidney is the most frequently affected organ, resulting in a microimmune segmental necrotizing crescentic glomerulonephritis, which is called ANCA-associated glomerulonephritis (AAGN).

[0141] Clinical and experimental evidence indicates that ANCA cause microimmune necrotizing crescentic glomerulonephritis (NCGN) and systemic small vessel vasculitis in humans.

[0142] In some specific embodiments, the methods, compositions, cells and kits of the present invention disclosed herein are applicable to P-ANCA associated disorders.

[0143] More specifically, one of the main target antigens of antineutrophil cytoplasmic antibodies is MPO.MPO-ANCA does not target a single epitope, but rather targets a small number of MPO regions, mainly in the carboxy terminus of heavy chain.Therefore, by removing the expression, level, and / or activity of MPO, the method, composition, cell and kit of the present invention address the variability of autoantibody targeting epitopes in MPO.

[0144] In some embodiments, the method of the present invention is applicable to P-ANCA-associated disorders, which are ANCA-associated vasculitis. AAV is classified into four categories according to clinical features: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic GPA (EGPA) and renal limited vasculitis (RLV). Organ involvement causes many variations in different categories of AAV, and clinical symptoms lack specificity.

[0145] At the population level, little is known about the epidemiology and outcome of oligoimmune GN. PICG accounts for up to 80% of cases of rapidly progressive glomerulonephritis (RPGN), and in the United States, its incidence is estimated to be 7-10 cases per million per year. Oligoimmune GN (PICG) is more prevalent in whites compared to blacks, and affects men and women almost equally.

[0146] Without treatment, oligoimmune GN-PICG has a 1-year mortality rate of 80%. However, with aggressive immunosuppression, 5-year survival is up to 75%. Increasing age, dialysis dependency, and pulmonary hemorrhage all worsen the odds of survival. For example, irreversible dialysis-dependent renal failure reduces the 5-year survival rate to 35%. In terms of renal outcomes, approximately 25% of patients progress to renal failure, also known as end-stage renal disease (ESRD), which is the end stage of chronic kidney disease.

[0147] Thus, in some embodiments, ANCA-associated or related disorders include, but are not limited to, ANCA-associated vasculitis (AAV), ANCA-associated glomerulonephritis (AAGN), crescentic glomerulonephritis (NCGN), and rapidly progressive glomerulonephritis (RPGN). Further, the methods, compositions, cells, and kits of the present invention, in some embodiments, are applicable to the treatment of any of the P-ANCA-associated disorders disclosed herein.

[0148] In some further embodiments, the method of the present invention is applicable to the treatment of immune-related disorders such as inflammatory diseases. In some embodiments, the method of the present invention is applicable to the treatment of inflammatory diseases. The term "inflammatory disease" or "inflammatory-related condition" refers to any disease or pathological condition that benefits from at least one reduction in inflammatory parameters, such as induction of IFN gamma and IL-2, and reduction of IL-6 levels. The condition may be (mainly) caused by inflammation, or inflammation may be one of the symptoms of a disease caused by another physiological cause. In some embodiments, the inflammatory disease applicable to the method of the present invention may be any one of atherosclerosis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). As disclosed by the examples, the present invention shows that MPO-deficient 5XFAD mice show superior behavioral performance compared to MPO-expressing 5XFAD mice, thus reflecting limited cognitive decline. The present invention also shows a lower inflammatory response in the brains of these mice, reflected in astrocyte activation, reduced APOE expression levels, and reduced levels of some pro-inflammatory cytokines.

[0149] Thus, in certain embodiments, the present invention provides methods, compositions, cells, and kits for inhibiting or reducing cognitive decline in a subject in need thereof. In some further embodiments, the present invention provides methods, compositions, cells, and kits for inhibiting or reducing brain inflammatory response in a subject in need thereof, particularly a subject suffering from AD. Still further, in some embodiments, the present invention provides methods, compositions, cells, and kits for inhibiting or reducing the level of astrocyte activation in a subject in need thereof. In some further embodiments, the present invention provides methods, compositions, cells, and kits for inhibiting or reducing APOE expression in a subject in need thereof. Still further, in some embodiments, the present invention provides methods, compositions, cells, and kits for inhibiting or reducing the level of some pro-inflammatory cytokines in a subject in need thereof. Such cytokines are, in some embodiments, at least one of IL-1 beta, CXCL10, CCL2, and TNF alpha. In some embodiments, such a subject may be suffering from a neurodegenerative disease. In some more specific embodiments, such a neurodegenerative disease may be AD.

[0150] Furthermore, MPO, which is central to neutrophil function and whose role in neurodegeneration has long been suspected, stands as a prominent mediator of neutrophil damage in AD. Indeed, several associations of MPO with AD have been reported in the past. A polymorphism at the 463G / A locus in the promoter of human MPO, associated with increased MPO expression, increased the risk of developing late-onset AD. Furthermore, an interaction between MPO and the APOE ε4 allele (the most common genetic risk factor for late-onset AD), was identified. However, after investigation, studies showed conflicting findings regarding the association of the 463G / A polymorphism with AD. Green and coworkers reported elevated MPO immunoreactivity and activity in the cortex of AD patients, accompanied by an increased incidence of its oxidation products. However, MPO expression in that study was attributed to neurons. Reynolds and coworkers detected MPO expression in CD68-expressing cells around amyloid-β plaques and therefore attributed it to microglia / macrophages. Recently, MPO expression was reported in association with amyloid-β plaques in the brains of AD patients. Interestingly, MPO mRNA expression was not detected in these brains, suggesting that the observed origin of MPO is from peripheral myeloid origin. Although these observations provide strong evidence for the involvement of MPO in AD pathogenesis, to the best of our knowledge, this invention is the first investigation of the effect of MPO deficiency in an experimental model of AD. This invention focuses primarily on peripheral MPO derived from neutrophils by establishing a deficiency of MPO in peripheral myeloid cells without affecting CNS-derived MPO, utilizing a hematopoietic depletion and repopulation method. Oxidative stress and vascular damage are considered to be key events in the pathogenesis of AD. These may lead to blood-brain barrier dysfunction, reduced cerebral blood flow, and substantial oxidative and inflammatory damage within the CNS. Recent suggestions regarding neutrophil function in neurodegeneration include hyperactivation and senescence, enhanced adhesion at cortical capillaries, extravasation and degranulation in the brain parenchyma, and formation of NETs leading to severe inflammatory responses. The data disclosed by the present invention also show that hematological MPO deficiency limits inflammatory responses.In addition, the profound protection against cognitive decline after MPO depletion explains the reduction of neutrophil-derived oxidative damage, which is considered a key part of the pathology in AD. In this context, the results disclosed herein are consistent with recent reports by Zenaro et al. and Cruz-Hernandez et al., which show functional protection in AD mouse models after neutrophil depletion (Zenaro, E. et al. Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 21, 880-886 (2015), and Cruz Hernandez, JC et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. Nat. Neurosci. (2019). doi:10.1038 / s41593-018-0329-4).

[0151] MPO function has been linked to endothelial dysfunction and vascular injury in the context of cardiovascular and renal disease. Positively charged MPO, secreted by activated neutrophils, accumulates along the endothelium and subendothelial space through its interaction with the anionic glycocalyx. Oxidants from bound MPO have been shown to reduce glycocalyx thickness and damage the endothelium, while MPO has also been shown to promote neutrophil recruitment and extravasation. This may result in an amplified MPO response, and in situ neutrophil accumulation. Interestingly, we found a decrease in VCAM1 expression in hippocampal samples from MPO-deficient 5XFAD mice, suggesting increased endothelial inflammation. However, the impact of MPO deficiency on neutrophil recruitment in the endothelium of capillaries and its impact on capillary arrest and cerebral blood flow, as well as neutrophil migration, remains to be determined.

[0152] The results presented here clearly demonstrate that neutrophil-derived MPO plays a central role in AD-like pathogenesis in 5XFAD mice. These results suggest MPO inhibition as a novel therapeutic target for the treatment of AD.

[0153] Thus, in some further embodiments, the MPO-associated condition may be a neurodegenerative disease. In some particular embodiments, the method of the present invention is applicable to the treatment of a neurodegenerative disease. In some embodiments, the neurodegenerative disease may further include inflammatory and / or vascular causes.

[0154] Neurodegeneration is a comprehensive term for the progressive loss of neural structure or function, including synaptic dysfunction and neuronal death. Many neurodegenerative diseases, including Alzheimer's and Parkinson's, are associated with neurodegenerative processes. Other examples of neurodegeneration also applicable herein include Friedreich's ataxia, Lewy body disease, spinal muscular atrophy, multiple sclerosis, frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, hereditary spastic paraplegia, amyloidosis, amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease. It should not be overlooked that the normal aging process includes progressive neurodegeneration, particularly age-related cognitive decline (ACD), and mild cognitive impairment (MCI) are also applicable in the present invention. In some further embodiments, the methods, kits, compositions, and cells of the present invention are applicable to Duchenne muscular dystrophy (DMD), or any associated condition thereof. In some further embodiments, the methods, kits, compositions and cells of the present invention are applicable to Becker muscular dystrophy.In some further embodiments, the methods, kits, compositions and cells of the present invention are applicable to tuberous sclerosis complex (TSC).

[0155] In further particular embodiments, the methods of the present invention are applicable to the treatment of neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease.

[0156] As used herein, Alzheimer's disease (AD) refers to a disorder with deterioration of memory and other cognitive domains that typically leads to death within 3-9 years after diagnosis. The major risk factor for Alzheimer's disease is age. The incidence of the disease doubles every 5 years after age 65. Up to 5% of humans with the disease have early-onset AD (also known as early-onset), which occurs at age 40-50 years. While many molecular lesions have been detected in Alzheimer's disease, a key theme emerging from the data is that accumulation of misfolded proteins in the aging brain leads to oxidative and inflammatory damage, which in turn leads to energy insufficiency and synaptic dysfunction. More specifically, accumulation of Aβ has been shown in structurally damaged mitochondria isolated from the brains of patients with Alzheimer's disease.

[0157] Alzheimer's disease is primarily a synaptic disorder. Hippocampal synapses begin to decline in patients with mild cognitive impairment (a limited cognitive impairment that often precedes dementia). In these patients, the remaining synaptic properties show a compensatory increase in synapse size. In mild Alzheimer's disease, there is an approximately 25% reduction in the presynaptic vesicle protein synaptophysin. In progressive disease, synapses are lost disproportionately compared to neurons, and this loss correlates well with dementia. Aging itself causes synaptic loss, which particularly affects the dentate region of the hippocampus.

[0158] There is no known single linear chain of events or pathways that may initiate and drive Alzheimer's disease. AD is a progressive disease, and dementia symptoms gradually worsen over many years. In its early stages, memory loss is mild, but in late-stage AD, individuals lose the ability to carry on a conversation and respond to their environment. People with AD survive an average of eight years after their symptoms become noticeable to others, but survival can range up to 20 years, depending on age and other health conditions.

[0159] Because AD changes usually begin in parts of the brain that affect learning and memory, the most common early symptom of AD is difficulty recalling newly learned information. As AD progresses throughout the brain, it progresses to increasingly severe symptoms, including disorientation; changes in mood and behavior; increasing confusion about events, times, and places; false accusations against family, friends, and professional caregivers; more severe memory loss and behavior changes; and problems speaking, swallowing, and walking.

[0160] The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA, now known as the Alzheimer's Association) defined the most commonly used NINCDS-ADRDA Alzheimer's diagnostic criteria in 1984 and updated extensively in 2007. These criteria require the presence of cognitive impairment and a suspected dementia syndrome to be confirmed by neuropsychological testing for a possible or probable clinical diagnosis of AD. Histopathological confirmation, including microscopic examination of brain tissue, is required for a definitive diagnosis. Good statistical reliability and validity have been demonstrated between the diagnostic criteria and definitive histopathological confirmation. The following eight cognitive domains are most commonly impaired in AD: memory, language, perceptual abilities, attention, constructional abilities, orientation, problem-solving abilities, and functional abilities. These domains are equivalent to the NINCDS-ADRDA Alzheimer's Disease criteria as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) published by the American Psychiatric Association. Other than symptomatic treatments to temporarily slow the deterioration of dementia symptoms, AD has no current cure, and current therapeutic agents cannot stop the progression of AD. It should be understood that the methods of the present invention and the compositions, cells and kits, uses and systems provided by the present invention are applicable to any stage, condition or symptom associated with AD, any of the MPO-associated conditions discussed herein. It should be further understood that in some embodiments, the methods, compositions, cells and kits of the present invention are applicable to any stage, type, symptom or degree of disease in AD patients.

[0161] As shown by Figures 5 and 6, adoptive transfer of MPO-KO BM cells into AD animals (5XFAD) clearly improved spatial learning and memory, associative learning, and anxiety / risk assessment behavior. Thus, in some embodiments, the methods, compositions, cells, and kits of the present invention are applicable to improve and enhance spatial learning in AD patients with disease. In some further embodiments, the methods, compositions, cells, and kits of the present invention are applicable to improve and enhance memory in AD patients with disease. In some further embodiments, the methods, compositions, cells, and kits of the present invention are applicable to improve and enhance associative learning in AD patients. In some further embodiments, the methods, compositions, cells, and kits of the present invention are applicable to improve and enhance anxiety / risk assessment behavior in AD patients.

[0162] As indicated above, AD is considered a condition involving protein misfolding (e.g., Aβ peptide). Thus, and in some further embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to any condition associated with protein misfolding, such as synucleinopathies and tauopathies. More specifically, "alpha-synuclein pathological disorder" or "synucleinopathy" is used to name a group of neurodegenerative diseases characterized by fibrillar aggregates of alpha-synuclein protein in the cytoplasm of selective populations of neurons and glia. Alpha-synuclein aggregates, including monomers, oligomeric intermediates, or fibrillar forms, are believed to be involved in key steps in the pathogenesis of Parkinson's disease (PD) and other alpha-synucleinopathies, such as multiple system atrophy (MSA) and dementia with Lewy bodies (DLB). Thus, in some embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to any synucleinopathies disclosed herein. Furthermore, in some embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to any condition associated with the accumulation of tau protein. More specifically, as used herein, "tau protein" refers to neurofibrillary tangles, which are filamentous inclusions in pyramidal neurons that are characteristic of Alzheimer's disease and other neurodegenerative diseases called tauopathies. Elucidation of the mechanism of their formation may provide targets for future therapeutics. The accumulation of hyperphosphorylated tau protein in pyramidal neurons as paired helical fibrils is a major feature of Alzheimer's disease. In addition to hyperphosphorylation, other modifications of tau protein, such as crosslinks, may contribute to the characteristics of paired helical fibrils, including their insolubility and resistance to proteolysis. These neurofibrillary tangles consist of hyperphosphorylated and aggregated forms of the microtubule-associated protein tau.

[0163] As shown in Example 2, adoptive transfer of undifferentiated MPO KO BM cells resulted in a clear suppression of cognitive impairment in AD and improved cognitive function and associative learning. Thus, in some embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to any condition associated with cognitive decline or impairment. In some embodiments, the present invention is applicable to MCI. As used herein, "age-associated mild cognitive impairment (MCI)" is a condition that produces cognitive changes. MCI that primarily affects memory may be classified as "amnestic MCI", where the subject experiences impaired memory of recent events, appointments or conversations or information related to recent events. MCI that affects thinking abilities other than memory is known as "non-amnestic MCI". Thinking abilities that may be affected by non-amnestic MCI include correct judgment, the ability to judge the time or sequence of steps required to complete a complex task, or the ability to perform visual perception.

[0164] Normal aging is associated with a decline in various memory abilities in many cognitive tasks, a phenomenon known as age-associated memory impairment (AMI), age-associated memory impairment (AAMI) or age-associated cognitive decline (ACD). The ability to encode new memories and working memory of events or facts shows declines in both cross-sectional and longitudinal studies. Studies comparing the effects of aging on episodic, semantic, short-term and stimuli memory have revealed that episodic memory is particularly impaired in normal aging, and that some types of short-term memory are also impaired. The impairment may be related to the impairment observed in the ability to refresh recently processed information. While there is usually little age-related decline in some mental functions, such as language abilities, some arithmetic abilities and general knowledge, other mental abilities decline from middle age onwards or even earlier. The latter include aspects of memory, executive functions, processing speed and reasoning. Thus, it should be appreciated that in some embodiments, the present invention provides methods and compositions for the treatment of any cognitive decline, particularly cognitive decline associated with age, particularly age 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and above.

[0165] In some further embodiments, the method, composition, system, kit and use of the present invention are applicable to DLB. As used herein, "dementia with Lewy bodies (DLB)" is a relatively common cause of dementia, estimated to account for up to 30% of dementia cases, affecting up to 5% of people over 75 years of age. Pathologically, it is defined by the presence of alpha-synuclein containing Lewy bodies in the brain, the distribution of which affects the neocortex, limbic system and brainstem. Clinically, DLB is characterized by progressive dementia with prominent visual hallucinations and delusions, and parkinsonism with bradykinesia and rigidity, but usually with minimal tremor. Prominent cognitive fluctuations are a common feature of this condition, with episodes of confusion, excessive somnolence, and disorganized speech that may return to near-normal status within a few hours.

[0166] In some further embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to PD. As used herein, "Parkinson's disease (PD)" is a neurodegenerative disease resulting from the degeneration of midbrain dopamine neurons and the accumulation of Lewy body-containing α-synuclein in surviving neurons. The diagnosis of PD is based on cardinal motor features in the absence of other pathogenetic conditions. These motor features include the classic triad: bradykinesia, resting pill-rolling tremor, and muscular rigidity (usually together with masked facies, dysphonia, micrographia and postural control disorders). Non-motor features of PD may even precede its diagnosis, constituting the prodromal or premotor PD. These premotor features include disorders related to smell, constipation, mood and sleep, which may become more pronounced after clinical diagnosis of PD. Cognitive impairment and dementia also usually develop in PD, affecting nearly 50% by 10 years from diagnosis. However, in some individuals with α-synucleinopathy, significant cognitive impairment precedes the onset of parkinsonism motor symptoms, and these cases are clinically classified as dementia with Lewy bodies. There is clearly a large overlap between these two conditions, both clinically and pathologically, but currently, the clinical distinction is based on the time interval between the onset of motor symptoms and dementia, with a minimum of one year interval required for the diagnosis of PD, in contrast to dementia with Lewy bodies (DLB). Furthermore, in some embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to MSA. "Multiple system atrophy (MSA)" is a neuropathology that includes cell loss and gliosis in olivopontocerebellar structures in the form of glial cytoplasmic inclusions containing fibrillar α-synuclein in the substantia nigra-striatum and oligodendrocytes. It exists with various combinations of parkinsonism and cerebellar dysfunction plus autonomic dysfunction and is clinically classified as being predominantly cerebellar (MSA-C) or predominantly parkinsonian (MSA-P).

[0167] Furthermore, as shown above, neurodegenerative diseases are clearly related to vascular and ischemic conditions. Thus, in some embodiments, the methods, compositions, systems, kits and uses of the present invention are applicable to any vascular and / or ischemic conditions. More specifically, cerebral ischemia (or cerebral ischemia, cerebrovascular ischemia) is a condition in which there is insufficient blood flow to meet the metabolic demands of the brain. This leads to insufficient oxygen supply or hypoxic encephalopathy, and thus to the death of brain tissue or cerebral infarction / ischemic stroke. It is a subtype of stroke, along with subarachnoid hemorrhage and intracerebral hemorrhage. Ischemia leads to alterations in cerebral metabolism, reduced metabolic rate, and energy crisis. There are two types of ischemia: focal ischemia, which is limited to a specific area of ​​the brain; and global ischemia, which encompasses a wide area of ​​brain tissue.

[0168] The main symptoms involve impaired vision, body movement, and speech. Causes of cerebral ischemia are diverse, ranging from sickle cell anemia to congenital heart disease. Symptoms of cerebral ischemia can include loss of consciousness, blindness, impaired coordination, and physical weakness. Other effects that can result from cerebral ischemia are stroke, cardiac arrest, and irreversible brain damage.

[0169] In an ischemic stroke, the blood supply to a part of the brain is reduced, leading to dysfunction of brain tissue in that area. There are four main causes of ischemic stroke: thrombosis (blockage of a blood vessel due to localized blood clot formation), embolism (blockage due to an embolus from elsewhere in the body), systemic hypoperfusion (a generalized reduction in blood supply due to, for example, shock), and cerebral venous sinus thrombosis.

[0170] There are various classification systems for acute ischemic stroke. The Oxford Community Stroke Project classification (OCSP, also known as the Bamford or Oxford classification) relies primarily on initial symptoms and classifies stroke episodes as total anterior circulation infarction (TACI), partial anterior circulation infarction (PACI), lacunar infarction (LACI) or posterior circulation infarction (POCI), based on the severity of symptoms. These four components predict the extent of the stroke, the area of ​​the brain affected, the underlying cause, and the prognosis. The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification is based on clinical symptoms as well as further laboratory findings; it classifies stroke as being due to (1) atherosclerotic thrombosis or embolism of the large arteries, (2) embolism of cardiac origin, (3) complete occlusion of small vessels, (4) other determined causes, or (5) undetermined causes (two possible causes, unspecified cause, or incomplete testing).

[0171] Small chronic intracerebral hemorrhages (<5-10 mm diameter) are termed cerebral microbleeds (CMH; also called microbleeds, multifocal signal loss lesions, and petechial hemorrhages). CMH result from the rupture of small arteries, arterioles, and / or capillaries (in human CMH, the diameter of the ruptured vessels is estimated to be less than 200 μm, with most hemorrhage occurring at the arteriolar and capillary levels). CMH appear as small oval hypointense lesions corresponding to focal hemosiderin deposits, which are not seen on T2 * Gradient-weighted recalled echo (T2 * -GRE) are best detected using MRI sequences.

[0172] Age is the most important independent risk factor for CMH. The incidence of CMH is low in younger subjects and increases progressively with age. Most studies of CMH report that in older patients, the incidence of CMH is 24%-56%. Hypertension is another major independent risk factor for CMH. Cerebral amyloid angiopathy and Alzheimer's disease (AD) also constitute important risk factors for CMH. An increased incidence of CMH has been reported in type 1 diabetic patients with proliferative diabetic retinopathy, suggesting that systemic microangiopathy may contribute to both cerebral and retinal capillary injury. CMH has also been found in nearly half of individuals affected by cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), an adult-onset inherited stroke disorder caused by mutations in the Notch3 gene.

[0173] Furthermore, in some embodiments, the method, composition, system, kit and use of the present invention are applicable to cSVD. Cerebral small vessel disease (cSVD) is a term used for different pathological processes that affect the small blood vessels of the brain, including small arteries, arterioles, capillaries, and venules. cSVD plays an important role in lacunar cerebral infarction and deep or subcortical hemorrhage. In addition to cognitive decline and dementia, gait disorders are also frequently associated with cSVD. Approximately one-fifth of symptomatic strokes are lacunar stroke syndromes, which are often more severe types of stroke, namely spontaneous parenchymal cerebral hemorrhage (PBH). These are associated with cSVD. However, although sporadic cSVD is the main cause of PBH, the topography of the underlying capillary pathology is different in each case. cSVD is classified into two main forms. The first is amyloid type, which includes cerebral amyloid angiopathy (CAA), which is a chronic degenerative disease. The second form is characterized as the non-amyloid form of cSVD and is often associated with common vascular risk factors such as older age, hypertension, diabetes, and many other factors.

[0174] Cerebral amyloid angiopathy (CAA), also known as congophilic angiopathy, is a form of vascular disease in which amyloid deposits occur in the walls of blood vessels in the central nervous system. The term congophilic is used because microscopic examination of brain tissue after application of a special stain called Congo red can show the presence of abnormal amyloid aggregates. Amyloid material is found only in the brain, and therefore this disease is not related to other forms of amyloidosis.

[0175] CAA is the common amyloid form of cSVD. The incidence of CAA is mostly associated with advanced age. It is due to progressive deposition of beta-amyloid in the cortical walls and leptomeningeal arterioles, which leads to vascular dysfunction and brain parenchymal injury. Deposition of beta-amyloid is thought to be involved in vascular occlusion and rupture. CAA-associated vasculopathy includes features such as fibrinoid necrosis, loss of smooth muscle cells, wall thickening, microaneurysm formation, and perivascular blood breakdown with resultant product deposition. Based on the specific location of amyloid deposition and allelic differences, at least two pathological subtypes of CAA have been identified: CAA type 1, characterized by amyloid in cortical capillaries, and CAA type 2, in which amyloid deposition is restricted to leptomeningeal and cortical arteries, but not in capillaries. Reduced cortical gray matter in the occipital lobe and reduced flux in the basilar artery have been identified in patients with symptomatic hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWA-D). The appearance of cortical thinning in patients with HCHWA-D indicates that vascular amyloid is an independent contributor to cortical atrophy. CAA-associated cortical atrophy is driven by vascular dysfunction and has been observed even in the absence of Alzheimer's disease. Furthermore, apolipoprotein E (APOE) gene polymorphisms are associated with two subtypes of CAA. The APOE ε4 allele and APOE ε2 are reasonably associated with type 1 and type 2 disease, respectively.

[0176] It should therefore be understood that the methods, compositions, systems, kits and uses of the present invention are applicable to any ischemic condition, and in particular any of the conditions disclosed herein.

[0177] Furthermore, neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and initiate inflammatory responses that protect the host from infection. The formation of neutrophil extracellular DNA traps (NETs) has defined a new role for neutrophils in inflammation and immunity, but also in cancer biology and pathological conditions including thrombosis, and related conditions (e.g., Trousseau's syndrome). Release of neutrophil chromatin has been shown to affect different steps of tumor growth, including tumor proliferation, angiogenesis, metastasis, and immune suppression. As shown above, MPO is involved in NET formation in neutrophils. Thus, by regulating, and in particular by suppressing MPO expression, levels, and / or activity, the present invention provides a strategy for regulating and suppressing NET formation in a subject, thereby providing an approach for the treatment of cancer and related disorders. Thus, in some embodiments, the MPO-related condition that may be accompanied by elevated MPO expression or activity may be a proliferative disorder. Thus, in some specific embodiments, the method of the present invention is applicable to the treatment of a proliferative disorder. The proliferative disorder in some embodiments of the present invention may be any related pathology, such as cancer and / or metastasis. As used herein, "cancer", "tumor" and "malignant tumor" all relate equally to hyperplasia of tissue or organ. If the tissue is part of the lymphatic or immune system, the malignant cells may include non-solid tumors of circulating cells. Malignant tumors of other tissues or organs may produce solid tumors. In general, the methods and compositions of the present invention may be used in the treatment of non-solid and solid tumors. The malignant tumors contemplated by the present invention may be any one of carcinoma, melanoma, lymphoma, leukemia, myeloma and sarcoma.

[0178] As used herein, carcinoma refers to an aggressive malignant tumor composed of transformed epithelial cells, or it refers to a malignant tumor composed of transformed cells of unknown histogenesis, which have specific molecules associated with epithelial cells or histological characteristics such as the production of cytokeratins or intercellular crosslinks.

[0179] As used herein, melanoma is a malignant tumor of melanocytes. Melanocytes are the cells that produce the dark pigment melanin and are responsible for skin color. They occur primarily in the skin, but are also found in other parts of the body, including the intestine and eyes. Melanoma can occur in any part of the body that contains melanocytes.

[0180] Leukemia refers to progressive malignant diseases of the blood-forming organs, usually characterized by distorted proliferation and development of white blood cells and their precursors in the blood and bone marrow. Leukemias are usually classified clinically on the basis of (1) the duration and nature of the disease-acute or chronic; (2) the type of cells involved-myeloid (myeloid), lymphocytic (lymphotropic), or monocytic; and (3) increased or non-increased numbers of abnormal cells-leukemic or non-leukemic (subleukemic).

[0181] Sarcomas are cancers that arise from transformed connective tissue cells. These cells originate from the embryonic mesoderm, or intermediate layer, which forms bone, cartilage, and adipose tissue. This is in contrast to carcinomas, which originate in the epithelium. Epithelium lines the surfaces of structures throughout the body and is the origin of breast, colon, and pancreatic cancers. Myeloma, as referred to herein, is a cancer of plasma cells, a type of white blood cell that is usually involved in the production of antibodies. Collections of abnormal cells accumulate in the bones, where they cause bone lesions, and in the bone marrow, where they interfere with the production of normal blood cells. Most myeloma cases are also characterized by the production of abnormal antibody paraproteins that can cause kidney damage and interfere with the production of normal antibodies, resulting in immune deficiency. Hypercalcemia (high calcium levels) often occurs. Lymphoma is a cancer of the lymphatic cells of the immune system. Lymphomas usually present as solid tumors of lymphatic cells. These malignant cells often originate in the lymph nodes and appear as enlargements of the nodes (tumors). It may also affect other organs, in which case it is called extranodal lymphoma.Non-limiting examples of lymphomas include Hodgkin's disease, non-Hodgkin's lymphoma, and Burkitt's lymphoma.

[0182] Further non-limiting examples of malignancies that may be treated or inhibited by the present invention include non-solid cancers, e.g., hematopoietic malignancies such as all types of leukemia, e.g., acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS), mast cell leukemia, hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, and multiple myeloma. Non-limiting examples of solid tumors that may be treated or inhibited by the present invention include tumors of the lips and oral cavity, pharynx, larynx, paranasal sinuses, major salivary glands, thyroid, esophagus, stomach, small intestine, colon, colorectum, anal canal, liver, gallbladder, extrahepatic bile duct, ampulla of Vater, exocrine pancreas, lung, pleural mesothelioma, bone, soft tissue sarcoma, carcinoma, and malignant melanoma of the skin, breast, vulva, vagina, cervix, uterus, ovary, fallopian tube, gestational trophoblastic neoplasm, penis, prostate, testis, kidney, renal pelvis, ureter, bladder, urethra, eyelid, carcinoma of the conjunctiva, malignant melanoma of the conjunctiva, malignant melanoma of the uvea, retinoblastoma, carcinoma of the lacrimal gland, sarcoma of the orbit, brain, spinal cord, vasculature, angiosarcoma, and Kaposi's sarcoma. In some embodiments, the cancer is a solid tumor. In some embodiments, the solid tumor is breast cancer.

[0183] MPO is the etiology of atherosclerosis and multiple inflammatory diseases, including cardiovascular disease, renal disease, pulmonary inflammation, rheumatoid arthritis, skin inflammation, neurological disease, and metabolic syndrome. More specifically, in glomerular and tubulointerstitial diseases, polymorphonuclear- and monocyte-derived reactive oxygen species may contribute to the oxidative modification of proteins, lipids, and nucleic acids. In part, the process induced by reactive oxygen species is comparable to the events that lead to the development of atherosclerosis. Thus, in some embodiments, the methods and compositions of the present invention are applicable to atherosclerosis and cardiovascular disease, such as endotoxemia, myocardial infarction / ischemia, vascular insufficiency, and atrial fibrillation.

[0184] Furthermore, in the presence of chloride ions, hydrogen peroxide is converted to hypochlorous acid / hypochlorite (HOCl / OCl). -The ability of MPO to generate chlorinated proteins is a unique and characteristic activity of this enzyme. The MPO-hydrogen peroxide-chloride system leads to a variety of chlorinated protein and lipid adducts, which in turn can cause cellular dysfunction in different compartments of the kidney. Thus, in some embodiments, the methods and compositions of the present invention are applicable to a variety of renal diseases, which can include chronic kidney disease, ischemia / reperfusion injury, glomerulonephritis, and lupus nephritis.

[0185] In some further embodiments, the methods, compositions, cells and kits of the present invention are applicable to at least one respiratory condition. As used herein, a respiratory condition or disease encompasses pathological conditions that affect organs and tissues that are part of the respiratory tract. These conditions include conditions of the airways, including the trachea, bronchi, bronchioles, alveoli, pleura, pleural cavities, and respiratory nerves and muscles. Respiratory diseases range from mild and self-limited to life-threatening diseases and include chronic and acute conditions. Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lungs. They are characterized by high inflammatory cell recruitment (neutrophils) and / or harmful infection cycles. Respiratory diseases can be classified in many different ways, such as by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

[0186] In some embodiments, respiratory conditions encompassed by the present invention include, but are not limited to, at least one of pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and chronic granulomatous disease (GCD). More specifically, Klinke et al. (Klinke et al. (2018) JCI Insight; 3(11): e97530) demonstrated a mechanistic link between MPO and dysfunctional pulmonary vascular function, suggesting that pulmonary arterial hypertension may be reversed by MPO inhibition. Specifically, they showed that MPO is elevated in patients with pulmonary arterial hypertension, which correlates with subsequent adverse outcomes. In addition, they showed that patients with high MPO levels (>583 pmol / L) had reduced survival compared to a median of 65 weeks compared to patients with low MPO levels (P=0.023). Furthermore, MPO-deficient mice (MPO- / -) showed less increase in right ventricular pressure during hypoxia compared to wild-type mice. Hypoxia-induced activation of the Rho kinase pathway, a key intracellular signaling pathway involved in vasoconstriction and structural vascular remodeling, was attenuated in MPO- / - mice. Thus, this study shows a clear mechanistic link between MPO, Rho kinase activation, and adverse pulmonary vascular function. Thus, in some embodiments, the methods of the present invention are applicable to reducing MPO levels in subjects suffering from PAH. In some further embodiments, the methods of the present invention are applicable to treating subjects suffering from PAH.

[0187] As used herein, pulmonary arterial hypertension (PAH) is a non-cure, progressive disease characterized by remodeling and narrowing of the pulmonary arteries, which leads to elevated right ventricular pressure, heart failure, and death. The leukocyte-derived heme enzyme myeloperoxidase (MPO) has been clearly established as a central mediator of humoral dysfunction of the vascular wall, making it a potential mediator of PAH.

[0188] Furthermore, myeloperoxidase is a potent oxidant stored in the primary granules of neutrophils, with potent antibacterial and proatherogenic properties.Myeloperoxidase has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD).More specifically, increased serum myeloperoxidase levels are associated with rapid lung function decline and poor cardiovascular outcomes in COPD patients, supporting the emerging role of myeloperoxidase in the pathogenesis of COPD progression.

[0189] Furthermore, myeloperoxidase is the major peroxidase enzyme in neutrophil granules and has been implicated in the pathogenesis of inflammatory lung injury in cystic fibrosis.Free myeloperoxidase is present in cystic fibrosis lung fluid and generates hypochlorous acid.Thus, in some embodiments, the methods and compositions of the present invention are applicable to various pulmonary inflammation conditions, including cystic fibrosis, COPD, sepsis-induced injury, influenza virus-induced injury, asbestos-induced injury and acute pulmonary inflammation.

[0190] Other inflammatory diseases that can be used with the present invention include rheumatoid arthritis and skin inflammation. In providing methods and compositions for regulating MPO expression, levels, and activity in a subject in need, the present invention further encompasses providing treatment of disorders associated with reduced or decreased MPO expression and / or activity, or disorders or conditions that are alternatively or additionally associated with other factors but that can be ameliorated or affected by regulating MPO expression and / or activity. In some embodiments, such conditions or disorders are referred to herein as indirectly associated with MPO. By regulating and enhancing MPO levels using the methods of the present invention, the present specification further provides methods for the treatment of conditions, for example, associated with ROS deficiency and / or MPO deficiency. Thus, in some embodiments, MPO-related conditions to which the methods of the present invention are applicable can be associated with reduced or absent ROS levels. A non-limiting example of a disorder associated with other factors, for example, ROS, is chronic granulomatous disease (GCD), which is defined as a genetic defect in the reactive oxygen species (ROS)-producing phagocyte NADPH oxidase NOX2. In such cases, increasing levels of MPO may result in increased ROS, thereby providing a tool to treat ROS-associated disorders.

[0191] Thus, in some specific embodiments, the present invention is further applicable to chronic granulomatous disease (CGD), which may be associated with ROS damage. In some embodiments, the methods of the present invention are applicable to any condition associated with MPO deficiency or caused directly or indirectly by MPO depletion.

[0192] It should be understood that the present invention provides a therapeutic method for treating MPO-related disorders, such as AD, MS, P-ANCA-associated disorders and PAH, or any of the disorders disclosed by the present invention, by removing or reducing MPO levels in undifferentiated BM cells of a subject. As disclosed above, the present invention provides therapeutic methods, compositions, kits and cells for manipulating the immune system of a subject, in particular by targeting MPO in undifferentiated BM cells of a subject, thereby leading to the manipulation of MPO levels in any tissue and organ of said subject. As shown in this aspect, such modulation is effectively used by the present invention for therapeutic applications, in particular for the treatment of MPO-related conditions, such as AD, MS, P-ANCA-associated disorders and PAH. Thus, it should be understood that in some specific non-limiting embodiments, the present invention provides methods, compositions and kits for treating subjects suffering from MPO-related conditions, such as AD, MS, P-ANCA-associated disorders and PAH, by manipulating the immune system of the subject, in particular the subject's BM cells, to exhibit regulated MPO levels, expression and / or activity. More specifically, the therapeutic methods of the present invention are based on the provision of an engineered immune system (of autologous or allogeneic or syngeneic origin). Alternatively, the immune system of a subject can be engineered in vivo using the gene editing system provided herein (e.g., administering the compounds of the gene editing system to the subject), whereby the BM cell population of said subject exhibits regulated MPO levels, expression and / or activity. Thus, the therapeutic methods, kits and compositions of the present invention provide an effective therapeutic strategy for treating such pathologies. Also, in some further specific embodiments, such therapeutic strategies can be carried out by transplanting BM cells exhibiting regulated levels, expression and / or activity of MPO into subjects suffering from MPO-related conditions, such as MS or AD, in some embodiments, subjects that have been subjected to immune ablation prior to transplantation. By transplanting BM cells exhibiting regulated (e.g., reduced or eliminated) levels, expression or activity of MPO, the transplanted subject exhibits regulated expression of MPO in any tissue and organ.As will be explained in more detail by the present invention, it should be understood that the transplanted BM cells can be autologous BM cells obtained from the same subject and ex vivo engineered using the gene editing system of the present invention to modulate MPO levels, expression or activity. For example, in some specific embodiments, BM cells obtained from a subject can be subjected to the gene editing system of the present invention ex vivo. This can result in the removal and reduction of MPO levels, expression and / or activity. Alternatively, undifferentiated BM cells of allogeneic or syngeneic origin that exhibit modulated MPO levels, expression and / or activity (naturally or by applying the gene editing system of the present invention) can be used. Such autologous or allogeneic BM cells that are MPO deficient are reintroduced into the subject, which in some embodiments can be treated with an immune ablative compound, so that these engineered and transplanted BM cells replace at least a portion of the subject's immune system. This procedure results in the depletion of MPO in any organ or tissue of the subject. As indicated above, MPO-depleted BM cells can be obtained from the subject or from an allogeneic or syngeneic subject. More specifically, transplantation of these autologous or allogeneic BM cells into a subject, or in other words replacement of the subject's immune system cells with BM cells exhibiting regulated MPO levels, expression and / or activity (e.g., ablated or reduced MPO levels, expression and / or activity), leads to modulation of MPO levels, expression and / or activity in all tissues and organs of said subject, thereby providing a novel and original approach for the treatment of any MPO-associated disorder or condition, in particular AD, MS, P-ANCA-associated disorders and PAH, or any disorder or condition disclosed by the present invention.

[0193] As mentioned above, the present invention provides a method of treating the above-named disorders. As used herein, the term "treatment" refers to the administration of a therapeutic amount of the compositions of the present invention, particularly BM cells exhibiting the above-mentioned CRISPR system or regulated MPO expression, effective to ameliorate undesirable symptoms associated with the disease, to prevent such symptoms before they occur, to slow the progression of the disease, to slow the worsening of symptoms, to promote the onset of a period of remission, to slow irreversible damage that occurs in the progressive chronic stage of the disease, to delay the onset of the progressive stage, to reduce the severity or cure the disease, to improve survival or recover more rapidly, or to prevent the onset of the disease or a combination of two or more of the above. Treatment can be administered when the immune-related autoimmune, neurodegenerative, respiratory, inflammatory or proliferative condition first occurs, or can be administered continuously, for example, by administration twice or more per day, every 1-7 days, every 7-15 days, every 15-30 days, every month to every two months, every two months to every six months, or more.

[0194] As mentioned above, the present invention further provides a preventative tool for preventing MPO-related disorders even before the appearance of any symptoms of the disease, based on the expression and / or activity of MPO in a subject. The term "prevention" refers to preventing or reducing the risk of the occurrence of a biological or medical event, particularly an immune-related, autoimmune, neurodegenerative, inflammatory condition, that is sought to be prevented in a tissue, system, animal or human by a researcher, veterinarian, physician or other clinician, and the term "prophylactically effective amount" is intended to mean that the amount of active ingredient administered achieves this purpose. Thus, in certain embodiments, the method of the present invention is particularly effective in preventing, i.e., preventing conditions associated with immune-related, autoimmune, neurodegenerative, inflammatory or proliferative disorders discussed herein. Thus, subjects treated by the method of the present invention or administered the composition are less likely to experience symptoms associated with the above-mentioned neurodegenerative, vascular and / or inflammatory diseases. Also, subjects who have already experienced them in the past are similarly less likely to have them reoccur.

[0195] As referred to herein, the term "amelioration" refers to the reduction in symptoms and improvement in the condition of a subject brought about by the compositions and methods according to the present invention, said improvement may be manifested in the form of suppression of, significant reduction in the magnitude of, or improvement in the physiological condition of an afflicted subject, pathological processes associated with an immune-related, autoimmune, neurodegenerative, inflammatory or proliferative disorder as described herein.

[0196] The term "inhibit" and all variations of this term are intended to encompass the limiting or prohibition of the progression of a pathological symptom or pathological process, the progression and exacerbation of said pathological process symptom or process associated therewith.

[0197] The term "elimination" relates to the substantial eradication or elimination of the pathological symptoms and, optionally, the cause of the pathology, optionally by the methods of the invention described herein.

[0198] The term "delay" or "delayed onset" and all variations thereof are intended to encompass the slowing of the progression and / or exacerbation of disorders associated with immune-related, autoimmune, neurodegenerative, inflammatory or proliferative disorders and symptoms thereof, the slowing of their progression, further exacerbation or onset, so as to appear later than would be the case in the absence of treatment according to the present invention.

[0199] As mentioned above, treating or preventing includes preventing or delaying the onset of a disease, preventing or delaying the onset of symptoms and / or reducing the severity of such symptoms that develop or are predicted to develop. These further include reversing existing symptoms, preventing additional symptoms, and reversing or preventing the metabolic causes of the underlying symptoms. As referred to herein, the terms "suppressing", "alleviating", "reducing" or "attenuating" refer to the suppression or reduction of about 1% to about 5%, about 5% to 10%, about 10% to 15%, about 15% to 20%, about 20% to 25%, about 25% to 30%, about 30% to 35%, about 35% to 40% of a process, particularly an immune-related, autoimmune, neurodegenerative, inflammatory or proliferative disorder. It should be understood that this relates to any one of a delay, limitation or reduction of % to 40%, about 40% to 45%, about 45% to 50%, about 50% to 55%, about 55% to 60%, about 60% to 65%, about 65% to 70%, about 75% to 80%, about 80% to 85%, about 85% to 90%, about 90% to 95%, about 95% to 99%, or about 99% to 99.9%, 100% or more.

[0200] The present invention relates to the treatment of subjects, or patients, in need thereof. "Patient" or "subject in need" refers to any organism that may suffer from the above conditions and for which the preventive and prophylactic compositions and methods described herein are desirable. More specifically, the compositions, kits and methods of the present invention are intended to prevent mammalian pathologies. "Mammalian subject" refers to any mammal, including human, canine and feline subjects, bovine, simian, equine and murine subjects, and domestic and non-domestic mammals such as rodents, for which the proposed therapy is desirable. It is noted that in particular, in the case of non-human subjects, the method of the present invention can be carried out by administration via injection, drinking water, feeding, spray, oral lavage, and direct administration to the subject's digestive tract.

[0201] It should be understood that any systemic or local administration method can be applied in the present invention.The administration route of the MPO targeting CRISPR system of the present invention or any composition thereof or the BM cell population of the present invention or any composition thereof includes, but is not limited to, direct BM injection or implantation, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracapsular, intraspinal and / or perispinal administration route, by intracranial or intraspinal needle and / or catheter delivery with or without pump device.It should be understood that any further administration method can be applied in some embodiments, such as intraperitoneal (IP), intravenous (IV) and intradermal, subcutaneous, nasal, pulmonary, oral and intramuscular administration.

[0202] In yet a further aspect, the present invention relates to a pharmaceutical composition comprising a gene editing compound, in particular at least the MPO-targeting CRISPR system provided by the present invention, which is administered in free form directly to the subject to be treated. Alternatively, in some further embodiments, the present invention provides a pharmaceutical composition comprising a BM cell population and in particular undifferentiated BM cells, such as HSCs, that exhibit regulated MPO expression and / or activity, all of which have regulated MPO expression and / or activity. Thus, in some embodiments, the pharmaceutical composition of the present invention may comprise at least one therapeutically effective amount of (a) at least one gene editing compound capable of or adapted to regulate the expression and / or activity of MPO in at least one undifferentiated BM cell of a subject in need thereof, and (b) an undifferentiated BM cell population that exhibits regulated expression and / or activity of MPO. It is noted that the composition of the present invention may optionally further comprise at least one of a pharma- ceutically acceptable carrier, diluent, and / or excipient.

[0203] In some embodiments, the pharmaceutical composition may comprise at least one therapeutically effective amount of the gene editing compound described herein above according to the aspects of the present invention. More specifically, in some embodiments, the at least one gene editing compound is at least one PEN, or any nucleic acid molecule comprising a sequence encoding said PEN, or any kit, composition or vehicle comprising at least one PEN or any nucleic acid molecule encoding such PEN. In some embodiments, the composition of the present invention may comprise a gene editing compound which may be at least one PEN comprising at least one CRISPR / Cas system. In more specific embodiments, the CRISPR / Cas system comprised in the composition of the present invention may comprise at least one of (a) at least one CRISPR / cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA. It should be understood that the composition of the present invention may comprise any kit, composition or vehicle comprising at least one of (a) and (b).

[0204] In some embodiments, the cas protein of the composition of the invention may be at least one member of the CRISPR binding system of class 1 and class 2. In some particular embodiments, the Cas protein included in the composition of the invention may be at least one member of the CRISPR binding system of class 1 and class 2, in particular, any one of type II, type I, type III, type IV, type V and type VI. In more particular embodiments, such a cas protein may be a member of type II of the CRISPR binding system class 2. Still further, in some embodiments, the pharmaceutical composition of the invention may comprise, as a Cas protein, Cas9 or any fragment, mutant, variant or derivative thereof.

[0205] Thus, in some embodiments, the compositions of the invention may comprise a CRISPR / Cas gene editing system. This system may, in some embodiments, comprise two elements: at least one gRNA and at least one Cas9, or any mutant, fragment or variant thereof. It should be understood that both elements may be provided as a gRNA and a polypeptide (cas9), or as a nucleic acid sequence encoding these elements. In some embodiments, the nucleic acid sequence encoding the gRNA may be provided alone or in a nucleic acid molecule that also comprises a nucleic acid sequence encoding a Cas9 polypeptide, in particular in a single nucleic acid molecule or vector. In yet some further embodiments, the compositions of the invention may optionally further comprise at least one of a pharma- ceutically acceptable carrier, diluent, and / or excipient. In yet some further embodiments, the compositions of the invention may comprise at least one gRNA targeting a protospacer in the MPO gene. More specifically, in some embodiments, the gRNA or crRNA of the present invention may target a protospacer comprising a nucleic acid sequence represented by SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NOs: 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, and 106 of the human MPO gene, or any fragment thereof. Also, in some specific embodiments, the crRNA (gRNA) useful in the compositions of the present invention may comprise a nucleic acid sequence represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 42, 47, and any one of SEQ ID NOs: 50, 55, 60, 63, 66, 71, 74, 77, 80, 85, 88, and 91. In yet some further embodiments, a gRNA is used that targets a protospacer in the mouse MPO gene, and such a gRNA may comprise a nucleic acid sequence represented by any one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14. As noted above, in some alternative embodiments, the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a BM cell population, particularly an undifferentiated BM cell population, that may exhibit regulated expression and / or activity of MPO.The compositions of the present invention may include kits that include a cell population or any combination thereof, together with the gene editing compounds described above. In some embodiments, the compositions may optionally further include at least one of a pharma- ceutically acceptable carrier, diluent, and / or excipient.

[0206] As described herein above, the undifferentiated BM cell population exhibiting regulated MPO expression and / or activity may comprise isolated HSC and / or progenitor cells. Still further, in some embodiments, the undifferentiated BM cell of the composition of the present invention may be a BM cell population transduced or transfected with at least one gene editing compound capable of regulating the expression and / or activity of MPO in said cells. It should be understood that in some embodiments, the undifferentiated BM cell population may be from an autologous or allogeneic source. The use of cells of syngeneic origin is also encompassed by the present invention.

[0207] In yet some further embodiments, the undifferentiated BM cell population comprised in the compositions of the invention may be an allogeneic subject BM cell population that exhibits suppressed or ablated MPO expression and / or activity. It is to be understood that any of the cells previously disclosed herein in relation to any other aspect of the invention are also applicable in relation to this aspect as well.

[0208] In certain embodiments, the compositions of the present invention are applicable for use in a method for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-associated condition or disease in a mammalian subject as described herein. More specifically, in some embodiments, the compositions of the present invention may be suitable for use in treating an MPO-associated condition, which may be at least one of an immune-related disorder, a neurodegenerative disease, a proliferative disorder, a respiratory disorder, a vascular disorder, or any combination thereof. In some more particular embodiments, such immune-related disorder may be at least one of an autoimmune disease and an inflammatory disease. In certain embodiments, the present invention provides compositions for use in treating autoimmune diseases, such as MS, ANCA conditions, particularly any one of AAV, AAGN, NCGN, and RPGN, and SLE. In some further particular embodiments, the compositions of the present invention are applicable for neurodegenerative diseases, in some particular embodiments, neurodegenerative diseases, such as AD or PD. In some further embodiments, the pharmaceutical compositions of the present invention are applicable for treating proliferative disorders, particularly cancer. Yet further embodiments of the present invention provide the use of the pharmaceutical compositions of the present invention for treating inflammatory diseases, particularly any one of atherosclerosis, RA, and IBD. In some further embodiments, the present invention also provides the use of the pharmaceutical composition of the present invention for the treatment of respiratory diseases, in particular for the treatment of PAH. In some alternative embodiments, the present invention encompasses the provision of pharmaceutical compositions that lead to increased expression and / or activity of MPO. In some embodiments, the present invention further provides compositions for use in the treatment of disorders associated with MPO deficiency, e.g., with elevated H2O2 levels, particularly as discussed herein above. It is to be understood that any of the disorders or conditions disclosed by the present invention in relation to other aspects of the present invention, or any stages or symptoms associated therewith, are equally applicable to this aspect, particularly in relation to the compositions of the present invention.

[0209] The pharmaceutical composition of the present invention may be mixed in a pharma- ceutically acceptable carrier before administration. Therapeutic formulations may be administered in any conventional dosage form. The formulations usually include at least one active ingredient, as defined above, together with one or more carriers that are pharma- ceutically and physiologically acceptable in the sense that they are compatible with the other ingredients and not harmful to the patient. In some particular embodiments, the pharmaceutical composition of the present invention may be suitable for injection. Pharmaceutical forms suitable for use by injection include sterile aqueous solutions or dispersions, and sterile powders for extemporaneous preparation of injectable sterile solutions or dispersions. In all cases, the form must be sterile and fluid to the extent that it is easily injectable. Nanoscale drug delivery systems using micelle formulations, liposomes, and nanoparticles, such as gold nanoparticles, are emerging technologies for rational drug delivery, offering improved pharmacokinetic properties, controlled and sustained release of drugs, and more importantly, lower systemic toxicity. Thus, in some embodiments, nanoparticle-based delivery may be used to deliver the CRISPR system of the present invention. A particularly desirable strategy allows for external triggering of the release of the encapsulated compound. Controlled release from the outside can be achieved when drug delivery carriers such as micelles, liposomes, polyelectrolyte multilayer capsules, etc. incorporate nanoparticle (NP) manipulation devices. More specifically, controlled drug delivery systems (DDS) have several advantages over traditional forms of drugs.

[0210] It should therefore be understood that the present invention further encompasses the use of various nanostructures, including micelle formulations, liposomes, polymers, dendrimers, metals, particularly gold, silicon or carbon materials, polymeric nanoparticles and magnetic nanoparticles, as carriers in drug delivery systems. The terms "nanostructure" or "nanoparticle" are used herein to refer to any microscopic particle smaller than about 100 nm diameter. In some other embodiments, the carrier is an organized assembly of lipids. The pharmaceutical composition of the present invention typically includes a buffer, an agent to adjust its osmolality, and optionally one or more pharma- ceutically acceptable carriers, excipients and / or additives known in the art. As used herein, "pharma-ceutically acceptable carrier" includes any and all solvents, dispersion media, coating agents, antibacterial and antifungal agents, and the like. The use of such media and agents for pharmaceutical active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, their use in therapeutic compositions is contemplated. Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets.Thickening, flavoring, diluents, emulsifying, dispersing agents or binders may be desirable.

[0211] In some further embodiments, various administration methods are applicable, particularly when in vivo applications (e.g., CRISPR / Cas systems or nucleic acid sequences encoding same) are disclosed, and thus the compositions of the present invention may be adapted for any of the administration methods disclosed in the present invention, particularly intraperitoneal (IP), intravenous (IV), parenteral, and intradermal, subcutaneous, topical, nasal, pulmonary, oral, intramedullary, intramuscular, sublingual, buccal, rectal, vaginal administration. In some further embodiments, particularly for respiratory disorders, pulmonary administration is considered to be the preferred administration method. The term "administration" refers to pulmonary delivery by oral inhalation, such as liquid nebulizers, aerosol-based metered dose inhalers (MDIs), or dry powder dispersion devices, or by intraperitoneal injection, when related to the treatment of respiratory disorders. Alternatively, administration may be any one of sublingual, buccal, parenteral, intravenous, intramuscular, subcutaneous, intramedullary, or transdermal.

[0212] In yet another aspect, the invention provides at least one therapeutically effective amount of (a) at least one gene editing compound adapted to modulate expression and / or activity of MPO in at least one undifferentiated BM cell in a mammalian subject, and (b) an undifferentiated BM cell population exhibiting modulated expression and / or activity of MPO, for use in a method of treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-associated condition. In some embodiments, the undifferentiated BM cells are a BM cell population that has been transduced or transfected with at least one gene editing compound capable of modulating expression and / or activity of MPO in the cells.

[0213] In yet some further embodiments, the gene editing compound is at least one PEN comprising at least one CRISPR / cas system, the CRISPR / cas system comprising at least one of: (a) at least one CRISPR / cas protein, or any nucleic acid molecule encoding the Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding the gRNA, or a kit, composition, or vehicle comprising at least one of (a) and (b).

[0214] In some further of its aspects, the invention provides for the use of a therapeutically effective amount of at least one gene edit capable of regulating the expression and / or activity of MPO in at least one undifferentiated BM cell of a mammalian subject in the preparation of a composition for treating, preventing, ameliorating, suppressing or delaying the onset of an MPO-associated condition or disease in said subject.

[0215] In some further of its aspects, the invention provides for the use of a therapeutically effective amount of an undifferentiated BM cell population exhibiting regulated MPO expression and / or activity in the preparation of a composition for treating, preventing, ameliorating, suppressing or delaying the onset of an MPO-associated condition or disease in a mammalian subject.

[0216] In yet a further aspect, the present invention provides a therapeutic kit comprising at least one of: (a) at least one gene editing compound capable of modulating expression and / or activity of MPO in at least one undifferentiated BM cell of a subject in need thereof; and (b) a population of undifferentiated BM cells exhibiting modulated expression and / or activity of MPO.

[0217] Still further, in some other aspects, the present invention relates to at least one undifferentiated BM cell transduced or transduced with at least one gene editing compound capable of modulating the expression and / or activity of MPO in the cell.

[0218] In some particular embodiments, the cells may be derived from a subject suffering from an MPO-associated condition. In some further alternative disorders, the cells may be derived from an allogeneic or syngeneic subject. Any cell and any gene editing compound disclosed by the present invention are equally applicable to this aspect.

[0219] In yet some further embodiments, the invention provides any of the cells disclosed herein for use in a method for modulating MPO expression and / or activity in a mammalian subject. In yet some further embodiments, the invention provides any of the cells disclosed herein for use in a method for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-associated condition in a mammalian subject.

[0220] It is to be understood that any of the MPO disorders disclosed herein are applicable to this embodiment as well. It is further to be understood that all cells, gene editing systems disclosed herein in relation to any of the embodiments of the invention are also applicable to any other embodiment disclosed herein.

[0221] As shown above, MPO is involved in NETosis, and thus, by modulating the level, expression and / or function of MPO, the present invention further provides an approach for modulating NETosis. Thus, in some further aspects, the present invention provides a method for modulating NETosis, particularly in a subject. Furthermore, by providing a method for inhibiting MPO expression and / or activity, the present invention further provides, in some embodiments thereof, methods and compositions for inhibiting, eliminating or reducing NETosis, particularly in a subject in need thereof. It should be understood that in some further embodiments, the present invention provides methods and compositions for treating and preventing any NETosis-related disorder and condition in a subject. Upon stimulation, neutrophils rapidly activate NADPH oxidase to generate superoxide, a highly reactive molecule that dismutates to hydrogen peroxide (H2O2). H2O2 is consumed by MPO to produce hypochlorous acid (HOCl) and other oxidants. MPO is also required for NET formation, as shown in donors with complete MPO deficiency, although its role remains unclear. Although ROS are cytotoxic, they are also important signaling mediators that regulate protein function through the oxidation of specific amino acid residues. However, because ROS are highly reactive and short-lived molecules, it is unclear how they can generate specific cellular responses. In particular, it is not known how ROS regulate the selective movement of NE from granules to the nucleus during NET formation. Furthermore, as the nucleus begins to decondense during NET formation, neutrophil chemotaxis is halted by an unknown mechanism. Thus, in yet a further aspect thereof, the present invention provides a method for modulating neutrophil cell properties and functions.

[0222] As used herein, the term "about" refers to values ​​that may deviate up to 1%, more particularly 5%, more particularly 10%, more particularly 15%, and in some cases up to 20% higher or lower than the referenced value, the deviation range including integer values ​​and, where applicable, non-integer values ​​to form a continuous range. In some embodiments, the term "about" refers to ±10%.

[0223] The terms "comprises, comprising, includes, including," "having," and their cognates mean "including but not limited to." This term encompasses the terms "consisting of" and "consisting essentially of." The term "consisting essentially of" means that the composition or method may include additional components and / or steps and / or moieties, but only if the additional components and / or steps do not materially change the basic and novel characteristics of the claimed composition or method. Unless the context requires otherwise, throughout this specification and the examples and claims that follow, the terms "comprise," as well as variations such as "comprises" and "comprising," will be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.

[0224] As used in this specification and the claims, unless expressly indicated otherwise, the indefinite articles "a" and "an" should be understood to mean "at least one." It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise.

[0225] As used herein and in the claims, the phrase "and / or" should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctive in some cases and disjunctive in other cases. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so conjoined. Other elements, other than the elements specifically identified by the "and / or" clause, may optionally be present, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used with an open-ended term such as "comprising," can refer in one embodiment to A only (optionally including elements other than B); in another embodiment to B only (optionally including elements other than A); in yet another embodiment to both A and B (optionally including other elements); and so forth.

[0226] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" should be interpreted as inclusive, i.e., including at least one number or element of the list, but also including two or more number or elements of the list, and optionally additional non-list items. To the contrary, a clearly indicated "only," such as "only one" or "exactly one," or the term "consisting of," when used in the claims, refers to exactly one number or element of one list. In general, as used herein, the term "or" should only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by an exclusive term, such as "either," "one of," "only one of," or "exactly one." When used in the claims, "consisting essentially of" shall have its ordinary meaning as used in the field of patent law.

[0227] As used herein and in the claims, the phrase "at least one," in connection with a list of one or more elements, should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including each and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows that there may optionally be present elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, related or unrelated to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally, two or more, A and no B (and optionally including elements other than B); in another embodiment, to at least one, optionally, two or more, B and no A (and optionally including elements other than A); in yet another embodiment, to at least one, optionally, two or more, A, and at least one, optionally, two or more, B (and optionally including other elements); etc.

[0228] It should also be understood that, unless expressly indicated otherwise, in any method claimed herein that includes two or more steps, the order of the steps or acts is not limited to the order in which the method steps or acts are described.

[0229] Each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

[0230] As disclosed and described, the invention is not limited to the specific examples, method steps, and compositions disclosed herein, and it is to be understood that such method steps and compositions may vary somewhat. It is also to be understood that the terminology used herein is used only for the purpose of describing particular embodiments, and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims and equivalents thereof.

[0231] The following examples are representative of techniques employed by the inventors in carrying out aspects of the present invention. These techniques are illustrative of preferred embodiments for carrying out the invention, and it should be understood that, in light of this disclosure, one skilled in the art may make numerous modifications without departing from the spirit and intended scope of the invention.

[0232] Working Example reagent MOG35-55(Blavatnik center,Tel Aviv University) IFA (Sigma) Mycobacterium tuberculosis (MTB, H37Ra, Difco) Pertussis toxin (PT, Sigma) Ketamine (Bremer) Xylazine (Phibro) Sodium azide (Sigma, USA) Evans Blue dye (Sigma) Lipofectamine 2000 (Invitrogen)

[0233] Restriction enzymes BsmBI (NEB) T4 DNA ligase (NEB)

[0234] Plasmids pL-CRISPR.EFS.GFP (Addgene, Catalog no. #57818)

[0235] kit Magnetic cell separation kit (Miltenyi Biotech) DNeasy (Qiagen) ViraPower Promoterless Lentiviral Gateway Kit (Invitrogen, Carlsbad, CA, USA) Lenti-X p24 Rapid Titer Kit(Clontech,Mountain View,CA,USA)

[0236] antibody Mouse anti-myeloperoxidase (abcam); rabbit anti-neutrophil elastase (abcam); rabbit anti-Iba1 (abcam); rat anti-GFAP (Invitrogen); rat anti-CD3 (R&D Systems); mouse anti-TAU (abcam); mouse anti-amyloid beta (Covance); mouse anti-oligodendrocyte (Merck)

[0237] cell Competent E. coli cells (JM109, Promega), 293T cells (ATCC, CRL-3216®)

[0238] Media and supplements Stemspam SFEM medium (Stem cell technologies), TPO, SCF (Peprotech)

[0239] animal C57BL / 6 (Arlan); Mpo Tm1 / Lus (4265, Jackson labs), these mutant mice show impaired fungicidal activity due to myeloperoxidase deficiency. Under hyperlipidemic conditions, the mutant mice develop larger atherosclerotic lesions than control mice. These mice are useful for studying systemic inflammatory defense against pathogens. 5XFAD mice (34840, Jackson labs)

[0240] Experimental procedure Animal Housing C57BL / 6, Mpo Tm1 / Lus and 5XFAD mice were kept in a light-controlled environment (12-h light-dark cycle), housed in individually ventilated cages (IVCs), and provided with food and water ad libitum. All animal studies were approved by the Tel Aviv University Animal Care and Use Review Board (Supplementary Material B - Approval Nos. 01-17-069 and 01-18-010).

[0241] Mouse irradiation and cell transplantation Recipient mice received whole-body lethal irradiation of 9 Gy (3 Gy / min) from a gamma radiation source (Biobeam GM). 24 hours after irradiation, 2x10 6 Freshly isolated bone marrow cells or 5000 lentivirally transduced HSCs were injected intravenously via the tail vein of recipient mice using a 27 gauge needle. Mice were monitored and weighed every other day for the next 8 weeks.

[0242] MPO analysis of blood samples To confirm MPO knockdown, 200 μl of blood was collected from the facial vein 8 weeks after transplantation. The blood samples were analyzed for peroxidase activity using an ADVIA2120i (Siemens) blood testing system.

[0243] Bone marrow isolation and HSC enrichment C57BL / 6 (Arlan) or Mpo Tm1 / Lus (Jackson labs) Donor mice were sacrificed and bone marrow was harvested from femurs, tibias, and humeri using a 27 gauge needle. Red blood cells were lysed and cells were either immediately transplanted or enriched for lineage cells using a magnetic cell separation kit (Miltenyi Biotech). Cells were cultured in Stemspam SFEM medium (Stem Cell Technologies) supplemented with 50 ng / ml TPO and 100 ng / ml SCF (Peprotech).

[0244] Induction of the EAE model 14-16 week old C57BL / 6 mice were immunized subcutaneously at three injection sites with 300 μg of MOG35-55 (represented by SEQ ID NO: 7, MEVGWYRSPFSRVVHLYRNGK, Blavatnik center, Tel Aviv University) emulsified in IFA (Sigma) supplemented with 4 mg / ml Mycobacterium tuberculosis (MTB, H37Ra, Difco). On days 0 and 2 post-immunization, mice were administered intraperitoneally with 300 ng of pertussis toxin (PT, Sigma) in 200 μl of phosphate buffered saline (PBS). Disease severity was monitored daily and EAE clinical disease was scored according to the following scale: 0, no paralysis; 0.5, partial loss of tail flexibility; 1, complete loss of tail flexibility; 2, hind limb weakness and partial hind limb paralysis; 3, complete hind limb paralysis; 4, hind limb paralysis and forelimb weakness or partial forelimb paralysis; 5, moribund; and 6, death.

[0245] Behavioral testing Behavioral testing was performed starting at 7 months of age. Mice were acclimated to a reversed light environment 2 weeks prior to the start of testing. Before each trial, mice were transferred to the behavioral testing room 30 min prior to the start of trial acclimation. The order of trials was counterbalanced among the four treatments and genotypes. Between trials, the maze was cleaned with Virusolve. Open field, elevated plus maze, Y maze and Morris water maze tests were recorded, monitored and analyzed by an automated tracking system (Ethovision, Noldus).

[0246] An open field test was performed to assess risk assessment / anxiety-related behavior. The test was performed in a white Perspex empty arena (50x50x40cm). Mice were placed in the center of the arena and allowed to explore for 15 minutes. The total distance traveled and the time spent in the center of the maze and in the corners of the maze were measured.

[0247] An elevated plus maze test was performed to assess risk assessment / anxiety-related behavior. The test was performed in an apparatus consisting of four white Perspex arms (35x5cm) in a crossed configuration elevated 40cm above the floor. Two arms facing each other were enclosed with 15cm high walls, while the other two arms were open. Mice were placed in the center of the maze facing the closed arms and recorded for 7 minutes. The time spent in the open or closed arms of the maze was measured. Mice that fell from the open arms were excluded from the analysis.

[0248] Y-maze: A two-trial Y-maze was performed to assess spatial memory. Testing was performed in a white Perspex Y-shaped apparatus with arm length of 38 cm, width of 5 cm, and height of 15 cm. Testing consisted of a sample trial and a test trial. In the sample trial, the mouse was placed at the end of one arm of the maze facing the wall, while one arm of the maze was blocked and two arms of the maze were available for exploration for 5 min. After the sample trial, there was an intertrial interval of 5 min. In the test trial, the mouse was returned to the maze and all arms were opened for another 5 min. Novel arm entries (number of novel arm entries / total arm entries) and novel arm exploration time (novel exploration time / total arm exploration time) were measured during the first minute of the test trial.

[0249] Morris water maze was performed to evaluate spatial learning. Testing was performed in a pool (150 cm diameter, 30 cm depth) filled with water made opaque with skim milk. Black rectangular, triangular and circular markers were placed on the pool walls. The water temperature was 27±1°C. A transparent platform (12 cm×12 cm) was placed in the center of one quadrant of the pool, approximately 2 cm below the water surface. Each mouse received four trials per day for five consecutive days, starting each day from a different quadrant of the three quadrants that did not contain the platform. In each trial, the mouse was placed in the water and allowed to find the hidden platform for 60 seconds. If the mouse could not find the platform within 60 seconds, the rat was guided to the platform and remained there for 10 seconds. For each mouse, the latency to find the hidden platform within 60 seconds, as well as the total distance traveled, were recorded. Mice that did not find the platform were scored as reaching the platform in 60 seconds.

[0250] Fear conditioning test was performed to evaluate associative memory. Testing was performed in a fear conditioning chamber (Ugo Basile, 17x17x25cm). On day 1, mice were placed in the chamber for 5 minutes for habituation. On day 2, mice were placed in the chamber again for 3.5 minutes. After 2 minutes, mice received two foot shocks (0.8mA, 2 seconds) with an interval of 1 minute. On day 3, mice were placed in the chamber for 3 minutes. Fear conditioning was evaluated by scoring freezing behavior (absence of all movements except breathing).

[0251] Histological examination Mice are injected intraperitoneally with ketamine / xylazine (100 mg / kg and 10 mg / kg, respectively). Mice are then perfused intracardially with PBS, followed by ice-cold 4% paraformaldehyde (PFA) in PBS using an electric pump. Brains are removed and postfixed with 4% PFA at 4°C for 24 hours, then cryopreserved in 30% sucrose. Brains are then stored in PBS containing 0.02% sodium azide (Sigma, USA) at 4°C until immunohistochemical processing. Sucrose-treated brains are dried and then snap-frozen in 2-methylbutane in liquid nitrogen. Brains are sectioned (10 μm) using a cryostat and directly mounted on slides for analysis. Sections are blocked and permeabilized with PBS supplemented with 10% normal goat serum, 1% bovine serum albumin and 0.5% Triton 100 for 1 h, incubated with primary antibody overnight followed by incubation with secondary antibody for 1 h.

[0252] immunostaining Brains were snap frozen in liquid nitrogen-cooled 2-methylbutane and embedded in OCT compound before sectioning. Coronal sections (10 μm) were cut using a freezing sliding microtome (Leica CM1850) and stored at -20°C until use. For S100β immunostaining, slides were washed twice with PBS, blocked, permeabilized for 1 h with PBS supplemented with 1% bovine serum albumin, 5% goat serum (Biological Industries, Israel) and 0.05% Triton-X (Sigma-Aldrich), and incubated with S100β antibody (1:500, ab66028, Abcam) overnight at 4°C. Slides were washed three times with PBS and incubated with secondary goat anti-mouse antibody (1 / 700, Alexa-Flour) for 1 h at room temperature. DNA was stained with DAPI (1:1000, Sigma-Aldrich). For Thioflavin S (ThioS) staining, slides were incubated with a 0.01% ThioS solution in 50% ethanol for 8 min, after which sections were briefly incubated twice for 10 s with 80% ethanol and washed twice with double distilled water (DDW).

[0253] Confocal imaging Fluorescence images were acquired using a confocal microscope LSM710 (Carl Zeiss Micro Imaging). Confocal images were captured using 10x and 20x objectives (NA = 0.3, 0.8, Plan-Apochromat, respectively). Fluorescence emission from the Ar488 and 543 nm laser lines for EGFP and CY3, respectively, was detected using filter sets supplied by the manufacturer. For DAPI detection, we used a mode-locked Ti:sapphire, femtosecond-pulsed multiphoton laser (Chameleon Ultra II, Coherent, Inc.) at a wavelength of 720 nm. Images were generated using Zeiss ZEN 2011 software (Carl Zeiss, Inc.). All images were exported in TIF and their contrast and brightness were optimized using ImageJ. S100β mean intensity and ThioS plaque density were analyzed using ImageJ.

[0254] Tissue collection for RNA and protein analysis For RNA and protein analysis, mice were anesthetized with ketamine / xylazine and immediately perfused with PBS. Brains were removed, hippocampi dissected, divided into left and right hemispheres, snap frozen in liquid nitrogen, and stored at -80°C until use. For bone marrow RNA analysis, femurs were harvested and bone marrow was extracted by flushing in PBS with a 27 gauge needle. Bone marrow cells were frozen in Tri-Reagent (Sigma) and stored at -80°C until use.

[0255] Protein extraction and Western blot Hippocampi were thawed and homogenized in lysis buffer (200 mM HEPES, 5 mM EDTA supplemented with protease inhibitors (Roche), 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM Na2VO4, 150 mM NaCl and 50 mM NaF). Cells were incubated for 1 h at 4°C. Proteins were clarified by centrifugation at 14,000xg for 20 min at 4°C. Protein concentrations were quantified using the Pierce® BCA Protein Assay Kit (Thermo Scientific). 25 μg of protein from each sample was separated in SDS-PAGE. Nitrocellulose transfer membranes were blocked with 5% bovine serum albumin in 0.1% Tween 20 in PBS for 1 hour, detected with goat anti-APOE antibody (1:10,000, Chemicon) overnight at 4°C, and detected with goat anti-ACTIN antibody (1:5000, MAB1501, Millipore) for 1 hour at room temperature, followed by incubation with goat anti-mouse secondary antibody (1:5,000, Licor) for 1 hour at room temperature. Visualization and analysis of band intensity were performed using the Odyssey system (Licor) and Image Studio Lite 5.2 software. For each sample, APOE results were normalized to ACTIN.

[0256] RNA extraction and real-time PCR Hippocampal RNA was extracted using RNeasy Mini Kit (Qiagen). RNA was extracted from bone marrow samples and cleaned using RNeasy Mini Kit (Qiagen) as previously described. RNA was reverse transcribed into complementary DNA (cDNA) using verso cDNA synthesis kit (Thermo-Scientific). Semiquantitative PCR was performed on a Step-One Real time PCR system using Syber-Green Master mix (Thermo-Scientific) and custom-designed primers. Threshold cycle values ​​were determined in triplicate and presented as the mean relative to Actin. Fold changes were calculated as 2. -ΔΔCT was calculated using the method.

[0257] Primer set list (all for mouse genes) APOE forward, 5'-GAGCTGATCTGTCACCTCCG-3' (SEQ ID NO:17) and reverse 5'-GACTTGTTTCGGAAGGAGC-3' (SEQ ID NO:18); CCL2 forward, 5'-GGGATCATCTTGCTGGTGAA-3' (SEQ ID NO:19) and reverse 5'-AGGTCCCTGTCATGCTTCTG-3' (SEQ ID NO:20); CXCL10 forward, 5'-AACTGCATCCATATCGATGAC-3' (SEQ ID NO:21) and reverse 5'-GTGGCAATGATCTCAACAC-3' (SEQ ID NO:22); IL1β forward, 5'-GGAGAACCAAGCAACGACAAAATA-3' (SEQ ID NO:23) and reverse 5'-TGGGGAACTCTGCAGACTCAAAC-3' (SEQ ID NO:24); MPO Forward, 5'-TGGTGGCCTGCAGAGTATGA-3' (SEQ ID NO:25) and reverse 5'-GTTGAGGCCAGTGAAGAAGG-3' (SEQ ID NO:26); S100β forward, 5'-TTGCCCTCATTGATGTCTTCCA-3' (SEQ ID NO:27) and reverse 5'-TCTGCCTTGATTCTTACAGGTGAC-3' (SEQ ID NO:28); TNFα forward, 5'-AGGGTCTGGGCCATAGAACT-3' (SEQ ID NO:29) and reverse 5'-CCACCACGCTCTTCTGTCTAC-3' (SEQ ID NO:30); VCAM1 forward, 5'-GGAGCCTGTCAGTTTTGAGAATG-3' (SEQ ID NO:31) and reverse 5'-TTGGGGAAAGAGTAGATGTCCAC-3' (SEQ ID NO:32).

[0258] statistical analysis All data are expressed as mean ± SEM. Statistical analysis was performed using GraphPad Prism7. Behavioral data as well as bone marrow MPO mRNA levels were analyzed using unpaired Student's t-tests. Other mRNA analyses, blotting quantification, S100β intensity quantification and ThioS plaque density were analyzed using the Mann-Whitney non-parametric test. For all tests, the statistical significance threshold was set at p<0.05.

[0259] BBB permeability assay Mice were injected intraperitoneally with a 2% solution of Evans Blue dye in saline (4 ml / kg body weight). One hour after injection, mice were perfused with PBS, and brains and spinal cords were harvested and homogenized. Supernatants from homogenates were measured for absorbance at 610, indicating Evans Blue entry.

[0260] MPO CRISPR / Cas9 Plasmid Cloning Mouse MPO targeting guide RNAs (gRNAs), gRNA-3 (CCCCAACGATCAGCTGACCA) represented by SEQ ID NO:5 and gRNA-4 (CAGCGGGGTGTACGGCAGCG) represented by SEQ ID NO:6, and gRNA-2 (GCACTCATGTTCATGCAGTG) represented by SEQ ID NO:8 and gRNA-6 (TGCGATACTTGTCATTCGGT) represented by SEQ ID NO:9, were designed using Azimuth2.033 tools. The pL-CRISPR.EFS.GFP plasmid (gift from Benjamin Ebert, addgene plasmid #57818) was digested with BsmBI (NEB) and the gRNA sequences were ligated using T4 DNA ligase (NEB). The ligated plasmids were transformed into competent E. coli cells (JM109, Promega), selected with ampicillin, and ligation of the insert was confirmed by Sanger sequencing. MPO targeting was assessed by gene transfer into 293T cells followed by DNA extraction (DNeasy, Qiagen) and Sanger sequencing.

[0261] Lentiviral particle production The ligated plasmid was cloned using the ViraPower Promoterless Lentiviral Gateway Kit (Invitrogen, Carlsbad, CA, USA). Plasmids (3 μg) were cotransfected with packaging plasmids (9 μg): pLP1, pLP2, and pLP / VSVG into the 293T producer cell line using Lipofectamine 2000 (Invitrogen). Lentiviral titers were determined using the Lenti-X p24 Rapid Titer Kit and the manufacturer's recommended procedures (Clontech, Mountain View, CA, USA).

[0262] Lentiviral transduction of isolated HSCs 24 hours after isolation, HSCs were transduced with MPO CRISPR / Cas9 lentivirus in the presence of 4 μg / ml polybrene and 1 μg / ml rapamycin. Transduced cells were immediately transplanted into lethally irradiated mice or expanded ex vivo for CRISPR / Cas9 activity analysis. GFP expression was evident after 1 day in culture.

[0263] Example 1 Targeting MPO in the EAE model of multiple sclerosis EAE, or experimental allergic encephalomyelitis, is an induced inflammatory demyelinating disease of the central nervous system (CNS) that is widely accepted as an animal model for human CNS demyelinating diseases, including, but not limited to, multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). EAE can be induced in many species, including mice, rats, guinea pigs, rabbits, and primates. Induction of the disease is usually performed by exposure of the animals to various antigens. The most commonly used antigens are spinal cord homogenate (SCH), purified myelin, myelin proteins such as myelin basic protein (MBP), myelin proteolipid protein (PLP or lipophilin), and myelin oligodendrocyte glycoprotein (MOG), or peptides of these proteins, all of which generate distinct models with different disease characteristics in terms of both immunology and pathology.

[0264] Depending on the antigen used and the genetic factors of the animal, rodents can show monophasic attacks of EAE, relapsing-remitting, or chronic EAE. Typical susceptible rodents first show clinical symptoms approximately 2 weeks after immunization and exhibit symptoms of relapsing-remitting disease. Modeling of multiple sclerosis can be performed using C57BL / 6 female mice, and the disease is induced with myelin oligodendrocyte glycoprotein peptide (MOG). This model represents the progressive (also called chronic) form of the disease. Scoring indices shown in the experimental procedures are used to monitor the severity of the disease and the onset of relapse to measure the therapeutic effect of the compositions and kits of the present invention that modulate, particularly reduce or suppress MPO expression and / or activity.

[0265] Establishment of EAE model The EAE model of MS was induced by immunization of adult female mice with an adjuvant containing MOG35-55 peptide along with two immunizations with pertussis toxin (PT). To determine the minimal amount of these substances required to establish the EAE model, C57BL / 6 female mice were immunized with 200 ng of MOG35-55 and 200 μg of PT, 200 μg of MOG35-55 and 300 ng of PT, or 300 μg of MOG35-55 and 300 ng of PT. No difference in mouse clinical scores was noted between the first two doses, but the higher dose of 300 μg of MOG35-55 and 300 ng of PT induced severe disease in all immunized mice (Figure 1). This result indicates that this dose is the most suitable for enhancing EAE disease.

[0266] BM transplantation rescues lethality in irradiated C57BL / 6 mice. To identify radiation dose mortality and hematopoietic reconstitution capacity of BM cell transplantation, seven 8-week-old male C57BL / 6 mice were irradiated (9 Gy) and five of them were transplanted with 1 million freshly isolated BM cells via the tail vein. As expected, all mice showed a 4-10% weight loss after 48 hours (Figure 2). All transplanted mice showed rapid recovery and returned to their initial weight in 2 weeks, whereas non-transplanted mice deteriorated and died after 13-15 days. These results indicate that 9 Gy irradiation is lethal. Furthermore, all five mice transplanted with BM cells were able to recover after 14 days, indicating that indeed complete hematopoietic reconstitution was established at the time of transplantation.

[0267] To establish a more homogenous cell population for CRISPR-Cas9-mediated KO experiments, we further enriched for hematopoietic progenitors in BM cells by using magnetic activated cell sorting (MACS) to isolate BM cells that do not express markers of mature hematopoietic cells (i.e., Lin - To confirm that these cells retained their hematopoietic reconstitution potential, these cells were also transplanted into lethally irradiated C57BL / 6 mice. Similar to the BM-transplanted mice, these mice also showed a rapid loss of body weight after 48 hours, followed by recovery and survival (Figure 2). This result is in agreement with Lin's - This suggests that the hematopoietic progenitor cells retain their hematopoietic reconstitution potential and are suitable for CRISPR-Cas9 KO experiments.

[0268] MPO Tm1 / Lus Transplantation of derived BM into EAE mice To assess the impact of bone marrow MPO deficiency in the EAE mouse MS model, 28 female C57BL / 6 mice were lethally irradiated as described above and then cultured to generate WT C57BL / 6 mice expressing normal MPO or MPO knockout mice expressing MPO. Tm1 / Lus BM cells from mice (1x10 in 200 μl) 6 (individuals) were transplanted into irradiated EAE mice. Table 1 summarizes the experimental groups used in this study. [Table 1]

[0269] The impact of MPO deficiency on EAE disease course is evaluated by measuring disease clinical scores as described in the Experimental Procedures. Mice from all experimental groups are also evaluated by postmortem analysis to investigate EAE-related aspects such as neuronal loss, synaptic loss and microgliosis, as well as BBB permeability, leukocyte infiltration into the CNS, microgliosis and nephrosis rates.

[0270] Example 2 Targeting MPO in the FAD model of Alzheimer's disease (AD) MPO Tm1 / Lus Transplantation of BM from 5xFAD mice - Peroxidase activity assay To assess the impact of bone marrow MPO deficiency in the 5XFAD mouse model of AD, 70 male 5XFAD mice and their non-transgenic littermates were lethally irradiated and transformed into WT C57BL / 6 mice that normally express MPO, or into MPO knockout (KO) mice. Tm1 / Lus BM cells from mice (1x10 in 200 μl) 6 ) were transplanted into irradiated AD mice. The experimental groups are summarized in Table 2. Four weeks after transplantation, 84% of the mice survived and returned to their initial body weight (Figures 3A-3D). Eight weeks after transplantation, peroxidase activity was measured in blood samples from mice that received WT or MPO KO BM cell transplants. Indeed, blood samples from mice that received transplants of BM cells obtained from MPO KO mice showed lower peroxidase activity (Figures 3E-3F), confirming MPO KO hematopoietic reconstitution of MPO KO cells in these mice. [Table 2]

[0271] MPO Tm1 / Lus Transplantation of BM from 5XFAD mice - MPO-mRNA level study Hematological MPO deficiency was generated in adult 5XFAD mice and non-transgenic littermates. Two-month-old mice were subjected to hematopoietic ablation by exposure to myeloablative irradiation and repopulated with bone marrow (BM) cells from MPO-KO or WT C57BL / 6 mice. This formed four experimental groups: (1) WT with WT BM (WT-WT), (2) WT with MPO-KO BM (WT-MPO KO), (3) 5XFAD mice with WT BM (5XFAD-WT), and (4) 5XFAD with MPO-KO BM (5XFAD-MPO KO) (Figure 4A). To confirm MPO reduction in mice injected with MPO-KO BM, MPO-mRNA expression analysis was performed. Nearly undetectable MPO-mRNA levels were detected in BM from WT-MPO KO and 5XFAD-MPO KO mice compared to high levels in controls, indicating efficient replacement of hematopoietic populations in transplanted mice (Figure 4B).

[0272] MPO deficiency suppresses cognitive impairment in 5XFAD mice We investigated the impact of MPO KO on cognitive dysfunction in 5XFAD mice. To this end, transplanted mice were subjected to a series of behavioral tests starting at 7 months of age (Figure 4C). In the open field test, 5XFAD mice are known to show a dysfunction risk assessment reflected by a longer stay in the center of the maze rather than at the ends of the maze. Indeed, 5XFAD-WT mice stayed significantly shorter in the corners of the maze and longer in the center of the maze compared to WT-WT mice. In contrast, 5XFAD-MPO KO mice stayed significantly shorter in the center of the maze compared to 5XFAD-WT mice, exhibiting behavior comparable to the control WT mouse group (Figures 5A-5B). Notably, no differences in total distance traveled were measured between the four experimental groups, indicating similar mobility abilities (Figure 5C).

[0273] In the elevated plus maze test, WT mice tended to spend a longer time in the closed arms of the maze, whereas 5XFAD mice tended toward the open, exposed arms, reflecting dysfunctional risk / anxiety-related evaluation. In this experiment, 5XFAD-WT and 5XFAD-MPO KO mice spent significantly longer in the open arms, reflecting disrupted risk evaluation behavior. However, 5XFAD-MPO KO mice spent significantly shorter time in the open arms of the maze compared to 5XFAD-WT mice (Figures 5D-5E). Taken together, these results indicate that MPO KO reduces risk evaluation / anxiety-related behavior in 5XFAD mice.

[0274] We next tested whether MPO deficiency suppressed the cognitive decline seen in 5XFAD mice. In the Y-maze test, 5XFAD-WT mice showed reduced exploration time and fewer entries into novel arms compared to WT-WT, while 5XFAD-MPO KO mice showed approximately 50% more entries into novel arms of the maze compared to 5XFAD-WT (Figure 6A). No significant difference in exploration time was measured between 5XFAD-WT and 5XFAD-MPO KO mice (Figure 6B). We then tested the spatial learning ability of these mice in the Morris water maze test. During the 5 days of trials, 5XFAD-WT showed significantly longer latency to find the platform from day 3, reflecting dysfunctional spatial learning (Figure 6C). However, 5XFAD-MPO KO mice showed better marked learning ability and showed significantly shorter latency to find the platform on day 5 compared to 5XFAD-WT mice (Figure 6C). The improvement in learning of WT mice could also be reflected in the total distance traveled by the mice, since early on these mice traveled greater distances than on later days. 5XFAD-WT mice showed a relatively constant distance traveled throughout the trial, whereas 5XFAD-MPO KO mice, similar to the WT group, showed shorter distances traveled as the test progressed (Figure 6D). Finally, associative learning was assessed using a fear conditioning test. In this test, freezing behavior was measured 1 day after conditioning with a noxious footshock. WT-WT and WT-MPO KO mice showed approximately 40% freezing behavior, reflecting valid associative memory reconsolidation, whereas 5XFAD-WT mice showed significantly less freezing behavior. Notably, MPO-deficient mice show 2.45-fold more freezing behavior in 5XFAD mice (Figure 6E). Thus, hematological MPO deficiency suppresses cognitive dysfunction in the 5XFAD AD model, as demonstrated in five different behavioral tests.

[0275] MPO KO mice show similar amyloid-β plaque burden After behavioral testing, mice were sacrificed and brain sections were stained for ThioS to measure the effect of MPO KO on plaque density. WT mice showed no detectable ThioS staining, whereas 5XFAD-WT and 5XFAD-MPO KO mice showed comparable high levels of Aβ plaques, indicating that MPO KO has no effect on Aβ generation and accumulation in the brains of 5XFAD mice (Figures 7A-7E).

[0276] 5XFAD-MPO KO mice exhibit reduced inflammation To assess the effect of MPO deficiency on encephalitis, hippocampal sections were stained with an antibody against S100β. This protein is known to be overexpressed in activated astrocytes and has been linked to degenerative neuritogenesis in AD. As expected, 5XFAD-WT mice showed significantly higher S100β expression in their hippocampus compared to WT-WT mice (Figures 8A-8M). However, 5XFAD-MPO KO mice showed lower S100β levels comparable to 5XFAD-WT mice, indicating a more limited inflammatory response in these mice. Real-time PCR (RT-PCR) analysis of hippocampal mRNA samples also showed significantly elevated S100β expression in 5XFAD-WT mice compared to WT-WT mice, reflected by the restricted expression pattern in MPO-deficient 5XFAD mice.

[0277] To further test the impact of MPO deficiency on inflammation, RT-PCR was used to analyze hippocampal mRNA expression of several recognized inflammatory markers. MPO-deficient 5XFAD mice exhibit significantly reduced expression levels of pro-inflammatory mediators IL-1β and CXCL10 (Figures 9A-9B) and to some extent reduced CCL2 and TNFα expression (Figures 9C-9D). Interestingly, enhanced VCAM1 levels in 5XFAD-WT mice were reduced in 5XFAD-MPO KO mice (Figure 9E). Given the known association of VCAM1 with endothelial dysfunction, this result may suggest a beneficial effect of MPO KO on endothelial integrity in MPO KO 5XFAD mice.

[0278] MPO deficiency reduces APOE expression in 5XFAD mice The ε4 allele of the APOE genotype is considered the greatest genetic risk factor for sporadic adult-onset AD. Although the exact role of APOE in AD is still under debate, APOE clearly plays a central role in AD progression and has been linked to many pathological processes related to AD, including amyloid metabolism and aggregation and tau pathology. Interestingly, APOE expression was found to be significantly increased in the brains of 5XFAD mice. Indeed, Western blot analysis of hippocampal protein lysates showed a significant increase in APOE levels in the brains of 5XFAD-WT mice compared to WT-WT mice, whereas APOE levels were significantly lower in 5XFAD-MPO KO mice (Figure 10A, Figure 10B). This result was further confirmed on the RNA level (Figure 10C), indicating that MPO deficiency prevented APOE elevation in the CNS.

[0279] Example 3 MPO knockout in isolated HSCs using CRISPR / Cas9 technology CRISPR / Cas9-based gene alteration is considered an efficient platform for gene-based therapy. Isolation and ex vivo culture of targeted cells facilitates the application of this approach to hematopoietic system-related diseases. Thus, we utilize this platform for lentivirus-mediated MPO knockout in isolated HSCs. For this purpose, bone marrow cells are isolated and HSCs are enriched using magnetic-based cell sorting. These cells are transduced with lentiviral vectors expressing Cas9 protein, GFP and MPO-targeting guide RNA (gRNA). After 24 hours of culture, GFP-positive cells are FACS-sorted and injected into lethally irradiated model animals. For the generation of MPO-targeting lentiviral vectors, different gRNA primers were designed and inserted into the pL-CRISPR.EFS.GFP plasmid. Proper ligation was verified using Sanger sequencing. These plasmids were then used for the generation of lentiviral particles using the Virapower lentiviral packaging kit (Invitrogen). Proper lentivirus construction and integration into hematopoietic stem cells (HSCs) was evaluated by transducing isolated HSCs at increasing concentrations (0.5, 2 and 10 μl per 200,00 cells). As a control, a GFP-expressing lentivirus was used. GFP analysis 24 and 48 hours after transduction confirmed that HSCs were indeed transduced (FIG. 11), showing 33% and 45% GFP+ cells, respectively, after 24 and 48 hours of culture under the highest concentration tested. These results indicate that isolated HSCs can be transduced and FACS selected 24 hours after transplantation into irradiated mice.

[0280] GFP positive cells are FACS sorted and injected into lethally irradiated model animals.

[0281] The following animal experiments using lentiviral transduced HSCs are performed in both EAE and 5XFAD models. A lentiviral vector not expressing gRNA is used as a control for these experiments. The classification for these experiments is described in Table 3 (EAE experiments) and Table 4 (5XFAD experiments). [Table 3] [Table 4]

[0282] Example 4 MPO knockout in human cells (HEK293) using CRISPR / Cas9 technology Human HEK293 cells were transfected with ribonucleoprotein (RNP) complexes containing Cas9 protein, fluorescently labeled tracrRNA and each of the following crRNA sequences targeting the human MPO coding sequence (SEQ ID NOs: 33-35 and 42) and the corresponding protospacer (SEQ ID NOs: 43-46, respectively) (PAMs are shown in bold): T173: TGCACATCCCGGTGATGGTG, represented by SEQ ID NO: 33; D260: CAGGGGTGAAGTCGAGGTCG, represented by SEQ ID NO: 34; H502: GGATGAGGGTGTGGCCGTAG, represented by SEQ ID NO: 35; C319: GGATGGTGATGTTGCTCCCG, represented by SEQ ID NO: 42; T173: TGCACATCCCGGTGATGGTGCGG, represented by SEQ ID NO: 43; D260: CAGGGGTGAAGTCGAGGTCGTGG, represented by SEQ ID NO: 44; H502: GGATGAGGGTGTGGCCGTAGCGG represented by SEQ ID NO: 45; and C319: GGATGGTGATGTTGCTCCCGGGG, as represented by sequence number 46.

[0283] As shown by the following Example 5, these specific targets are also used as HDR targets that result in amino acid substitutions that form conformational changes in the protein or alterations in protomer biosynthesis and processing (C319A), substitutions that mimic human MPO defective substitutions (T173C), and amino acid substitutions that disrupt protomer heme binding D260A and H502A, in addition to targets for knockout of the MPO gene. Transfection was performed using the Alt-R system according to the manufacturer's protocol (Integrated DNA Technologies, Inc., USA). 72 hours after transfection, cells were harvested for DNA extraction or labeled with tracrRNA and FACS sorted for cell enrichment, and harvested for DNA extraction after another 72 hours of culture. DNA samples were analyzed using the T7 endonuclease I (T7EI) mismatch detection assay according to the manufacturer's protocol (Integrated DNA Technologies, Inc., USA). More specifically, the T7EI assay was used to assess the gene editing efficiency of CRISPR-Cas9 reagents for a given guide RNA target site in the cell population to be edited.

[0284] The following primers were used for the T7EI assay: 1.For T173 gRNA: Fw primer (approximately 182 bp downstream): T173_T7-Fw: TCTTCCTCCAGGGAGTCTCA, represented by SEQ ID NO:36. Rv primer (approximately 673 bp downstream) T173_T7_Rv: GCAGGAAGGAGACAGGTCAT, represented by sequence number 37. Amplicon size: 915 2.For D260 gRNA: Fw primer (approximately 621 bp downstream): D260_T7-Fw: TCTTCCTCCAGGGAGTCTCA, represented by SEQ ID NO:36. Rv primer (approximately 234 bp downstream): D260_T7_Rv: GCAGGAAGGAGACAGGTCAT, represented by SEQ ID NO:37. Amplicon size: 915 3.For C319 gRNA: Fw primer (approximately 263 bp downstream): C319_T7_Fw: CCAGGTTCCCAGTTCAGTGT, represented by sequence number 38. Rv primer (approximately 558 bp downstream): C319_T7_Rv: CCACAGCGTTCTCTGTCCTT, represented by SEQ ID NO:39. Amplicon size: 881 4.For H502 gRNA: Fw primer (approximately 297 bp downstream): H502_T7_Fw: ATGCCTCTCAGTGCCACTCT, represented by SEQ ID NO:40. Rv primer (approximately 566 bp downstream): H502_T7_Rv: AGCCAGGTCAGGGGAAGTAT, represented by SEQ ID NO:41. Amplicon size: 923.

[0285] As shown in Figure 12, cleavage of MPO was observed in human cells, particularly in H502-transfected (27.3) and T173-transfected (19.8%) crRNAs as shown in sorted cells. These results clearly demonstrate the feasibility of specifically and effectively targeting MPO in human cells.

[0286] Example 5 Using the CRISPR / Cas9 system to manipulate human MPO function and levels Encouraged by the successful knockout of MPO in human cells using the gene editing system of the present invention, the inventors next use the CRISPR / Cas9 system as a tool to replace specific amino acid residues in human MPO that induce changes in MPO biosynthesis and function. The specific target amino acid residues are subdivided into the following groups: 1. Amino acid substitutions that create conformational changes in the protein or changes in protomer biosynthesis and processing-C167A, C180A, C319A, C158A, R128A, N355A. 2. Amino acid substitutions that mimic human MPO deletion substitutions- T173C, M251T, R569W, R499C, G501S. 3. Amino acid substitutions that prevent protomer heme binding- Q257A, D260A, M409A, E408A, H261A, H502A. 4. An amino acid that prevents proper protein glycosylation-N355A. The target residues specified herein relate to the human MPO amino acid sequence set forth in SEQ ID NO:2.

[0287] Cysteine ​​167 Cysteine ​​167 is a conserved amino acid in the light chain of MPO that forms a disulfide bridge with C180. Substitution of this amino acid with a neutral amino acid prevents the formation of the disulfide bridge. The cysteine ​​to alanine substitution, C167A (changing TGC to GCC / GCA / GCT / GCG) is made as described herein. A Cas9-mediated double strand break (DSB) within the codon sequence for cysteine ​​167 is performed using the following gRNA sequence: C167A-1 : GGACGTGGGGGGTGACTT^GCC, represented by SEQ ID NO: 47. This gRNA has the nucleic acid sequence GGACGTGGGGGGTGACTT^GCC, represented by SEQ ID NO: 94. CGG It targets protospacers containing: Before cleavage: CAGGACGTGGGGGTGACTTGC represented by SEQ ID NO: 48 167 C CGG AGCAGGACAAA. After cleavage: CAGGACGTGGGGGTGACTT^GC, as represented by SEQ ID NO:48 167 C CGG AGCAGGACAAA. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0288] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. The template ssODN oligo for C167A contains: Represented by SEQ ID NO: 49: GTTGTCCAAGTCAAGCGGCTGCGCCTACCAGGACGTGGGGGTGACTGCC 167 C CTG AGCAGGACAAATACCGCACCATCACCGGGATGTGCAACAACAGGTGCGGC.

[0289] Cysteine ​​180 Cysteine ​​180 is a conserved amino acid in the light chain of MPO that forms a disulfide bridge with C167. Substitution of this amino acid with a neutral amino acid prevents the formation of the disulfide bridge. The cysteine ​​to alanine substitution C180A (changing TGC to GCC / GCA / GCT / GCG) is performed by a Cas9-mediated DSB within the codon sequence for cysteine ​​180 using the following gRNA sequence: C180A-1: TCACCGGGATGTGCAAC^AAC, represented by SEQ ID NO: 50. This gRNA has the nucleic acid sequence TCACCGGGATGTGCAAC^AAC, represented by SEQ ID NO: 95. AGG It targets protospacers containing: Before cleavage: ACCATCACCGGGATGTGC represented by SEQ ID NO:51 180 AACAA AGG TGCGGCTGGCTG. After cleavage: ACCATCACCGGGATGTGC, as represented by SEQ ID NO:51 180 AAC^AAC AGG TGCGGCTGGCTG. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0290] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. The template ssODN oligo for C180A contains: CTTGCCGGAGCAGGACAAATACCGCACCATCACCGGGATGGCC represented by SEQ ID NO: 52 180 AACAA AGC TGCGGCTGGCTGGGGGTGGCTGCAGGAACCGGGCTCAGAGAGGCGTCCCG.

[0291] Tyrosine 173 It was previously reported that a missense mutation in the codon for tyrosine 173 resulting in a substitution to cysteine ​​results in MPO deficiency and causes abnormal protein processing leading to its degradation. Thus, as shown by Example 4, a tyrosine to cysteine ​​substitution Y173C (changing TAC to TGT / TGC) is performed by a Cas9-mediated DSB within the codon sequence of tyrosine 173 using the following gRNA sequence: Y173C-1: The nucleic acid sequence represented by SEQ ID NO: 43: TGCACATCCCGGTGATG^GTG CGG Targeting a protospacer comprising: TGCACATCCCGGTGATG^GTG, represented by sequence number 33. Before cleavage: TGCCCGGAGCAGGACAAATA represented by SEQ ID NO:53 C 173 CG CACCATCACCGGG. After cleavage: TGCCCGGAGCAGGACAAATA, as represented by SEQ ID NO:53 C 173 CG CAC^CATCACCGGG. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0292] Single-stranded oligodeoxynucleotides (ssODNs) were used as templates for HDR. The ssODNs contain two homology arms flanking the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Furthermore, PAM-blocking mutations were introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for Y173C: Represented by SEQ ID NO: 54: GGCTGCGCCTACCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATG T 173 CG CACCATCACCGGGATGTGCAACAACAGGTGCGGCTGGCTGGGGGTGGCTG.

[0293] Glutamine 257 Glutamine 257 has been reported to form hydrogen bonds with the heme cavity and to be involved in halide binding. Substitution of this amino acid with a neutral amino acid prevents the carbonyl residue from interacting with the water molecule and forming a hydrogen bond. A glutamine to alanine substitution, Q257A (CAG to GCC / GCA / GCT / GCG), is performed by a Cas9-mediated DSB within the codon sequence for glutamine 257 using the following gRNA sequence: Q257A-1: CATGCAATGGGGCCAGC^TGT, represented by SEQ ID NO: 55. This gRNA has the nucleic acid sequence CATGCAATGGGGCCAGC^TGT, represented by SEQ ID NO: 96. TGG It targets protospacers containing: Before cleavage: CATGTTCATGCAATGGGGCCAG, as represented by SEQ ID NO:56 257 CTGT TGG ACCACGA. After cleavage: CATGTTCATGCAATGGGGCCAG, as represented by SEQ ID NO:56257 C^TGT TGG ACCACGA. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0294] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for Q257A: GACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCGCG represented by SEQ ID NO: 57 257 CTGT TTG ACCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTC.

[0295] Aspartic Acid 260 Aspartic acid 260 forms an ester bond with the pyrrole group of heme and is probably the only covalent link to the heme group of the MPO light chain. Substitution of this amino acid residue with a neutral amino acid prevents protein-heme interactions. An aspartate to alanine substitution, D260A (changing GAC to GCC / GCA / GCT / GCG), was performed as disclosed in Example 4 using a Cas9-mediated DSB within the codon sequence of aspartate 260 using the following gRNA sequence: D260A-1: The nucleic acid sequence represented by SEQ ID NO: 44: CAGGGGTGAAGTCGAGG^TCG TGG Targeting a protospacer comprising: CAGGGGTGAAGTCGAGG^TCG, represented by sequence number 34. Before cleavage: GCAATGGGGCCAGCTGTTGGA represented by SEQ ID NO:58 C 260 CACGACCTCGACTTCACCCCT. After cleavage: GCAATGGGGCCAGCTGTTGGA, as represented by SEQ ID NO:58 C 260 CA CGA^CCTCGACTTCACCCCT. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0296] Single-stranded oligodeoxynucleotides (ssODNs) were used as templates for HDR. The ssODNs contain two homology arms flanking the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Furthermore, PAM-blocking mutations were introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for Q260A: CCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGC represented by SEQ ID NO: 59 A 260 CA CGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTG.

[0297] Methionine 409 Methionine 409 forms an ester bond with the pyrrole group of heme and is probably the only covalent linkage of the MPO light chain to the heme group. Substitution of this amino acid residue with a neutral amino acid prevents this protein-heme interaction. A methionine to alanine substitution, M409A (ATG to GCC / GCA / GCT / GCG), is performed by a Cas9-mediated DSB within the codon sequence of methionine 409 using the following gRNA sequence: M409A-1: GGTGAGCTCGGGCATCT^CAC, represented by SEQ ID NO: 60. This gRNA has the nucleic acid sequence represented by SEQ ID NO: 97: GGTGAGCTCGGGCATCT^CAC TGG It targets protospacers containing: Before cleavage: AGGGGACACCCGTT, represented by SEQ ID NO:61 CCA GTGAGATG 409 CCCGAGCTCACCTCCA. After cleavage: AGGGGACACCCGTT, as represented by SEQ ID NO:61 CCA GTG^AGATG 409 CCCGAGCTCACCTCCA. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0298] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for M409A: GAGGCCTTAAGAATGACAGTGGCTTTTGCCTCCCCAAGGGGACACCCGTT represented by SEQ ID NO: 62 ACA GTGAGGCG 409 CCCGAGCTCACCTCCATGCACACCCTCTTACTTCGGGAGCAC.

[0299] Glutamic Acid 408 Glutamic acid 408 forms an ester bond with the pyrrole group of heme. Substitution of this amino acid residue with a neutral amino acid prevents this protein-heme interaction. A glutamic acid to alanine substitution, e408a (GAG to GCC / GCA / GCT / GCG), is performed by a Cas9-mediated DSB within the codon sequence for glutamic acid 408 using the following gRNA sequence: E408A-1: GGTGAGCTCGGGCATCT^CAC, as represented by sequence number 63. The gRNA has the nucleic acid sequence represented by SEQ ID NO: 98: GGTGAGCTCGGGCATCT^CAC TGG It targets protospacers containing: Before cleavage: AGGGGACACCCGTT, represented by SEQ ID NO:64 CCA GTGAG 408 ATGCCCGAGCTCACCTCCA. After cleavage: AGGGGACACCCGTT, as represented by SEQ ID NO:64 CCA GTG^AG 408 ATGCCCGAGCTCACCTCCA. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0300] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for E408A: GAGGCCTTAAGAATGACAGTGGCTTTTGCCTCCCCAAGGGGACACCCGTT represented by SEQ ID NO: 65 ACA GTGCG 408 ATGCCCGAGCTCACCTCCATGCACACCCTCTTACTTCGGGAGCAC.

[0301] Histidine 261 Histidine 261 is the distal ligand that coordinates the heme iron. Substitution of this amino acid residue with a neutral amino acid prevents this protein-heme interaction. A histidine to alanine substitution, H261A (CAC to GCC / GCA / GCT / GCG), is performed by a Cas9-mediated DSB within the codon sequence of histidine 261 using the following gRNA sequence: H261A-1: CAGGGGTGAAGTCGAGG^TCG, represented by SEQ ID NO: 66. This gRNA has the nucleic acid sequence represented by SEQ ID NO: 99: CAGGGGTGAAGTCGAGG^TCG TGG CAGGGGTGAAGTCGAGG^TCG TGG It targets protospacers containing: Before cleavage: GCAGCGCAGGGA represented by SEQ ID NO: 67 CCA C 261 GACCTCCCAGGTGAGGGGCT. After cleavage: GCAGCCAGCAGGGA, represented by SEQ ID NO: 67 CCA C 261 GA^CCTCCCAGGTGAGGGGCT. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0302] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for H261A: ATGAGGATTGGGCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGA represented by SEQ ID NO: 68 C GCC 261 GACCTCCCAGGTGAGGGGCTGCAGGAGTCTCCCCTGATGCTCACCTCCCC.

[0303] Cysteine ​​319 Cysteine ​​319 forms the only disulfide bridge between the two protomers that comprise the MPO homodimer. Mutation of cysteine ​​319 to alanine disrupts MPO biosynthesis and reduces its peroxidase activity. A cysteine ​​to alanine substitution, C319A (changing TGC to GCC / GCA / GCT / GCG), was performed as shown in Example 4 using a Cas9-mediated DSB within the codon sequence of cysteine ​​319 with the following gRNA sequence: C319A-1: the nucleic acid sequence GGATGGTGATGTTGCTC^CCG represented by SEQ ID NO: 46 GGG Targeting a protospacer comprising the following, represented by sequence number 42, GGATGGTGATGTTGCTC^CCG. Before cleavage: CCTGGCCCAGATCTCATTGC represented by SEQ ID NO: 69 319 CC CGGATCATCTGCGACAA. After cleavage: CCTGGCCCAGATCTCATTGC, as represented by SEQ ID NO:69 319 CC CGG^ATCATCTGCGACAA. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0304] Single-stranded oligodeoxynucleotides (ssODNs) were used as templates for HDR. The ssODNs contain two homology arms flanking the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Furthermore, PAM-blocking mutations were introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for C319A: Represented by SEQ ID NO: 70: GGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATGCC 319 AC CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACAT.

[0305] Methionine 251 A missense mutation in the coding region for methionine 251 resulting in a substitution to threonine causes inherited MPO deficiency. In vitro data suggest that the M251T substitution affects MPO processing and reduces peroxidase activity. A methionine to threonine substitution, M251A (ATG to ACC / ACA / ACT / ACG) was performed using a Cas9-mediated DSB within the codon sequence for methionine 251 using the following gRNA sequence: M251A-1: GCTCACTCATGTTCATG^CAA, represented by SEQ ID NO: 71. This gRNA has the nucleic acid sequence represented by SEQ ID NO: 100: GCTCACTCATGTTCATG^CAA TGG It targets protospacers containing: Before cleavage: GAGCGCTCACTCATG, represented by SEQ ID NO: 72 251 TTCATGCAA TGG GGCCAGCTGTTG. After cleavage: GAGCGCTCACTCATG, represented by SEQ ID NO:72 251 TTCATG^CAA TGG GGCCAGCTGTTG. (The PAM sequence is underlined, ^ indicates the cleavage site, and bold indicates the codons that are replaced).

[0306] A single-stranded oligodeoxynucleotide (ssODN) is used as a template for HDR. The ssODN contains two homology arms that flank the new codon sequence. The homology arms are symmetrical and have 50 bases from both ends of the PAM. Additionally, PAM-blocking mutations are introduced into the PAM sequence to prevent CRISPR re-cutting. Template ssODN oligo for M251A: Represented by SEQ ID NO: 73, CCACTGATCAGCTGACTCCGGACCAGGAGCGCTCACTCACG 251 TTCATGCAA TGT GGCCAGCTGTTGGACCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCG.

[0307] Arginine 569 A missense mutation in the coding region for arginine 569 resulting in a substitution to tryptophan causes inherited MPO deficiency. In vitro data suggest that the R569W substitution affects MPO processing, disrupts he...

Claims

1. In preparing a composition for modulating myeloperoxidase (MPO) expression and / or activity in a mammalian subject, (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; wherein said modulation comprises suppressing or eliminating MPO expression and / or activity in said subject, and optionally said undifferentiated BM cells are hematopoietic stem cells (HSCs) or progenitor cells.

2. The PEN comprises at least one clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (cas) protein system, and the CRISPR / cas system is (a) at least one CRISPR / Cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one guide RNA (gRNA) that targets a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA; or any kit, composition or vehicle comprising at least one of (a) and (b); and optionally, at least one of The use of claim 1, wherein the gRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:88 and SEQ ID NO:

91.

3. The undifferentiated BM cell population (a) a BM cell population that has been transduced or transfected with at least one gene editing compound that reduces the expression and / or activity of MPO in said cells; or 3. The use of claim 1 or 2, wherein (b) the BM cell population of an allogeneic subject exhibits suppressed or ablated expression and / or activity of MPO.

4. The use according to any one of claims 1 to 3, wherein the undifferentiated BM cell population is derived from an autologous or allogeneic source.

5. In preparing a composition for treating, preventing, ameliorating, inhibiting or delaying the onset of MPO-related disorders in a mammalian subject, (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated BM cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; Use of at least one of the MPO-related disorder is at least one of a neurodegenerative disorder, an immune-related disorder, a respiratory disorder, a proliferative disorder, a vascular disorder, or any combination thereof; (I) the neurodegenerative disease is any one of Alzheimer's disease (AD) and Parkinson's disease (PD); (II) the immune-related disorder is at least one of an autoimmune disease and an inflammatory disease, and optionally, (i) the autoimmune disease is any one of multiple sclerosis (MS), antineutrophil cytoplasmic antibody (ANCA)-associated disorder, and systemic lupus erythematosus (SLE); or (ii) the inflammatory disease is any one of atherosclerosis and rheumatoid arthritis (RA); (III) the respiratory disorder is pulmonary arterial hypertension (PAH); or (IV) The use, wherein the proliferative disorder is cancer.

6. The undifferentiated BM cell population (a) a BM cell population transduced or transfected with at least one gene editing compound that reduces expression and / or activity of MPO in said cells, and optionally said undifferentiated BM cell population is derived from an autologous or allogeneic source, or 6. The use of claim 5, wherein (b) the BM cell population of an allogeneic subject exhibits suppressed or ablated expression and / or activity of MPO.

7. The at least one PEN comprises at least one CRISPR / Cas system, and the CRISPR / Cas system is (a) at least one polypeptide comprising at least one Cas protein, or any nucleic acid sequence encoding said Cas protein; and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA; or any kit, composition or vehicle comprising at least one of (a) and (b); The use according to claim 5 or 6, comprising at least one of the following:

8. The use according to any one of claims 5 to 7, wherein the gRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:88 and SEQ ID NO:

91.

9. 9. The use according to any one of claims 5 to 8, wherein the MPO-related disease is at least one of Alzheimer's disease (AD), multiple sclerosis (MS), pulmonary arterial hypertension (PAH), or crescentic glomerulonephritis (CGN).

10. The use according to any one of claims 5 to 9, wherein the MPO-related disease is Alzheimer's disease (AD).

11. (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated BM cell of a subject in need thereof, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding said PEN; any kit, composition, or vehicle comprising said at least one PEN; or a nucleic acid molecule encoding said PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; 1. A pharmaceutical composition for use in a method of modulating myeloperoxidase (MPO) expression and / or activity in a mammalian subject, said modulation comprising inhibiting or eliminating MPO expression and / or activity in said subject, said composition optionally further comprising at least one of a pharma- ceutical acceptable carrier, diluent and / or excipient.

12. The at least one PEN comprises at least one CRISPR / Cas system, the CRISPR / Cas system comprising: (a) at least one CRISPR / Cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA; or any kit, composition or vehicle comprising at least one of (a) and (b); and optionally, at least one of 12. The pharmaceutical composition of claim 11, wherein the gRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:88 and SEQ ID NO:

91.

13. The undifferentiated BM cell population (a) a BM cell population transduced or transfected with at least one gene editing compound that reduces expression and / or activity of MPO in said cells, and optionally said undifferentiated BM cell population is from an autologous or allogeneic source, or 13. The pharmaceutical composition of claim 11 or 12, wherein (b) said undifferentiated BM cell population is an allogeneic subject BM cell population exhibiting inhibited or ablated expression and / or activity of MPO.

14. 1. A pharmaceutical composition for use in a method for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-related disease or disorder in a mammalian subject, said pharmaceutical composition comprising: (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of a subject in need thereof, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding said PEN; any kit, composition, or vehicle comprising said at least one PEN; or a nucleic acid molecule encoding said PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; At least one of the MPO-related disorder is at least one of a neurodegenerative disorder, an immune-related disorder, a respiratory disorder, a proliferative disorder, a vascular disorder, or any combination thereof; (a) the neurodegenerative disease is any one of AD and PD; (b) the immune-related disorder is at least one of an autoimmune disease and an inflammatory disease, and optionally the autoimmune disease is any one of MS, an ANCA-related disorder, and SLE; (c) the respiratory disorder is PAH; (d) the proliferative disorder is cancer; The composition optionally further comprises at least one of a pharma- ceutically acceptable carrier, diluent and / or excipient.

15. The at least one PEN comprises at least one CRISPR / Cas system, the CRISPR / Cas system comprising: (a) at least one CRISPR / Cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA; or any kit, composition or vehicle comprising at least one of (a) and (b); and optionally, at least one of 15. The pharmaceutical composition of claim 14, wherein the gRNA comprises a nucleic acid sequence represented by any one of SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:88 and SEQ ID NO:

91.

16. The undifferentiated BM cell population, (a) a BM cell population transduced or transfected with at least one gene editing compound that reduces expression and / or activity of MPO in said cells, and optionally said undifferentiated BM cell population is derived from an autologous or allogeneic source, or 16. The pharmaceutical composition of claim 14 or 15, wherein (b) is an allogeneic subject BM cell population that exhibits suppressed or ablated expression and / or activity of MPO.

17. The pharmaceutical composition according to any one of claims 14 to 16, wherein the MPO-related disease is at least one of Alzheimer's disease (AD), multiple sclerosis (MS), pulmonary arterial hypertension (PAH), or crescentic glomerulonephritis (CGN).

18. The pharmaceutical composition according to any one of claims 14 to 17, wherein the MPO-related disease is Alzheimer's disease (AD).

19. At least one undifferentiated BM cell transduced or transfected with at least one gene editing compound that reduces expression and / or activity of MPO in the cell, said at least one gene editing compound comprising at least one of at least one programmable genetically engineered nuclease (PEN), any nucleic acid molecule comprising a sequence encoding said PEN, any kit, composition or vehicle comprising said at least one PEN, or a nucleic acid molecule encoding said PEN, optionally wherein said cell is derived from a subject suffering from an MPO-related disease.

20. In preparing a composition for inhibiting nephropathy and related disorders in a mammalian subject, (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated BM cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced MPO expression and / or activity; and optionally using at least one of The at least one PEN comprises at least one CRISPR / Cas system, the CRISPR / Cas system comprising: (a) at least one CRISPR / Cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in said MPO gene, or any nucleic acid sequence encoding said gRNA, or any kit, composition or vehicle comprising at least one of (a) and (b); The use of the present invention includes at least one of the following:

21. A pharmaceutical composition for use in a method for inhibiting nephrosis and related disorders in a mammalian subject, said pharmaceutical composition comprising: (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; At least one gene editing compound, optionally comprising at least one PEN comprising at least one CRISPR / Cas system, wherein the CRISPR / Cas system is a) at least one CRISPR / Cas protein, or any nucleic acid molecule encoding said Cas protein, and (b) at least one nucleic acid sequence comprising at least one gRNA targeting a protospacer in the MPO gene, or any nucleic acid sequence encoding said gRNA; or any kit, composition or vehicle comprising at least one of (a) and (b); A pharmaceutical composition comprising at least one of the following:

22. In the preparation of a composition for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-related disease in a mammalian subject, comprising: (a) at least one gene editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of a subject, the at least one gene editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding said PEN; any kit, composition or vehicle comprising said at least one PEN; or a nucleic acid molecule encoding said PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; Use of at least one of The use, wherein the MPO-related disease is one of Alzheimer's disease (AD), multiple sclerosis (MS), pulmonary arterial hypertension (PAH), and crescentic glomerulonephritis (CGN).

23. A composition for use in a method for treating, preventing, ameliorating, inhibiting, or delaying the onset of an MPO-related disease in a mammalian subject, said composition comprising: (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; At least one of The composition, wherein the MPO-related disease is one of Alzheimer's disease (AD), multiple sclerosis (MS), pulmonary arterial hypertension (PAH), and crescentic glomerulonephritis (CGN).

24. In the preparation of a composition for treating, preventing, ameliorating, inhibiting or delaying the onset of an MPO-related disease in a mammalian subject, comprising: (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; Use of at least one of The use, wherein the MPO-related disease is Alzheimer's disease (AD).

25. A composition for use in a method for treating, preventing, ameliorating, inhibiting, or delaying the onset of an MPO-related disease in a mammalian subject, said composition comprising: (a) at least one gene-editing compound that reduces expression and / or activity of MPO in at least one undifferentiated bone marrow (BM) cell of the subject, the at least one gene-editing compound comprising at least one of: at least one programmable genetically engineered nuclease (PEN); any nucleic acid molecule comprising a sequence encoding the PEN; any kit, composition, or vehicle comprising the at least one PEN, or the nucleic acid molecule encoding the PEN; and / or (b) an undifferentiated BM cell population exhibiting reduced expression and / or activity of MPO; At least one of The composition, wherein the MPO-related disease is Alzheimer's disease (AD).

Citation Information

Patent Citations

  • Delivery, use and therapeutic applications of crispr-cas systems and compositions for genome editing

    JP2017504312A